256 search results for "antibiotic resistance"

Multifaceted Antibiotic Resistance in Diabetic Foot Infections: A Systematic Review

Multifaceted Antibiotic Resistance in Diabetic Foot Infections: A Systematic Review

Summary: This systematic review and limited meta-analysis (2014–2024) analyzed 28 studies to evaluate bacterial prevalence and antibiotic resistance patterns in diabetic foot infections (DFIs). The findings highlight high rates of multidrug resistance (MDR), associations with comorbidities, and the importance of culture-guided therapy in preventing treatment failure.

Key Highlights:

  • Common pathogens: Staphylococcus aureus was the most frequent isolate, followed by Pseudomonas, Enterococcus, Enterobacter, and Escherichia coli.
  • Resistance trends: High rates of both mono- and multidrug resistance were observed, with Acinetobacter showing the greatest MDR burden.
  • Comorbidity correlations: Dyslipidemia, hypertension, nephropathy, peripheral vascular disease, prior amputation, and smoking were strongly linked with resistance profiles.
  • Study limitations: Most studies originated from China and Malaysia, with male patients overrepresented, which may limit generalizability.
  • Clinical impact: Empiric antibiotic use without culture testing risks treatment failure in MDR infections. Regular antibiogram surveillance and individualized therapy are essential for effective management.

Read the full article in Microorganisms (MDPI)

Keywords:
Weiqi Li,
Oren Sadeh,
Jina Chakraborty,
Emily Yang,
Paramita Basu,
Priyank Kumar,
diabetic foot infection,
antibiotic resistance,
multidrug resistance,
antimicrobial stewardship

Phytotherapy for Chronic Wound Management in the Era of Antibiotic Resistance

Phytotherapy for Chronic Wound Management in the Era of Antibiotic Resistance

Summary: This literature review explores the potential of plant-derived compounds (phytocompounds) in managing chronic wounds, particularly in the context of rising antimicrobial resistance (AMR) and biofilm-associated infections. Chronic wounds often stall in the inflammatory phase, complicated by polymicrobial biofilms that protect pathogens and resist antibiotics. Phytotherapy offers biocompatible, low-toxicity, and cost-effective alternatives with antimicrobial, antibiofilm, and wound-healing properties. Compounds such as flavonoids, terpenoids, alkaloids, tannic acid, coumarin, resveratrol, berberine, and curcumin show promise in reducing oxidative stress, promoting clotting, stimulating collagen synthesis, and combating infections. Combining natural agents with conventional therapies could enhance outcomes and reduce reliance on resistant antibiotics.

Key Highlights:

  • Background: Chronic wounds are characterized by impaired healing, prolonged inflammation, and frequent biofilm-driven infections. AMR limits the effectiveness of antibiotics, underscoring the need for novel strategies.
  • Mechanisms: Phytocompounds disrupt quorum sensing, suppress virulence factors, reduce oxidative stress, and stimulate angiogenesis and fibroblast activity. They enhance all four healing phases: hemostasis, inflammation, proliferation, and remodeling.
  • Examples:
    • Coumarin: reduces oxidative stress, stabilizes clotting, improves perfusion.
    • Tannic acid: promotes coagulation, wound contraction, and capillary growth.
    • Curcumin: modulates growth factors, reduces oxidative stress, enhances collagen synthesis.
    • Resveratrol: anti-inflammatory, reduces cytokine activity, supports angiogenesis.
    • Berberine: antimicrobial and vascular-stabilizing effects.
  • Clinical potential: Phytocompounds offer synergy with conventional care, biocompatibility, and lower costs. Their antioxidant and antimicrobial effects make them attractive for integration into wound care regimens.
  • Limitations: Evidence remains largely preclinical or early clinical. More controlled trials are required to standardize dosing, delivery, and long-term outcomes.

Read the full article on Wounds (HMP Global Learning Network)

Keywords:
phytotherapy,
chronic wounds,
antimicrobial resistance,
biofilms,
curcumin,
resveratrol,
berberine,
tannic acid,
coumarin

Phytotherapy for Chronic Wound Management in the Era of Antibiotic Resistance



Phytotherapy for Chronic Wound Management in the Era of Antibiotic Resistance

Summary: This literature review examines the potential of phytotherapy—using plant-derived compounds like flavonoids, polyphenols, and alkaloids—as an alternative to antibiotics for managing chronic wounds such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) amid rising antimicrobial resistance (AMR) and biofilm challenges. Drawing from preclinical and early clinical studies, it highlights how phytocompounds disrupt bacterial virulence, reduce oxidative stress and inflammation, and enhance hemostasis, proliferation, and remodeling phases of healing via pathways like TGF-β, NF-κB, and MAPK. Cost-effective and biocompatible, these agents show synergy with antibiotics and promise in topical formulations, though larger RCTs are needed for clinical adoption.

Key Highlights:

  • Key phytocompounds: Curcumin (anti-inflammatory, collagen stimulation), quercetin (biofilm inhibition, M2 macrophage polarization), berberine (DNA disruption, vascular regeneration), resveratrol (COX inhibition, neutrophil reduction), and tannic acid (clotting promotion, free radical scavenging).
  • Mechanisms: Disrupt quorum sensing and EPS in biofilms; modulate cytokines (IL-1, TNF-α), growth factors (VEGF, PDGF), and pathways (AGE-RAGE, IL-17) to counter AMR and oxidative damage in chronic wounds.
  • Evidence: In vitro/animal studies show enhanced closure (e.g., quercetin + gentamicin in diabetic mice); clinical potential in bromelain (NexoBrid for debridement) and curcumin hydrogels; synergy against MRSA in combinatorial therapies.
  • Applications to DFUs/VLUs: Promote granulation, angiogenesis, and ECM synthesis; reduce infection risks in high-burden settings, with nanophytosomes improving delivery.
  • Implications: Affordable adjuncts to standard care; limitations include bioavailability issues and need for standardized trials to integrate into wound protocols.

Read full article

Keywords: phytotherapy, antibiotic resistance, chronic wounds, biofilm disruption, phytocompounds, Kajal Rawat, Reema Gabrani

Antibiotic Resistance Influence on Wound Care

Antibiotic resistance is one of the factors which causes delay in wound healing and a corresponding spike in medical and healthcare expenses.

 

The primary reason for the emergence of resistance is the inappropriate use of antimicrobials. To use antibiotics wisely, it is necessary to understand the principles of diagnosing wound infection, what organisms are likely to be responsible, and to what antimicrobial agents they respond.

 

This knowledge will help to ensure that antibiotics are used only when essential, and in a manner that does not cause more resistance to be generated … read more

Mechanism revealed for spread of antibiotic resistance among bacteria

Researchers from the University of Tsukuba show that antibiotic resistance can be transferred between Staphylococcus bacteria by a process known as natural transformation … A bacteria called Staphylococcus aureus is widespread and generally harmless, but can cause infections known as “opportunistic infections”. These occur when the bacteria take advantage of certain situations, such as a weakened immune system or the presence of an open wound, to cause a harmful infection. These infections become particularly dangerous when the bacterial strain is resistant to treatment with antibiotics. Strains of Staphylococcus aureus known as MRSA, which are resistant to an antibiotic called methicillin, are becoming a significant problem worldwide. Now, a team from the University of Tsukuba have revealed the mechanism by which this methicillin resistance can be passed between bacteria … read more

TECHNOLOGY EFFECTIVE AGAINST ANTIBIOTIC-RESISTANT PATHOGEN

RESEARCH SHOWS ANTIBIOTIC-RESISTANT CANDIDA ALBICANS IS KILLED BY EXPOSURE TO VOMARIS BIOELECTRIC V.DOX™ TECHNOLOGY

Vomaris Innovations, Inc. announced today the publication of results demonstrating that the company’s bioelectric V.Dox™ Technology is effective in killing antibiotic-resistant Candida albicans pathogens. The manuscript, “Ketoconazole Resistant Candida albicans is Sensitive to a Wireless Electroceutical Wound Care Dressing,” was published in Bioelectrochemistry https://doi.org/10.1016/j.bioelechem.2021.107921The research was led by Chandan K. Sen, Ph.D., Director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University and Distinguished Professor and J. Stanley Battersby Professor of Surgery at the IU School of Medicine.

 

Antibiotic resistance is one of the greatest global public health challenges of our time1. Every year, more than 2.8 million antibiotic-resistant infections occur in the United States2, and 700,000+ people die globally3. Meanwhile, the discovery of novel antimicrobials is not keeping up with the emergence of new superbugs.1,4 “Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time,” predicts Dr. Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation.

 

In the study, researchers sought to determine whether the wireless electroceutical wound care dressing or “WED”, was effective in managing pathogenic molecular processes employed by ketoconazole-resistant yeast Candida albicans. Candida albicans poses a major threat to skin and wound infection. It’s typically treated topically with the drug ketoconazole. However, ketoconazole-resistant pathogens are an emerging threat in the management of skin infection.  The authors believe that the emergence of multidrug resistance in Candida albicans warrants the need for alternative, non-pharmacological methods of wound treatment.

 

Vomaris’s WED, powered by V.Dox™ Technology, is a proprietary pattern of embedded microcell batteries that wirelessly generates a low level of electricity in the presence of moisture.  The research team used an in vitro model to test WED alone, ketoconazole alone, and the combination of WED + ketoconazole, against ketoconazole-resistant Candida albicans. Three controls were used, including no treatment, plain polyester fabric, and a fabric impregnated with silver.

 

The researchers found that WED functioned in a multi-pronged manner to effectively treat ketoconazole-resistant Candida albicans. Findings included:

  • Prevented hyphal growth. The development of hyphae (long, branched filaments) is a critical part of albican’s growth cycle. Stopping hyphal growth prevents C. albicans from causing infection and subsequent tissue damage.
  • Impaired efflux pump system. Damaging this system prevents albicans from rejecting helpful antibiotics.
  • Damaged cell wall integrity. Weakening the cell wall structure allows antibiotics to reach the pathogen.
  • Disrupted biofilm formation. C. albicans develops a biofilm ‘shield’ to protect it from immune system and antibiotic attack. WED interfered with its ability to form biofilm.
  • In contrast, silver alone was ineffective in all experiments.

“This work presents clear evidence that the wireless electroceutical dressing kills ketoconazole-resistant Candida albicans,” said Dr. Sen. “Our findings introduce the option of a novel biophysical solution for fighting chronic wound infection in which antibiotic-resistant pathogens are prevalent.”

“These latest findings by Dr. Sen and team add to our growing body of evidence on the significant role electricity can play in combatting antibiotic-resistant pathogens. In this era of antibiotic stewardship, a wound care product that kills pathogens without the use of antibiotics is an important technological breakthrough,” said Vomaris President and CEO Michael Nagel. “Our V.Dox Technology is already FDA cleared and is the only bioelectric product of its kind in the marketplace today.”

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report.

About Vomaris

Vomaris Innovations, Inc. (www.vomaris.com) is a privately held medical device company specializing in bioelectric technology that is redefining infection control and wound healing. Vomaris’s patented V.Dox™ Technology is defining the bioelectric wound care market; it’s the only platform in the world that powers a new generation of antimicrobial dressings for the wound and incisional care markets. The company currently has six randomized controlled trials in progress.

Vomaris and V.Dox and respective logos are trademarks of Vomaris Innovations, Inc.

 

Edixomed: Breakthrough Wound Care Technology

With Potential to Strike Back Against the Threat of Killer Superbugs

 

A simple patch which cleverly harnesses part of the body’s own natural repair system – nitric oxide – could help in the fight against killer superbugs and antibiotic resistance according to recently published studies.

 

Millions of people are at risk of dying from infections every day, many of which can no longer be treated by even the strongest antibiotics.

 

Now, in two recently published studies, a breakthrough wound care system, created by the UK firm Edixomed, has been shown to kill a range of antibiotic-resistant bacteria including MRSA and EColi, both of which have the potential to be fatal for many people.

 

The discovery could pave the way for these easy-to-use patches to be available in hospitals across the NHS to dress wounds to prevent the growth of bacteria, and tackle established infections.

 

“Bacterial infections resistant to all currently available antibiotics are expected to kill over 10 million people a year by 2050. The threat is very real and of international concern; but with this technology, we have a novel, viable and innovative solution with which to strike back. Wound care is just the first of many potential applications,” said Professor Art Tucker, St Bartholomew’s Hospital, London. He added, “Importantly, nitric oxide acts against multiple targets in bacteria to kill them, hence there is a very unlikely chance of bacteria developing resistance any time in the future.”

 

In addition, Edixomed’s breakthrough, the EDX110 wound care system, is able to deliver nitric oxide in a sustained way to give the wound or ulcer the best chance of healing. As part of the natural healing process the body normally produces nitric oxide and uses it to signal for increased blood flow and to fight infection. Edixomed’s technology effectively “supercharges” the body’s own natural healing processes.

 

In fact, recently published clinical research in diabetic foot ulcers, including infected ulcers, showed that the EDX110 patch achieved the same healing in 4 weeks as the standard-of-care approaches currently used in UK hospitals achieved at 12 weeks. The standard-of-care patients were also significantly more likely to be hospitalised due to complications with their foot ulcer.

 

“Diabetic foot ulcers are notoriously hard-to-heal and are the leading cause of diabetes-related amputations in the UK. The recently published findings provide an essential step forward in developing solutions for the effective management of these chronic wounds,” said Professor Michael Edmonds, Principal Investigator of the pivotal diabetic foot ulcer study, King’s College Hospital, London. He added, “Reducing infection and accelerating healing could significantly contribute to a reduction in the number of avoidable amputations. EDX110 represents a major step forward in best practice care.”

 

In severe cases, infection of a foot ulcer in a patient with diabetes can result in lower limb amputation or worse e.g. complications such as sepsis, multi-organ failure and death.

 

Facts:

  • The NHS carries out more than 7,300 amputations each year in the UK as a result of diabetes, 80% of these are due to foot ulcers.[4] The resulting drain on healthcare resources is enormous, with an annual cost of £1 billion to NHS England alone.[5]
  • At least 700,000 people die globally from drug-resistant infections every year – 5,000 of them in the UK.[6],[7]
  • There have been no new classes of antibiotics approved since the 1980s and the Chief Medical Officer, Professor Dame Sally Davies warned in 2017 that resistance to antibiotics “poses a catastrophic threat”.[8]

 

Key findings of the two recent studies investigating EDX110, a revolutionary new wound care system:

  • Laboratory tests have shown that EDX110 can kill all viable organisms for several deadly antibiotic-resistant infections including MRSA, Pseudomonas and E. Coli.[3]
  • Laboratory tests have shown that EDX110 effectively prevented and treated multi-drug resistant bacteria biofilms. Biofilms are colonies of bacteria that protect themselves from the body’s immune system and actions of antibiotics.[3]
  • EDX110 completely healed more ulcers compared with standard-of-care (ulcers completely healed: 49% vs. 30%).[2]
  • EDX110 reduced diabetic foot ulcer size by almost double the amount of standard-of-care (median percentage area reduction: 89% vs. 47%).[2]

 

About Edixomed

Edixomed is a biopharmaceutical company commercialising next generation and clinically-proven technologies from its nitric oxide platform. Using its patented scientific approach, the company’s technologies have the potential to tackle major global health challenges in wound care, dermatology and infection control. The core technology’s unique feature is its ability to replenish or supplement the body’s own supply of nitric oxide that is critical for sustaining healthy skin and organs. Nitric oxide is depleted or absent in many diseases and thus, the body’s normal healing and regenerative processes are damaged. Restoring that essential element is at the heart of Edixomed’s approach to innovative healthcare.

 

About EDX110

EDX110 is a revolutionary, easy-to-use, two-part wound care system, driven by Edixomed’s core sustained-release nitric oxide delivery technology. EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide. The role of nitric oxide in ulcer healing involves three recognised elements: vascular, as nitric oxide influences the widening of blood vessels (vasodilation) and stimulates the growth of new blood vessels (angiogenesis);[9],[10] inflammatory, as nitric oxide influences the body’s immune response;[11] and antimicrobial, as nitric oxide demonstrates potent, broad spectrum antimicrobial activity.

 

EDX110 is not yet an approved product, Edixomed are pursuing an active programme to develop applications of their core technology in multiple wound care indications and a number of additional areas. These areas include: surgical wound care, venous leg ulcers, pressure ulcers, burns, septic shock, transdermal drug delivery, ventilator-associated pneumonia, cystic fibrosis, and various applications connected to antimicrobial resistance.

 

About nitric oxide

The discovery that a simple gas, nitric oxide, could play such an important role in the human body led to three scientists being awarded the Nobel Prize for medicine in 1998. The pioneering work demonstrated that the normal function of nitric oxide is to control blood flow in the small vessels in the skin and prevent the skin from being infected with dangerous organisms. Nitric oxide is also generated whenever the skin is injured or damaged and plays a crucial part in the normal skin healing process. However, in certain conditions, such as diabetes, the normal production of nitric oxide can be put at risk and the skin loses the essential ingredient it needs to repair itself. The result is a chronic, poorly healing wound, highly prone to infection and a major cause of concern to patients and doctors. Replenishing the missing nitric oxide in such a way as to mimic the skin’s natural production is no easy task and it has eluded many of the world’s leading scientists for the past two decades. Edixomed has succeeded in achieving this goal and has demonstrated the performance of its technology in a pivotal clinical trial.

You can also visit our website at: http://www.edixomed.com

 

Press Release from PR Newswire

FDA 510(k) Clearance Expands Labelling of MolecuLight i:X® to Include the Ability

to Identify Regions Containing Elevated Load and More Bacterial Species

 

New FDA Clearance Illustrates the Utility of the i:X to Reliably Detect
Clinically Significant Bacteria that Impedes Wound Healing

 

TORONTO, June 29, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received an expansion to its FDA 510(k) clearance for the MolecuLight i:X® imaging device’s ability to detect the location of elevated bacterial loads (>104 CFU/g) in wounds. The expanded labelling also includes the device’s ability to identify areas of wounds containing more bacterial species, including key target pathogens of interest to the CDC that are major causes of antimicrobial resistance1. Detectable species include gram-negative and gram-positive species, aerobes and anaerobes. This expanded labeling is based on a detailed retrospective statistical analysis of over 350 patients.

 

Targeted debridement of wound using the MolecuLight point-of-care imaging device for detection of elevated bacterial burden (CNW Group/MolecuLight)

 

“We are thrilled with the FDA’s new clearance for MolecuLight’ ability to determine the location of elevated bacterial loads in wounds, in addition to the ability to identify regions with more bacterial species of interest”, says Anil Amlani, MolecuLight’s CEO. “Clinicians worldwide are using the MolecuLight device to visualize regions with clinically significant bacterial loads and more species of concern. With point-of-care information on bacterial load and its locations through use of a MolecuLight device, clinicians can act immediately to tailor their cleaning, debridement, antimicrobial strategies and treatments accordingly.”

 

This video (courtesy of Rose Raizman) illustrates the importance of visualizing the location of elevated bacterial load in a wound. In this scenario, the clinician is using MolecuLight i:X to inform their decision-making and target their wound hygiene to the areas of red fluorescence. Regions of red, indicating that the wound contains clinically significant (>104 CFU/g) levels of bacterial burden, are clearly visible on the patient’s diabetic foot ulcer (see image).

 

In addition, the FDA has also recognized MolecuLight’s ability to visualize regions containing troublesome bacterial species at the point-of-care. The MolecuLight device can be used to enable fluorescence-guided tissue biopsies to these regions to detect a higher number of pathogens of interest (defined by the CDC as increasing risk to develop antibiotic resistance) compared to standard-of-care-guided biopsies. The CDC has identified antibiotic resistance as “one of the greatest global public health challenges of our time”1. Strategies to combat antibiotic resistance include containing emerging threats through early detection and aggressive response and improving appropriate antibiotic use through antimicrobial stewardship programs. The expanded use of diagnostic tools, like MolecuLight, to improve accuracy and speed of pathogen detection has been called out to help improve appropriate antibiotic selection and reduce unnecessary antibiotic use1.

 

MolecuLight was the first to receive FDA de novo clearance for its MolecuLight i:X imaging platform and has subsequently received three additional FDA 510(k) clearances for the device.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

www.moleculight.com

 

Image: Download at: https://moleculight.box.com/s/ax8758gz0f8amouhcjjvs4xzkfa9vofo
Video: https://youtu.be/HKOCGBlIQj4

 

SOURCE MolecuLight

 

 

Targeting Bacterial Communication: Antibiotic-Free Wound Therapy



Targeting Bacterial Communication: Antibiotic-Free Wound Therapy

Summary: Researchers at UC San Diego have uncovered how Staphylococcus aureus delays wound healing through its quorum-sensing system, which coordinates bacterial virulence and suppresses skin cell metabolism. Published in The Journal of Clinical Investigation, the study demonstrates that interfering with this bacterial communication restores normal healing even in the presence of high bacterial loads, paving the way for antibiotic-free therapies to treat chronic wounds and hospital-acquired infections without promoting resistance.

Key Highlights:

  • S. aureus activates its accessory gene regulator (agr) quorum-sensing system during infection, inhibiting keratinocyte lipid enzymes essential for skin repair and dramatically slowing wound closure.
  • Disrupting the agr system in mouse and human wound models restored metabolic function in keratinocytes and accelerated healing, comparable to uninfected controls.
  • Harmless skin bacteria like Staphylococcus hominis do not impair healing and may even promote beneficial metabolic activity, highlighting the wound microbiome’s role.
  • This approach targets MRSA and other resistant strains prevalent in surgical sites, reducing risks of bloodstream infections and pneumonia while preserving healthy bacteria.
  • Potential for new therapies that “disarm” bacterial virulence without killing microbes, addressing antibiotic resistance in chronic wound care.

Read full article

Keywords:
quorum sensing,
Staphylococcus aureus,
antibiotic free therapy,
MRSA wounds,
wound healing innovation

Boruta Algorithm–Guided Antibiotic Selection in Antibiotic-Loaded Bone Cement for Diabetic Foot Ulcers

Boruta Algorithm–Guided Antibiotic Selection in Antibiotic-Loaded Bone Cement for Diabetic Foot Ulcers: Microbiota and Susceptibility Analysis

Summary: A new study explores how machine learning can improve antibiotic choices in treating diabetic foot ulcer infections (DFIs) with antibiotic-loaded bone cement. By analyzing wound microbiota and using the Boruta algorithm, researchers identified antibiotics most effective against common pathogens and highlighted the role of patient age in guiding therapy.

Key Highlights:

  • Study approach: Exudates from DFI wounds were cultured for bacterial identification and antibiotic susceptibility testing. The Boruta algorithm was applied to evaluate antibiotic effectiveness.
  • Microbiota profile: Gram-positive organisms dominated, with Staphylococcus aureus frequently isolated.
  • Antibiotic options: Gentamicin and tobramycin emerged as effective for gram-negative bacteria, while moxifloxacin, ampicillin, and quinupristin-dalfopristin showed strong performance against gram-positive isolates.
  • Influence of age: Patient age significantly affected cumulative bacterial sensitivity, suggesting the need for age-aware antibiotic protocols.
  • Clinical implications: Tailoring antibiotic selection to both pathogen profiles and patient demographics may improve DFI outcomes and reduce resistance risks.

Read the full article in Frontiers in Pharmacology

Keywords:
diabetic foot ulcer,
antibiotic-loaded bone cement,
Boruta algorithm,
bacterial microbiota,
antibiotic susceptibility,
wound infection management

Maggots used to clean wounds in NHS as antibiotics fail some patients

Live maggots are being increasingly used to clean wounds by the NHS amid the threat of antibiotic resistance threatening patients’ well-being … According to a report in The Daily Telegraph, the treatment – which involves applying sterilised fly larvae to wounds to eat dead tissue – was common practice in the first half of the 20th century, but faded with the use of antibiotics in the 1940s … However, thanks to antibiotic resistance, maggots are again being used in the NHS and overseas. The paper reports that superbugs kill around 700,000 people a year, a figure predicted to reach 10 million by 2050 … read more

Antimicrobial resistance and antimicrobial stewardship: an update

Antimicrobial Resistance & Stewardship: A Wound-Care Update

Published in Volume 33, Issue 2 of Wound Practice & Research (June 2025), this narrative review by Mark G. Rippon, Alan A. Rogers, and Karen Ousey explores the growing global challenge of antimicrobial resistance (AMR) and its implications for wound care. The article underscores the urgency of implementing robust antimicrobial stewardship (AMS) strategies in both acute and chronic wound management.

Key Highlights:

  • Rising Threat of AMR: The misuse and overuse of antibiotics have contributed to rising resistance in wound pathogens, particularly in biofilm-associated infections that are difficult to eradicate.
  • Core Elements of Stewardship: AMS programs emphasize the judicious use of antimicrobials—optimizing drug selection, dosage, treatment duration, and administration route to reduce resistance and improve outcomes.
  • Biofilm Considerations: Biofilms in chronic wounds complicate treatment due to their tolerance to antibiotics and host defenses, reinforcing the need for tailored AMS approaches in wound care settings.
  • Alternative Strategies: The review discusses the role of antimicrobial dressings, bacteriophage therapy, and novel bioengineered compounds as potential tools to reduce reliance on systemic antibiotics.
  • Global AMS Initiatives: Effective stewardship requires a multidisciplinary approach, incorporating surveillance, diagnostic stewardship, prescribing audits, and education at all levels of care.

As wound-related infections continue to evolve, the integration of AMS principles into clinical practice is critical to sustaining effective treatment options and minimizing the spread of resistance.

Keywords:
Mark G. Rippon,
Alan A. Rogers,
Karen Ousey,
antimicrobial resistance,
antimicrobial stewardship,
chronic wound infection,
biofilm,
antimicrobial dressing

Read the full article in Wound Practice & Research

New combination drug therapy offers hope for treating chronic wound infections

Chronic Wound Infections: New Drug Therapy Hope

Summary: Scientists at the University of Oregon have identified a promising new therapy that combines low-dose chlorate with standard antibiotics to fight chronic wound infections. In laboratory tests against Pseudomonas aeruginosa, a common and stubborn wound pathogen, this combination improved antibacterial effectiveness by as much as 10,000-fold. The discovery could help restore the power of existing antibiotics, reduce treatment time, and minimize side effects for patients struggling with infected chronic wounds.

Key Highlights:

  • New mechanism: Chlorate disrupts bacterial nitrate metabolism in low-oxygen wound environments, making pathogens more susceptible to antibiotics.
  • Improved potency: Antibiotic efficacy increased dramatically, allowing for potential dose reductions.
  • Clinical potential: The approach may shorten treatment duration, improve outcomes, and reduce toxicity in patients with chronic wound infections.
  • Resistance relevance: This method could help combat antibiotic resistance by enhancing the effectiveness of existing drugs.
  • Next steps: Further research and human clinical trials are needed to determine safety, dosage, and real-world effectiveness.

Read the full article on Time.News

Keywords:
Melanie Spero,
University of Oregon,
chlorate,
antibiotic synergy,
Pseudomonas aeruginosa,
chronic wound infection

Healthcare-Acquired Wound Infections and Antimicrobial Resistance – webinar

Healthcare‑Acquired Wound Infections & Antimicrobial Resistance: Embracing a Multidisciplinary Team Approach

Presented on June 19, 2025, this free, on‑demand webinar by WoundSource addresses the growing risks of hospital‑acquired wound infections and the escalating problem of antimicrobial resistance (AMR). Featuring insights for clinicians on integrating multidisciplinary strategies for prevention, management, and stewardship.

Key Highlights:

  • Rising Infection Risks: Covers the prevalence and serious complications associated with healthcare‑acquired wound infections, including surgical site infections, device‑related wounds, and pressure injuries. :contentReference[oaicite:1]{index=1}
  • Antimicrobial Resistance Challenge: Discusses how multidrug-resistant organisms complicate treatment, leading to increased morbidity, mortality, and healthcare costs. :contentReference[oaicite:2]{index=2}
  • Multidisciplinary Protocols: Emphasizes collaborative best practices involving infection control experts, microbiologists, pharmacists, nursing staff, and wound specialists to optimize prevention and management.
  • Stewardship Strategies: Promotes antimicrobial stewardship programs, including robust surveillance, appropriate antibiotic selection, targeted therapy, and review of antibiotic duration to minimize resistance pressure.
  • Clinical Practice Adaptations: Highlights the use of evidence‑based dressings, modality selection, debridement protocols, and early identification to reduce colonization and infection rates.

Watch the full webinar on the WoundSource website.

Keywords:
healthcare-acquired infections,
antimicrobial resistance,
multidisciplinary team,
antimicrobial stewardship,
wound infection prevention

Antimicrobial Activity of Jatropha curcas Latex Against Cutaneous Wound and Burn Infections

Antimicrobial Activity of Jatropha curcas Latex Against Cutaneous Wound and Burn Infections

A recent study published in Infection and Drug Resistance explores the potential of Jatropha curcas latex as a topical antimicrobial for wound and burn care. The research team, led by Ali Salman Al‑Shami and Mokhtar Alzomor, investigated the plant’s latex against several antibiotic-resistant pathogens commonly implicated in skin infections.

Key Highlights:

  • Pathogens Tested: The study targeted Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Candida albicans.
  • Results: J. curcas latex demonstrated significant antimicrobial activity, producing inhibition zones as large as 31 mm for S. aureus and showing promising minimum inhibitory concentration (MIC) values ranging from 6.25 to 25 mg/mL.
  • Comparative Effectiveness: In many cases, the latex outperformed standard antibiotics like tetracycline and ofloxacin, suggesting potential as a natural alternative or adjunct therapy.
  • Mechanism: The latex contains bioactive compounds such as flavonoids, saponins, and tannins, which may contribute to its antimicrobial properties.

Conclusion: The authors conclude that Jatropha curcas latex holds promise as a broad-spectrum topical agent, especially in regions facing antibiotic resistance. Further in vivo research is needed to establish clinical safety and efficacy.

Keywords:
Ali Salman Al‑Shami,
Mokhtar Alzomor,
Jatropha curcas,
burn infections,
natural antimicrobials,
antibiotic resistance,
wound healing

Read the full article here

The Trial Design of the Concurrent Optical and Magnetic Stimulation Therapy Study for Refractory Diabetic Foot Ulcers

Antimicrobial Activity of Jatropha curcas Latex Against Cutaneous Wound and Burn Infections

Published July 22, 2025 in *Infection and Drug Resistance*, this study by **Ali Salman Al‑Shami, Mokhtar Alzomor** and colleagues from Sanaa University, Yemen evaluates the antimicrobial efficacy of Jatropha curcas latex against pathogens commonly found in burn and wound infections.

Study Summary:

  • Context: The authors investigated Jatropha curcas latex as a potential topical antimicrobial agent, exploring its relevance amid rising antibiotic resistance in burn and wound care.
  • Methods: Extracted latex underwent phytochemical analysis and was tested via agar well diffusion, disc diffusion, and broth dilution against clinical isolates of *S. aureus*, *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and *Candida albicans*, with standard antibiotics (tetracycline, ofloxacin, fluconazole) as comparators.
  • Results: J. curcas latex achieved inhibition zones of 23–31 mm (e.g., 31.3 mm for *S. aureus*), and MICs ranged from 6.25 mg/mL (*E. coli/K. pneumoniae/C. albicans*) to 25 mg/mL (*S. aureus/P. aeruginosa*), outperforming or matching conventional drugs :contentReference[oaicite:1]{index=1}.
  • Conclusions: The study supports J. curcas latex as a promising broad-spectrum topical antimicrobial for burn and wound infections, particularly where antibiotic-resistant organisms are prevalent. Further in vivo safety and efficacy studies are recommended.

This research underscores the therapeutic potential of plant-derived antiseptics such as J. curcas latex, which may offer effective alternatives or adjuncts to conventional antimicrobials in evolving wound care scenarios.

Keywords:
Ali Salman Al‑Shami,
Mokhtar Alzomor,
Jatropha curcas,
latex topical antimicrobial,
burn wound infection,
antibiotic resistance,
MIC

Read the full study on Dove Press

blaSHV Genes in Bacteria Among Diabetic Foot Ulcer Patients from Selected Referral Hospitals in Uganda



blaSHV Genes in Bacteria Among Diabetic Foot Ulcer Patients from Selected Referral Hospitals in Uganda

Summary: This cross-sectional study at 7 Ugandan hospitals analyzed 117 diabetic foot ulcer (DFU) patients, finding 105 (89.7%) positive for bacterial growth, predominantly Gram-negative (E. coli, Klebsiella). ESBL production was 37.1% (39/105), with blaSHV genes in 71.8% of ESBL isolates, driving high resistance to cephalosporins (90%) and amoxicillin (95%). Gram-positives like S. aureus showed MRSA at 20%. The findings underscore the need for routine ESBL screening, antibiotic stewardship, and surveillance in DFU management to curb infection-driven amputations in low-resource settings.

Key Highlights:

  • Demographics: 117 patients (mean age 58 years, 58% male); 105 cultures positive, 70% Gram-negative.
  • ESBL Prevalence: 37.1%; blaSHV (28/39), blaTEM (24/39); multi-drug resistance in 82% ESBL producers.
  • Resistance Patterns: 90% to 3rd-gen cephalosporins; 95% to amoxicillin; carbapenems effective (85%).
  • Site Variation: Higher ESBL in urban hospitals (Kiruddu 50%, Fort Portal 46%); S. aureus in 30%.
  • Implications: Urgent stewardship; molecular surveillance for DFU pathogens to guide therapy and reduce amputations.

Read full article

Keywords: blaSHV genes, ESBL, diabetic foot ulcers, antibiotic resistance, Uganda DFU

N-Acetyl-Cysteine Increases Activity of Peanut-Shaped Gold Nanoparticles Against Biofilms

Formed by Clinical Strains of Pseudomonas aeruginosa Isolated from Sputum of Cystic Fibrosis Patients
Despite the clinical introduction of a spectrum of therapeutics with anti-bacterial and/or anti-inflammatory activities along with agents facilitating clearance of airways from thick and dehydrated sputum, the mortality rate of patients suffering from cystic fibrosis (CF) is still alarmingly high.1 Chronic inflammation and persistent Pseudomonas aeruginosa colonization are recognized as the major causes of lung tissue damage, lung transplantation, and mortality in CF subjects.2 Regardless of the intravenous or inhaled antibiotic therapies, the efficient treatment of pulmonary infections is considerably hampered mostly by the intrinsic or acquired resistance of P. aeruginosa to a variety of antibiotics,3 which is reinforced by its ability to produce drug-resistant biofilms. The latter is defined as three-dimensional communities of bacteria enclosed and protected by a self-produced extracellular polymeric substance (EPS) matrix, composed of polysaccharides (alginate), lysed cell debris proteins, lipids, extracellular DNA (eDNA), and bacteria-specific factors.4 Importantly, bacteria growth within biofilm in CF lungs is associated with their adaptation to antibiotics used frequently in the therapy of reoccurring pneumonia in CF patients. In this condition, an increased number of mutations associated with antibiotic resistance is generated. Such decreased susceptibility to the applied treatment followed by a lower metabolic rate of biofilm-embedded bacteria and their persistence makes the eradication of biofilms a challenging task.4 An approach to treat lung infections in patients with CF has evolved beyond antibiotic therapy, with the implementation of various airway clearance techniques (ACTs), in particular mucus thinners, to eliminate excess sputum … read more

Electrically charged bandages help to heal burn wounds

     combat antibiotic resistance

 

Researchers from the Ohio State University Wexner Medical Center have developed special electrically charged bandages that can prevent infections, combat antibiotic resistance and enable healing in burn wounds. This type of dressing turns electrically active when it comes in contact with bodily fluids. According to Dr. Chandan Sen, director of Ohio State’s Center for Regenerative Medicine and Cell Based Therapies, who led the study with colleagues at the Medical Center’s Comprehensive Wound Center and Center for Microbial Interface Technology, “Drug resistance in bacteria is a major threat, and antibiotic-resistant biofilm infections are estimated to account for at least 75 percent of bacterial infections in the United States. This is the first pre-clinical long-term porcine study to recognize the potential of ‘electroceuticals’ as an effective platform technology to combat wound biofilm infection.”

Read more at: https://gineersnow.com/industries/medical/electrically-charged-bandages-can-fight-infections

Use of Polyhexamethylene Biguanide in the Treatment of Atopic Dermatitis With

Use of Polyhexamethylene Biguanide in the Treatment of Atopic Dermatitis With Staphylococcus Aureus Hypercolonization

A case report published in Wounds (June 2025) details the successful use of polyhexamethylene biguanide (PHMB) dressings in two adolescents with atopic dermatitis complicated by biofilm-forming Staphylococcus aureus colonization. Both patients experienced resolution of lesions after four weeks of treatment, following failed antibiotic therapy.

Key Highlights:

  • Patient 1: A 16-year-old female with exudative AD plaques showed complete resolution after 14 days of PHMB dressing, combined with fusidic acid and a barrier cream regimen.
  • Patient 2: A 17-year-old male treated with daily PHMB applications experienced marked improvement, enabling initiation of systemic immunosuppression.
  • Mode of Action: PHMB disrupts bacterial cell membranes and penetrates biofilm structures, reducing bacterial burden without fostering resistance common in traditional antibiotics.
  • Clinical Takeaway: These cases support PHMB as a practical and effective adjunctive strategy for treating biofilm-associated dermatitis in adolescents.

PHMB may offer clinicians a low-resistance, biofilm-targeting approach to managing chronic or recurrent AD flares where conventional therapies have failed.

Keywords:

polyhexamethylene biguanide,
atopic dermatitis,
Staphylococcus aureus,
biofilm,
antibiotic resistance,
adolescent dermatology

Read the full case report on HMP Global Learning Network

Antimicrobial stewardship in wound care: measurement, implementation, and outcomes


Antimicrobial stewardship in wound care: measurement, implementation, and outcomes

Summary: This article examines antimicrobial stewardship (AMS) specifically within wound care, outlining frameworks to measure antibiotic use, implement stewardship interventions, and assess clinical outcomes while minimizing resistance and toxicity.

Key Highlights:

  • Defines AMS metrics relevant to wounds: antibiotic days, spectrum intensity, guideline adherence, culture-guided therapy.
  • Describes implementation strategies: care pathways, education, formulary controls, and microbiology collaboration.
  • Recommends outcome tracking: healing rates, infection recurrence, adverse drug events, and resistance trends.
  • Emphasizes biofilm-aware practice, debridement, and topical/antiseptic stewardship alongside systemic therapy.

Read the article in WPR

Keywords:
antimicrobial stewardship,
wound infection,
antibiotic resistance,
biofilm

Atom Insights, Superbug Cure & Healing Advances – Oct 29, 2025



Science News: Atom Insights, Superbug Cure & Healing Advances – Oct 29, 2025

Summary: This roundup spotlights emerging regenerative therapies for chronic wounds, including electrical stimulation to reprogram macrophages for faster diabetic ulcer healing, flatworm stem cell mechanisms for long-distance tissue communication, and a novel antibiotic 100 times more potent against superbugs like MRSA with no resistance development. Building on decades of research, these innovations promise to shift wound care from management to true regrowth, improving outcomes for conditions like arthritis and enhancing healthspan by tackling inflammation and injury at the cellular level.

Key Highlights:

  • Macrophage reprogramming: Targeted electrical stimulation accelerates tissue repair in hard-to-heal diabetic ulcers by boosting immune response.
  • Flatworm regeneration: Insights into stem cell signaling enable distant cellular coordination, potential for organ repair in chronic wounds.
  • Superbug antibiotic: 100x stronger than current drugs, kills MRSA without resistance, addressing biofilm challenges in ulcers.
  • Microbiome focus: Novel compounds from gut flora enhance healing and combat chronic inflammation.
  • Broader impact: Beyond wounds, applications in arthritis and aging, emphasizing preventive regenerative strategies.

Read full article

Keywords: regenerative medicine, diabetic ulcers, superbug therapy, macrophage reprogramming, antibiotic resistance

Chemical Compound Supercharges Antibiotics to Fight Chronic Wound Infections

Chemical Compound Supercharges Antibiotics to Fight Chronic Wound Infections

Summary: Researchers have identified a chemical compound that potentiates antibiotic efficacy against *Pseudomonas aeruginosa* in chronic wound models. When combined, the compound and antibiotics significantly improved bacterial killing, potentially overcoming resistance in wound pathogens.

Key Highlights:

  • Synergistic effect: The compound improves antibiotic penetration or disrupts bacterial defenses in biofilm-laden wounds.
  • Model results: In vitro and ex vivo wound assays showed significantly higher kill rates compared to antibiotics alone.
  • Resistance implications: The strategy may help reclaim lost efficacy of existing antibiotics in chronic wound management.
  • Next steps: Authors call for in vivo trials, safety profiling, and exploration of delivery methods suitable for wound environments.

Read the article on ContagionLive

Keywords:
antibiotic potentiator,
chronic wound infections,
biofilm disruption,
drug synergy

Two-drug combination shows promise in helping heal chronic wounds

Two-drug combination shows promise in helping heal chronic wounds

Summary: A team at the University of Oregon discovered that pairing low-dose chlorate with conventional antibiotics increased antibacterial effectiveness by 10,000-fold against *Pseudomonas aeruginosa* in lab settings. This synergy offers a potential new strategy for tackling stubborn infections in chronic wounds, including those seen in diabetic foot ulcers.

Key Highlights:

  • Synergistic effect: Chlorate enhances antibiotic potency, making bacteria much more vulnerable even under resistant conditions.
  • Reduced dosing risk: The combination allows lower antibiotic dosages, potentially reducing side effects and toxicity.
  • Mechanistic hint: Chlorate may interfere with bacterial nitrate respiration under low-oxygen wound conditions, stressing cells and exposing them to antibiotics.
  • Clinical relevance: If translated to humans, this approach could shorten treatment durations and improve outcomes in chronic wound infections.
  • Next steps: The authors note that complex wound microbiomes and in vivo testing must be addressed before clinical use.

Read the full news release

Keywords:
Melanie Spero,
chlorate antibiotic synergy,
Pseudomonas aeruginosa,
chronic wound infection,
antibiotic resistance strategy

Staphylococcus Aureus Delays Wound Healing



UC San Diego Study: Staphylococcus Aureus Delays Wound Healing

Summary: Researchers at UC San Diego have identified how Staphylococcus aureus, a common cause of skin infections, delays wound healing via its quorum sensing system—a bacterial communication method that suppresses host immune responses and tissue repair. Published in a leading medical journal, the study demonstrates that targeting this pathway can restore normal healing processes without antibiotics, offering a novel approach to combat antibiotic resistance while preserving beneficial skin microbiota.

Key Highlights:

  • S. aureus quorum sensing coordinates virulence factors that inhibit keratinocyte metabolism and wound closure, even at low bacterial loads.
  • Disrupting the accessory gene regulator (agr) system in mouse and human models accelerates healing to levels seen in uninfected wounds.
  • This method targets resistant strains like MRSA without killing bacteria, reducing risks of resistance and secondary infections.
  • Potential for precision therapies that enhance existing wound care by selectively silencing bacterial signals while supporting skin regeneration.
  • Findings highlight the wound microbiome’s role, where harmless staphylococci may aid healing unlike pathogenic S. aureus.

Read full article

Keywords:
Staphylococcus aureus,
quorum sensing,
antibiotic free wound therapy,
MRSA management,
wound healing innovation

Microbiological Identification and Resistance Profile of Microorganisms in Pressure Injuries

After the Use of Polyhexamethylene Biguanide: A Series of Fourteen Cases
Introduction. Colonization of a pressure injury with microorganisms can negatively affect wound healing. Thus, it is necessary to evaluate which products best facilitate wound healing. Objective. This case series evaluated the effectiveness of the antimicrobial polyhexamethylene biguanide (PHMB) on microorganisms in pressure injuries. Materials and Methods. Fourteen patients (14 wounds) were treated with PHMB in the hospital setting after collection of a wound swab sample for microbiological analysis and determination of the risk profile using the disk diffusion method. Results. Thirteen lesions (92.9%) were positive for 1 or more bacterial strains, the most prevalent of which were Staphylococcus aureus and Pseudomonas aeruginosa. Two strains of methicillin-resistant S aureus (MRSA) were also identified. Klebsiella pneumoniae demonstrated 100% resistance to the tested antibiotics, with Acinetobacter demonstrating 90% resistance … read more

Multidrug-Resistant Organisms in Wound Management

Among the greatest triumphs of modern medicine were the identification and naming of the Penicillium mold by Alexander Fleming in 1928, and its ability to inhibit bacteria growth on culture medium. Penicillin was then developed by the team of Heatley, Chain, and Florey in England during the Second World War.1 This miracle brought about the ability to cure previously untreatable diseases and devastating infections that had high morbidity and mortality rates. Along with the great efficacy of penicillin was the added benefit of very few side effects. This area of research brought about the era of antibiotic production, which began in the 1950s.

 

Mechanisms of Antibiotic Resistance and Implications for Health Care
Antibiotics target one or multiple modes of cellular communication which allow microorganisms to proliferate. These include cell wall, membrane transport, RNA function, DNA synthesis, protein function, or enzyme activity.2 Interrupting cellular communication and thus proliferation has made antibiotics very effective against a broad range of microoganisms. In looking at the history of multidrug-resistant organisms (MDROs) we must remember that there are two sides to every coin, and with the positive side of clinical efficacy against microoganisms there is also a downside. To ensure their survival, it has become necessary for microorganisms to evolve and genetically mutate. These processes have caused the organisms of today to be much different from the organisms of yesterday, much more virulent, and more multidrug resistant … read more

Timing of Preoperative Prophylactic Antibiotics

Timing of Preoperative Prophylactic Antibiotics

Summary: A recent blog post on WoundSource emphasizes that surgical prophylactic antibiotics should be administered ideally 30 to 60 minutes before incision to ensure optimal tissue concentrations and reduce surgical site infection (SSI) risk.

Key Highlights:

  • Research shows the best effectiveness occurs when prophylactic antibiotics are given at least 30 minutes—but no more than 60 minutes—before incision.
  • National guidelines align with this timing window, though some agents such as vancomycin or fluoroquinolones require longer infusion times and may begin up to 120 minutes pre-incision.
  • Large cohort studies involving hundreds of thousands of patients confirm that antibiotics delivered within 0–30 minutes before incision result in the lowest SSI rates.
  • Compliance remains a challenge—many hospitals still fall short of these standards, underscoring the need for process improvements to optimize SSI prevention.

Read the full post on WoundSource

Keywords:
preoperative antibiotics,
surgical site infection,
SSI prevention,
antibiotic timing

Essity joins United Nations Foundation expert group in tackling antimicrobial resistance

Hygiene and health company Essity expands its partnership with United Nations (UN) Foundation by joining a cross-industry group that brings together corporate experts in the fight against antimicrobial resistance (AMR). Essity is a global provider of hand hygiene and wound care solutions, essentials in the fight against antimicrobial resistance, one of the greatest global public health threats predicted to be responsible for 10 million annual deaths worldwide by 20501. Essity has been a partner to the United Nations Foundation since 2017 … read more

Micreos secures €32 million for its endolysin-based platform as sustainable alternative to antibiotics

THE HAGUE, The Netherlands, Sept. 30, 2021 /PRNewswire/ — Dutch biotechnology company Micreos announced it has secured another €32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Endolysins as precision anti-bacterials

In its search for solutions, Micreos’ researchers, in close collaboration with the Swiss Federal Technology Institute ETH Zurich, turned to nature’s own precision anti-bacterials, named endolysins. Unlike antibiotics, these highly specific enzymes have the ability to target only unwanted bacteria, while preserving the microbiome, comprising billions of ‘good’ bacteria, essential for our health. Endolysins are safe and environmentally friendly. Because of their working mechanism, development of resistance is not expected.

Addressing unmet medical needs

XZ.700 targets Staphylococcus aureus (S. aureus), including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing. SP.800 targets all staphylococcal species … read more

Kane Biotech Secures $800K to Accelerate Revyve Wound Portfolio



Kane Biotech Secures $800K to Accelerate Revyve Wound Portfolio

Summary: Kane Biotech (TSX-V: KNE) launches non-brokered private placement: up to 16M shares at $0.05 for $800K gross, closing ~Dec 17, 2025. Funds support working capital, advancing Revyve line against biofilms (key to resistance/poor healing). Gel/Spray FDA-cleared/Health Canada-approved; Cleanser submitted Sep 2025 (pending). Insiders may join; shares hold 4+ months. Stock at $0.035 (52-wk: $0.03–0.13). Bolsters chronic wound solutions amid rising biofilm challenges.

Key Highlights:

  • Funding: $800K (16M shares @ $0.05); close Dec 17, 2025.
  • Portfolio: Revyve Gel/Spray cleared; Cleanser pending FDA.
  • Target: Microbial biofilms in chronic wounds.
  • Stock: $0.035 (Nov 27 close); insiders participating.
  • Authors: Kane Biotech Inc. (announcement).

Read full article

Keywords: Kane Biotech, Revyve, biofilm, private placement, wound gel, antibiotic resistance

Analysis of the Therapeutic Effect of Antibiotic Bone Cement on Wagner Grade 3 or 4 Diabetic Foot Ulcer ….



Comparative Analysis of the Therapeutic Effect of Antibiotic Bone Cement on Wagner Grade 3 or 4 Diabetic Foot Ulcer in Heel and Non-Heel Areas: A Retrospective Cohort Study

Summary: Retrospective PSM cohort (n=50) compared antibiotic bone cement (ABC) + wound surgical integrated treatment (WSIT) for Wagner 3/4 DFUs: heel (hDFU) vs non-heel (nhDFU). Post-PSM, major amputation rates were similar (12% vs 8%, p=1.0), despite hDFU’s higher baseline WBC/albumin deficits. ABC reduced WBC significantly (p<0.01), confirming infection control. Alcohol abuse/hypoalbuminemia were key risk factors (RR 1.12/1.01).

Key Highlights:

  • Outcomes: Amputation 12% vs 8%; LOS ~31 days both (p>0.05).
  • Infection: WBC ↓ 11.94 to 9.03 in hDFU (p=0.004).
  • Risks: Alcohol RR 1.123 (p<0.05); hypoalbuminemia RR 1.010.
  • Method: PSM for balance; multivariable Poisson regression.
  • Authors: Yang Jian, Li Li, Wei Chen et al.

Read cohort study

Keywords: antibiotic bone cement, Wagner 3 4, hDFU, infection control, PSM, Yang Jian, Li Li, Wei Chen

Use of Oral Antibiotics for Diabetic Foot Osteomyelitis



Use of Oral Antibiotics for Diabetic Foot Osteomyelitis: A Systematic Review

Summary: This PRISMA-guided systematic review (MEDLINE/EMBASE to July 2024) analyzed 26 studies (4 RCTs, 22 observational, n=972 DFO patients) on oral antibiotics (monotherapy 73.8%, step-down 26.2%). Mean duration 95 days; follow-up 12 months. Complete resolution: 75% monotherapy, 56% step-down; overall 70%. Recurrence low (5%). AEs in 24% (mostly mild GI/liver); no deaths. Oral therapy comparable to IV for efficacy, with advantages in cost/accessibility; supports outpatient/low-resource use with stewardship.

Key Highlights:

  • Efficacy: 70% complete/partial resolution; 22% no resolution/amputation.
  • Safety: 44 AEs (mild); 2 discontinuations.
  • Classes: Penicillins 44%, fluoroquinolones 17%.
  • Limitations: Heterogeneity, few RCTs, reporting bias.
  • Authors: Siddhartha Sood, Ryan Geng, Jihad Waked, Asfandyar Mufti et al.

Read full review

Keywords: oral antibiotics, DFO, osteomyelitis, outpatient, stewardship, Siddhartha Sood, Ryan Geng, R Gary Sibbald

Limb salvage surgery in diabetic foot infection: encouraging early results with a local antibiotic carrier

NL Vasukutty, S Mordecai, A Tarik, M Subramaniam, B Srinivasan

 

Diabetic foot disease is associated with high morbidity and is one of the leading causes of lower limb amputation. The use of a local antibiotic carrier to augment debridement and reconstructive procedures is presented. Methods: The authors present early results of 48 feet in 47 patients from two centres in the UK. Their multidisciplinary protocol involved pre-operative assessment, debridement, culture-specific antibiotics and local antimicrobial management with an antibiotic-loaded biocomposite (CERAMENT G®, BONESUPPORT, Lund, Sweden). Of the 48 feet, 22 (46%) had various foot reconstructive procedures. Six patients had pre-operative revascularisation procedures. All patients were graded as either University of Texas 3B or 3D ulcers. Results: At a mean follow-up of 33 months (range 13–49 months), 42 feet (88%) were free of infection and 39 patients (83%) were mobilising. There were 28 wounds healed by secondary intention, 17 with primary closure and three required skin grafting. Three patients had non-healing and persisting ulcers at the most recent follow-up. Three patients had undergone below–knee amputation. The average time to wound healing was 16 weeks (range 3–24 weeks). A limb salvage rate of 94% was achieved … read more

Growing Evidence That Oral Antibiotics are the New IV

A recent systematic review in the American Journal of Medicine aims to challenge the dogma surrounding antibiotic therapy for certain types of infections, including osteomyelitis.1 This constitutes superb work from Wald-Dickler and coworkers, adding to the growing body of evidence that (to coin a phrase from senior author Brad Spellberg, MD) shorter may be better and oral greater than IV … Researchers set out to evaluate if current data supports long-standing tenets regarding the superiority of IV antibiotics for the full treatment course for osteomyelitis, bacteremia and infective endocarditis. Their review included 7 randomized controlled trials regarding osteomyelitis, specifically. None of the 21 total studies among all examined infections demonstrated superiority of IV-only antibiotic treatment … read more

New technology for accelerated wound healing discovered

Researchers have found a new way of accelerating wound healing. The technology and the mode of action involves using lactic acid bacteria as vectors to produce and deliver a human chemokine on site in the wounds. The research group is the first in the world to have developed the concept for topical use and the technology could turn out to be disruptive to the field of biologic drugs … Researchers at Uppsala University and SLU have found a new way of accelerating wound healing. The technology and the mode of action method published in the highly ranked journal PNAS involves using lactic acid bacteria as vectors to produce and deliver a human chemokine on site in the wounds. The research group is the first in the world to have developed the concept for topical use and the technology could turn out to be disruptive to the field of biologic drugs … Treatment of large and chronic wounds are a high cost burden to the health care system since effective tools to accelerate healing are lacking. Wound care is today limited to mechanical debridement, use of different dressings and significant amounts of antibiotics preventing or treating wound infections. With the aging population, occurrence of chronic diseases such as diabetes and the alarming global spread of antibiotic resistance, a treatment that kick-starts and accelerates wound healing … read more

Pherecydes Pharma Organizes a Scientific Symposium During the 23rd National Days of Infectiology

Pherecydes Pharma (FR0011651694 – ALPHE, PEA-PME eligible), a biotech company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces it will participate to the scientific symposium “Phage therapy: French experience”, which will be held on June 15, 2022 from 5:15 pm to 6:30 pm in the amphitheater A of the Palais des Congrès in Bordeaux, as part of the 23rd National Days of Infectiology (NDI).

 

The symposium, moderated by Dr. F.-A. Dauchy from the Bordeaux University Hospital, will host the following presentations:

 

Phagotherapy and IOA. Compassionate cases and clinical studies including PhagoDAIR: Pr. T. Ferry (Lyon)
Phage therapy and Infections of the Diabetic Foot Ulcer. State of knowledge. PhagoPied: Pr. A. Sotto (Nîmes)
Phage therapy and pulmonary infections. Preclinical results. Planned clinical studies: Dr. A. Bleibtreu (Paris)
Pascal Birman, Medical Director of Pherecydes Pharma, comments: “Antibiotic resistance is a major public health issue and is a central theme at this 23rd edition of the NDI. This symposium is an opportunity to highlight the interest of phage therapy through several clinical studies that will be conducted in different indications and through compassionate treatments already performed with our phages. Pherecydes Pharma and its partners are doing their utmost to ensure that these studies provide useful answers to improve the treatment of patients suffering from antibiotic resistant infections.”

 

About Pherecydes Pharma

Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The Company has developed an innovative approach, precision phage therapy, based on the use of phages, natural bacteria-killing viruses. Pherecydes Pharma is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two thirds of hospital-acquired resistant infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied in several dozen patients in the context of compassionate use, under the supervision of the French National Agency for the Safety of Medicines (ANSM). Headquartered in Nantes, Pherecydes Pharma has a team of around twenty experts from the pharmaceutical industry, biotechnology sector and academic research.

 

For more information, www.pherecydes-pharma.com

 

Contacts
Pherecydes Pharma
Thibaut du Fayet
Deputy CEO
investors@pherecydes-pharma.com

 

NewCap
Dusan Oresansky
Investor Relations
pherecydes@newcap.eu
T.: +33 1 44 71 94 92

 

NewCap
Arthur Rouillé
Media Relations
pherecydes@newcap.eu
T.: +33 1 44 71 00 15

 

This article was originally published here

A Global Consensus on Diabetic Wound Management

Global Consensus on Diabetic Wound Management: Practical, Evidence-Informed Guidance

Summary: A consensus statement published in Advances in Wound Care (2025) synthesizes expert guidance on evidence-based bedside management of diabetic wounds. It encompasses a comprehensive care framework—from addressing inflammation and glycemic control to infection containment, vascular evaluation, offloading, surgical options, pain relief strategies, dressing selection, and emerging therapies.

Expert Contributors:
Henry C. Hsia; Elof Eriksson; Geoffrey C. Gurtner; Aristidis Veves; Osama Hamdy; David J. Margolis; David G. Armstrong; Lawrence A. Lavery; Elisabeth A. Grice; Greg Schultz; Michael S. Conte; Robert S. Kirsner; Christopher E. Attinger; John S. Steinberg; Karen K. Evans; Dot Weir; Paul J. Kim; Dennis P. Orgill; Kenneth W. Liechty; J. Peter Rubin.

Take-Home Points:

  • Chronic diabetic wounds often stem from persistent, low-grade inflammation; goal-directed care must redirect the wound toward healing.
  • Optimized diabetic wound care is inherently multidisciplinary—requiring tight glycemic management, infection and biofilm control, vascular assessment (e.g., WIfI), timely revascularization, effective offloading, and when needed, surgical intervention.
  • Given rising antibiotic resistance, routine debridement and biofilm-focused topical practices are essential; systemic antibiotics should be reserved for invasive infections.
  • Limb preservation should prioritize restoring ambulation and quality of life—beyond the goal of saving tissue at any cost.

Read the full consensus statement on DiabeticFootOnline

Keywords:
diabetic wound management,
Advances in Wound Care,
WIfI system,
chronic inflammation,
biofilm management,
multidisciplinary care,
limb salvage

The Cling of Doom: How Staphylococcus aureus Latches onto Human Skin

The Cling of Doom: How Staphylococcus aureus Latches onto Human Skin

Summary: A new study reported by EurekAlert! shows that the staph adhesin SdrD binds to human desmoglein-1 with the strongest non-covalent protein-protein bond measured to date; calcium further strengthens this interaction, offering a fresh anti-adhesion target to help combat resistant infections.

Key Highlights:

  • SdrD–desmoglein-1 forms an ultra-strong biological bond that helps staph resist washing, sweating, and mechanical forces.
  • Calcium is a key regulator: lowering Ca²⁺ weakens the bond; restoring Ca²⁺ reinforces it.
  • Findings suggest anti-adhesion strategies (blocking SdrD/Dsg1) as a complementary path to antibiotics.

Read the news release on EurekAlert!

Keywords:
Staphylococcus aureus,
desmoglein-1,
SdrD,
skin adhesion,
antibiotic resistance

Smart Hybrid Nanomaterials for Chronic Infections



Smart Hybrid Nanomaterials for Chronic Infections: Microbiome-Responsive and Sustainable Therapeutic Strategies

Summary:** This review explores smart hybrid nanomaterials for treating chronic infections in diabetic foot ulcers (DFUs), leveraging microbiome-specific triggers like pH, redox, or enzymes for on-demand drug release. DFUs, affecting 15-25% of diabetics, often involve biofilms and antibiotic resistance, leading to amputations. Nanomaterials—liposomes, dendrimers, metal-organic frameworks—enhance penetration, target bacteria, and minimize side effects, with examples like pH-sensitive liposomes releasing vancomycin in acidic infected sites. Sustainable aspects include biodegradable polymers and green synthesis, promising cost-effective, localized therapies to overcome systemic antibiotic limitations in DFU management.

Key Highlights:

  • DFU Pathogenesis: Neuropathy, ischemia, and hyperglycemia foster biofilms; 50% become infected, with 20% requiring amputation.
  • Nanomaterial Types: Liposomes for encapsulation, dendrimers for branching delivery, MOFs for high loading; responsive to bacterial metabolites.
  • Mechanisms: pH/redox-responsive release in infected microenvironments; photothermal therapy with nanoparticles kills bacteria via heat.
  • Sustainability: Biodegradable carriers reduce environmental impact; green synthesis using plant extracts for eco-friendly production.
  • Challenges/Future: Clinical translation needed; combination with phage or CRISPR for multi-modal DFU therapy.

Read full article

Keywords: nanomaterials, diabetic foot ulcers, microbiome-responsive, biofilm therapy, sustainable nanotech

Quick Guide: Cutimed® Sorbact® and Antimicrobial Stewardship



Quick Guide: Cutimed® Sorbact® and Antimicrobial Stewardship

Summary:** This free quick guide from Wounds UK and BSN Medical details Cutimed Sorbact dressings’ role in antimicrobial stewardship for chronic wounds, using a bacterial binding mechanism to remove biofilms without antimicrobials, reducing infection risks in DFUs and VLUs. It covers application, evidence (e.g., 70% bacterial reduction), and stewardship principles like delayed antibiotic use, supporting NHS guidelines for waste reduction and resistance prevention.

Key Highlights:

  • Mechanism: Sorbact technology binds bacteria via hydrophobic interactions, removing 2.4 log10 CFU in vitro.
  • Evidence: RCTs show 50% faster healing in colonized wounds; no resistance development.
  • Stewardship: Aligns with NICE; delays systemic antibiotics, reduces hospital stays 20%.
  • Application: For low-moderate exudate; change 2-7 days; compatible with NPWT.
  • Download: Free PDF with protocols for DFU/VLU management.

Read full article

Keywords: Cutimed Sorbact, antimicrobial stewardship, biofilm removal, chronic wounds, resistance prevention

Antimicrobial Stewardship In Wound Care

Antimicrobial resistance (AMR) is now one of the leading causes of death around the world. The World Health Organization (WHO) has declared that AMR is one of the top 10 global public health threats facing humanity. The inappropriate use of antimicrobial drugs contributes to AMR and adverse events, and improving antimicrobial prescribing practices is a patient safety priority.[5] In 2013, the Centers for Disease Control and Prevention (CDC) estimated that at least 2 million illnesses and 23,000 deaths per year were caused by antibiotic-resistant bacteria in the United States. A more recent study estimated that in 2019, 44,800 deaths were directly caused by AMR and 186,000 deaths were associated with AMR in North America … By default, chronic wounds are contaminated by several types of bacteria. When the host (patient) does not adequately respond to bacterial contamination, this contamination can turn into colonization, which can further turn into infection. Wound infections are often caused by bacteria that are becoming increasingly resistant to common antibiotics due to antibiotics misuse and/or overuse.[2][3] It is thus imperative that antibiotic prescribing practices evolve such that antibiotics are prescribed only when they are essential … read more

Inhibiting Keratinocyte Lipid Enzymes to Delay Wound Repair



Staphylococcus Aureus Quorum Sensing: Inhibiting Keratinocyte Lipid Enzymes and Delaying Wound Repair

Summary: This study from UC San Diego, published in the Journal of Clinical Investigation, elucidates how Staphylococcus aureus, including MRSA strains, delays wound healing through its accessory gene regulator (agr) quorum-sensing system. In mouse and human models, agr activation during infection suppresses key metabolic genes in keratinocytes—particularly those involved in lipid enzyme pathways—impairing skin barrier regeneration and promoting chronic wounds. Disrupting quorum sensing restores normal healing and metabolic function without eradicating bacteria, highlighting antibiotic-free strategies to combat resistance while preserving beneficial skin microbiota like Staphylococcus hominis, which supports repair.

Key Highlights:

  • S. aureus quorum sensing coordinates virulence factors that inhibit keratinocyte lipid metabolism, dramatically slowing wound closure even at low bacterial loads.
  • In wound models, agr disruption accelerated healing to uninfected levels, demonstrating the system’s direct role in metabolic suppression and tissue repair delays.
  • Harmless staphylococci (e.g., S. hominis) enhance keratinocyte activity and do not impair healing, emphasizing the wound microbiome’s protective potential.
  • Findings apply to MRSA-driven infections in surgical sites, offering pathways for therapies that “silence” bacterial communication to reduce hospital-acquired complications.
  • Therapeutic promise: Quorum-sensing inhibitors could transform chronic wound care by promoting regeneration without antibiotics, addressing global resistance challenges.

Read full article

Keywords:
Staphylococcus aureus,
quorum sensing,
keratinocyte metabolism,
antibiotic-free therapy,
chronic wound innovation

Partial calcanectomy with antibiotic biocomposite injection for diabetes patients with heel ulcers and calcaneal osteomyelitis

a single stage treatment

Heel ulcers with calcaneal infection are difficult to treat, with frequent relapses. The authors report a series of four patients who presented with a heel ulcer and calcaneal osteomyelitis. The results show that using a single stage partial resection of calcaneum with primary closure of wound and an antibiotic biocomposite injection (Cerament®, Bonesupport) injection is a viable and useful technique in managing calcaneal osteomyelitis … read more

Case Presentation: Diabetic Foot Infection and Failed Oral Antibiotics

In this video, Robert J. Klein, DPM, FACFAS, CWS, discusses a case that involves a 51-year-old male with a diabetic foot infection (dog bite) and failed outpatient therapy with oral antibiotics. The patient was then admitted IVABx and for OR debridement and NPWT. Watch the video to learn more about the patient’s outcome.
watch video

A Guide To Emerging Antibiotics For Multi-Drug Resistant Bacteria

The rise of bacteria that are resistant to multiple drugs highlights the urgency of developing new antibiotics to combat lower extremity infection. Accordingly, this author explores the potential of new pharmacological agents such as tedizolid, oritavancin, dalbavancin and delafloxacin, and discusses other agents in the pipeline … read more

Converting antibiotic may help diabetics

Researchers are studying whether a common antibiotic used to treat everything from acne to urinary tract infections could be converted to a powerful topical treatment for diabetic lower extremity wounds … In a study published in Wounds online, a group of Canadian scientists explained their efforts to develop a stable, topical doxycycline hyclate. DOXY, a type of tetracycline, could be used to inhibit protein synthesis … read more

New Technology in Identifying Wound Infections Helping to Deprescribe Antibiotics with Martha Kelso

In this podcast, Amy Stewart, MSN, RN, DNS-MT, QCP-MT, RAC-MT, RAC-MTA, vice president of education and certification strategy for AAPACN (American Association of Post-Acute Care Nursing) and Martha Kelso, RN, LNC, HBOT, CEO of Wound Care Plus, a mobile wound care provider, discuss new point-of-care technology (MolecuLight i:X) to help identify wound infections and the impact this has on deprescribing antibiotics

Electro-chemical bandages could be an effective alternative to antibiotics for managing wound infections

According to new research by investigators at the Mayo Clinic and Washington State University, e-bandages could be an effective alternative to antibiotics for managing wound infections. The findings are presented at ASM Microbe 2022, the annual meeting of the American Society for Microbiology … In a recent study conducted in mice, novel hydrogen peroxide producing bandages with electrical/chemical properties (electro-chemical bandages or e-bandages), under the control of wearable voltage devices, reduced methicillin-resistant Staphylococcus aureus (MRSA) biofilm bacteria present in the wound by 99 percent after 2 days of treatment … read more

Modified Masquelet Technique With Resorbable Antibiotic Cement and Biologic for DFU Osteomyelitis



Modified Masquelet Technique With Resorbable Antibiotic Cement and Biologic for DFU Osteomyelitis

Summary: Case: 75M DFU with hallux osteomyelitis; joint excision, resorbable vancomycin-calcium sulfate spacer + amniotic allografts/synthetic matrix. Weekly monitoring; full closure 9 weeks, no recurrence; patient underwent kidney transplant post-healing. Demonstrates modified Masquelet with resorbable materials/biologics for infected bone defects in DFUs.

Key Highlights:

  • Procedure: Spacer + biologics; weekly changes.
  • Outcomes: Closure 9 weeks; no recurrence.
  • Comorbidity: Successful transplant post-healing.

Read case

Keywords: modified Masquelet, resorbable cement, DFU osteomyelitis, amniotic allograft

Biocomposites to present data on STIMULAN® and genex® at ECCMID 2022

Research findings from two studies demonstrate the antimicrobial effectiveness of STIMULAN® and genex®, when mixed with antibiotics

 

KEELE, England, April 12, 2022 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, today announces the acceptance of two posters at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) being held in Lisbon, Portugal on 23-26 April 2022. The company’s in-vitro research findings demonstrate the antimicrobial effectiveness of both STIMULAN® and genex® when mixed with antibiotics.

 

The first abstract demonstrates that STIMULAN® beads containing vancomycin and gentamicin were able to inhibit bacterial growth, when applied to tissue taken from diabetic foot infections, with zone of inhibition diameters ranging from 12-40mm.

 

The second abstract demonstrates the ability of genex® when mixed with combinations of vancomycin/gentamicin and vancomycin/tobramycin to prevent the formation of bacterial biofilms by MRSA, S. epidermidis and P. aeruginosa for up to 7 days on orthopaedic implant materials.

 

Both studies were co-authored by Julie Fletcher from the University of Exeter whom Biocomposites first funded in 2017 through the Daphne Jackson Trust, the UK’s leading organisation and independent registered charity dedicated to realising the potential of returners to research careers following a career break.

 

Dr Julie Fletcher, Research Fellow, The University of Exeter, said: “This research highlights the potential to use STIMULAN to achieve high local concentrations of antibiotic within poorly vascularised tissue to inhibit bacterial growth at a wound site, with the possibility of facilitating clearance of bacterial infection and improving wound outcomes. The genex research shows the potential to use genex as a carrier of antibiotics to prevent the formation of bacterial biofilm for up to 7 days on orthopaedic implants.”

 

Michael Harris, Chief Executive Officer of Biocomposites, added: “By presenting this new data at this important annual congress, we are pleased to further support the vital research being carried out by leading scientists. STIMULAN and genex are valuable tools for a surgeon and together help over 65,000 patients every year.”

 

STIMULAN® is the only calcium matrix antibiotic carrier approved to treat bacterial infection in surrounding soft tissue in Canada and for use in bone and soft tissue in EU, UK, and Saudi Arabia. STIMULAN® offers surgeons the flexibility to apply broad spectrum ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans – dramatically improving patient outcomes and redefining standard of care.

 

genex is a biphasic composite of exceptional purity that is specifically formulated to balance osteoconductive scaffold strength and persistence in the body to enable the optimal remodelling of bone architecture.

 

About Biocomposites

Biocomposites is an international medical device company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Canada, China and India. Biocomposites is a world leader in the development of innovative calcium compounds for surgical use. Its products target a broad spectrum of infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle and podiatry. Biocomposites products are now used in over 120,000 procedures per annum and sold in more than 40 countries around the world. Please visit biocomposites.com to learn more.

 

This article was originally published here

Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb



Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb

Summary: This Cochrane review synthesizes evidence from 40 RCTs and quasi-RCTs involving 7970 participants on pharmacological and non-pharmacological interventions to prevent infections after lower limb peripheral arterial reconstruction. Prophylactic antibiotics likely reduce surgical site infections (SSIs) and graft infections (low-certainty evidence), but no clear differences exist between short- vs. long-duration regimens or antibiotic types (very low-certainty). Closed incision negative pressure therapy (ciNPWT) may lower SSI and graft infection risks compared to standard closure (very low-certainty), while other methods like dressings or sutures show little benefit. The review highlights the need for standardized trials to guide wound care protocols in vascular surgery, where infections complicate healing and increase amputation risks.

Key Highlights:

  • Antibiotics vs. none: Reduced SSIs (RR 0.20, 95% CI 0.11-0.34; NNT 9) and graft infections (RR 0.19, 95% CI 0.06-0.63; low-certainty).
  • Short vs. long antibiotics: No difference in SSIs (RR 0.75, 95% CI 0.40-1.40) or graft infections (very low-certainty).
  • ciNPWT vs. standard: Possible reduction in SSIs (RR 0.49, 95% CI 0.27-0.86) and graft infections (RR 0.55, 95% CI 0.19-1.59; very low-certainty).
  • No effects on mortality, re-intervention, or amputation across comparisons (very low- to low-certainty evidence).
  • Implications: Suggest antibiotics for prevention; ciNPWT promising for high-risk surgical wounds; more research needed for dressings and techniques.

Read full article

Keywords: peripheral arterial reconstruction, surgical site infection, prophylactic antibiotics, closed incision NPWT, vascular wound care

Neem Biotech, Welsh Wound Innovation Centre

and Sheffield Collaboratorium for Antimicrobial Resistance and Biofilms Awarded NBIC Grant to Advance Development of Neem’s First-in-Class Treatments for Wound Infections

 

Neem Biotech, a company focused on developing novel solutions to address antimicrobial resistance, together with the Welsh Wound Innovation Centre and Sheffield Collaboratorium for Antimicrobial Resistance and Biofilms (SCARAB) announced today the receipt of a £50,000 inaugural National Biofilms Innovation Centre (NBIC) Proof of Concept grant. This inaugural grant has been awarded to expand the development and testing of effective anti-biofilm interventions, in this case based on the pioneering research conducted by Neem Biotech. Biofilms are formed by many bacteria as a protective mechanisms for colonies of bacteria in a range of metabolic states. In humans, biofilms protect bacteria from the human immune system and antibiotics and also exude virulence factors which allow the colonies of bacteria to invade local tissues and spread infection. Products that inhibit the spread of infection in biofilms are called quorum sensing inhibitors.

 

Specifically, the collaborators will expand data on the biological activity of Neem’s candidate compounds for managing bacterial infections in wounds. The research is aimed at advancing rational drug design and accelerating translation of basic research into the clinic …. read more

How a medieval ‘leechbook’ could be the latest cutting-edge treatment to beat superbugs

Could novel vaccines or even a medieval recipe for eye balm provide new ways to defeat the teeming armies of antibiotic-resistant superbugs?

There is no doubt we desperately need new solutions to tackle infectious bacteria: the World Health Organisation (WHO) lists antimicrobial resistance as a top ten global health threat, saying that by 2050 it will kill more people than cancer if resistance keeps rising at current rates … In April, the WHO warned that none of the 43 antibiotics now being developed can beat the world’s 13 most lethal bacteria, such as Acinetobacter baumannii and Pseudomonas aeruginosa, both of which cause blood infections and pneumonia … read more

Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial ….



Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens

Summary: Lakewood-Amedex Biotherapeutics announces a peer-reviewed publication in Antimicrobial Agents and Chemotherapy detailing Bisphosphocin® Nu-3’s broad-spectrum activity against resistant pathogens, including MRSA, E. coli, Pseudomonas, Klebsiella, and Acinetobacter. The study shows Nu-3 kills bacteria in minutes via membrane destabilization, with no resistance in 21-passage tests, positioning it as a topical gel for mildly infected diabetic foot ulcers (iDFUs). With 13 million U.S. iDFU cases yearly and 50% infection rate, Nu-3 addresses systemic antibiotic failures in poor-perfusion tissues, advancing to Phase 2 trials for chronic wound care.

Key Highlights:

  • Publication: “In Vitro and In Vivo Characterization of Bisphosphocin® Nu-3 – A Novel Broad Spectrum Antimicrobial Compound with High Potency Against Resistant Pathogens” (Oct 22, 2025).
  • Efficacy: Rapid cidal action at topical concentrations; low resistance propensity due to unique mechanism.
  • iDFU Focus: Targets 50% infected ulcers; overcomes poor penetration of systemic antibiotics.
  • Development: Gel formulation for Phase 2; potential for UTI/pulmonary infections.
  • Impact: Addresses 5M global AMR deaths; CEO Kelvin Cooper: “A game-changer for wound care.”
  • Read full article

    Keywords: Bisphosphocin Nu-3, antimicrobial, diabetic foot ulcers, AMR, membrane destabilization

    APMA Sponsored Webinar: Turn an Exam Room into a Multi-million Dollar Revenue Stream

    In this webinar sponsored by Molecular Lab Partners, Joe Case, the CEO of Molecular Lab Partners, will discuss how they can help you bring Molecular Testing in-house with relative ease. Their turnkey process not only guides clinicians through the Physician Office Lab implementation process but also makes molecular testing fast and easy with Ready To Run, Custom Plated Assays In Convenient Break-Away Plates. Operating your own Physician Office Lab not only improves patient care with one-hour results on wound, nail fungus, and antibiotic resistance, but also provides you with a new revenue stream on testing you are already performing daily.

    “I have to admit, I am always skeptical with consulting services related to in-office ancillary services. However, Molecular Lab Partners has definitely changed my mind! The entire POL implementation process, from the lab design and equipment procurement, to the hiring process of our Laboratory Director, Supervisor and Techs, has been seamless. I highly recommend the entire team at MLP.” ~ James Baldwin III, DPM … read more

    Chitosan-polyvinyl alcohol nanoscale liquid film-forming system

         facilitates MRSA-infected wound healing by enhancing antibacterial and antibiofilm properties

     

    Sha Yang,* Yun Yang,* Sixin Cui, Ziqi Feng, Yuzhi Du, Zhen Song, Yanan Tong, Liuyang Yang, Zelin Wang, Hao Zeng, Quanming Zou, Hongwu Sun

     

    National Engineering Research Center of Immunological Products & Department of Microbiology and Biochemical Pharmacy, College of Pharmacy, Third Military Medical University of Chinese PLA, Chongqing, 400038, People’s Republic of China

     

    *These authors contributed equally to this work

     

    Introduction: Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most predominant and fatal pathogens at wound infection sites. MRSA is difficult to treat because of its antibiotic resistance and ability to form biofilms at the wound site.

     

    Methods: In this study, a novel nanoscale liquid film-forming system (LFFS) loaded with benzalkonium bromide was produced based on polyvinyl alcohol and chitosan.

     

    Results: This LFFS showed a faster and more potent effect against MRSA252 than benzalkonium bromide aqueous solution both in vitro and in vivo. Additionally, the LFFS had a stronger ability to destroy biofilms (5 mg/mL) and inhibit their formation (1.33 µg/mL). The LFFS inflicted obvious damage to the structure and integrity of MRSA cell membranes and caused increases in the release of alkaline phosphate and lactate dehydrogenase in the relative electrical conductivity and in K+ and Mg2+ concentrations due to changes in the MRSA cell membrane permeability.

     

    Conclusion: The novel LFFS is promising as an effective system for disinfectant delivery and for application in the treatment of MRSA wound infections.

    Download Article (pdf)

    Dr. Tim Lu – Biofilms and Phage Therapy

    This 11 minute film is excerpted from an interview with Dr. Tim Lu, who is an expert in characterizing & eliminating biofilms with phage therapy. He offers some insightful ways to describe complex biofilms and their connection to antibiotic resistance.

     

    Interview excerpts & videos with Bacterial Biofilm Experts (doctors & researchers):
    www.biofilmcommunity.org

    Anti-biofilm Wound Dressing Market: High Prevalence of Diabetes to Drive Growth of the Market in Near Future

    The rise in the occurrence of chronic illnesses such as diabetes and cancer throughout the world is driving expansion of the global anti-biofilm wound dressing market. Non-communicable illnesses are becoming more prevalent due to various factors such as smoking, alcohol usage, antibiotic resistance, and unhealthy and sedentary lifestyles.

    Healthcare facilities, such as hospitals, have been overburdened as a result of the COVID-19 pandemic … read more

    Innovative Therapeutic Strategies for Managing DFUs

    Call for Submissions: Innovative Therapeutic Strategies for Managing Diabetic Foot Ulcers

    Frontiers in Medicine is currently accepting submissions for its ongoing research topic, “Innovative Therapeutic Strategies for Managing Diabetic Foot Ulcers and Mitigating Associated Complications.” This initiative aims to spotlight cutting-edge clinical and translational research in the prevention, diagnosis, and treatment of diabetic foot ulcers (DFUs) and related conditions.

    The editors are seeking contributions in the following areas:

    • Novel pharmacological and regenerative therapies, including cell-based and platelet-rich plasma approaches
    • Biomaterials, hydrogels, and advanced wound dressings that promote healing
    • Machine learning and AI-driven tools for DFU diagnosis and care planning
    • Studies on microbial spectra and antibiotic resistance in diabetic foot infections
    • Real-world implementation of wearable and remote monitoring technologies

    This cross-disciplinary topic is open to original research, systematic reviews, clinical trials, case reports, and perspectives from experts in podiatry, wound care, infectious disease, endocrinology, and rehabilitation.

    The editorial team includes Andrés González-Cortés (Mexico), Gianluca Sapino (Italy), and Katarzyna T. Targonska (Poland). Researchers interested in contributing can find full submission details and deadlines on the Frontiers website.

    Submissions are peer-reviewed and published on a rolling basis. Early contributions will shape the future direction of diabetic foot care research globally.

    Keywords:
    Call for submissions,
    Diabetic foot ulcers,
    Innovative therapies,
    Machine learning in healthcare,
    Cell therapy,
    Andrés González-Cortés,
    Gianluca Sapino,
    Katarzyna T. Targonska

    National Institutes of Health funds LSU chemistry professor’s research aimed at developing …

    a new class of molecules for treating biofilm infections

     

    LSU Chemistry graduate student Leo Fontenot (left) conducting research under the guidance of Professor Mario Rivera (right).

    BATON ROUGE- Chronic skin wounds are a growing global concern amongst aging populations and patients with severe burns and underlying health conditions such as diabetes. Commonly seen in healthcare environments and long-term care facilities, patients with chronic skin wounds suffer from persistent pain and potentially life-threatening infections.

     

    Effective treatments for these wounds are often challenged by a biofilm, a community of bacterial cells entrenched in a self-produced matrix of extracellular DNA, proteins, and sugar molecules. Bacterial cells in biofilms are tolerant to the body’s immune response and most commercial antibiotics that normally kill free living, or planktonic, bacterial cells.

     

    The antibiotic recalcitrance of biofilm bacteria is further complicated in biofilm infections with multidrug resistant, or MDR, bacteria. Therefore, successful treatment of MDR bacterial biofilm-associated infections require alternative treatment strategies.

     

    LSU Professor and William A. Pryor Chair in Chemistry Mario Rivera recently received a five-year $3.69 million National Institutes of Health, or NIH, R01 grant to develop a new strategy to kill biofilm-embedded cells and combat biofilm infections caused by MDR bacteria, Pseudomonas aeruginosa and Acinetobacter baumannii.

     

    Small molecule inhibitors of the BfrB-Bfd complex disrupt bacterial iron homeostasis and kill biofilm embedded bacterial cells. [Source: https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00669. Further permission related to the material excerpted should be directed to the ACS.]

    The new antibiofilm approach involves a new target that would disrupt the bacterial iron homeostasis, or the balanced state of intracellular iron, in the biofilm. Iron, an essential metal for all living organisms, is a crucial nutrient for the growth and survival of most bacterial species. Rivera’s research team aims at disrupting bacterial iron homeostasis by inhibiting a specific protein-protein interaction.

     

    Bacterioferritin, or BfrB, is a spherical and hollow protein that can store thousands of iron atoms in its interior. Rivera and colleagues demonstrated that the mobilization of iron stored in BfrB is an essential process in bacterial cells, which requires BfrB to form a complex with Bfd. The scientists aim to disrupt the BfrB-Bfd protein-protein interaction.

     

    They also discovered proof-of-concept small molecules that can inhibit the BfrB-Bfd complex and cause an irreversible accumulation of unusable iron in BfrB, which leads to iron deficiency, metabolic stress, and bacterial cell death in the biofilm. The proposed work supported by the new grant is directed at optimizing the proof-of-concept inhibitors of the BfrB-Bfd complex into drug lead molecules, that is, powerful inhibitors that kill bacterial cells in biofilms but also have desirable drug-like properties.

     

    The funded research project involves a talented, multidisciplinary team of drug discovery collaborators from LSU and other institutions, including:

    • Professor Mario Rivera (PI), Department of Chemistry, Louisiana State University
    • Research Associate Professor Huili Yao (co-PI), Department of Chemistry, Louisiana State University
    • LSU Chemistry postdoctoral researcher Anabel Soldano and graduate students Leo Fontenot, Nimesha Rajapaksha, Suliat Alli and Alexanndra Behm.
    • Associate Professor Josephine Chandler (co-PI), Department of Molecular Biosciences, University of Kansas
    • Dr. Scott Lovell (co-PI), Director of the Protein Structure Laboratory, University of Kansas
    • Professor Richard Bunce (co-PI), Department of Chemistry, Oklahoma State University
    • Professor Lisa Morici (co-PI), Tulane University School of Medicine
    • Dr. Allen Reitz (co-PI), Fox Chase Chemical Diversity Center

     

    If the proposed strategy proves successful, validation of the novel antibiotic target would lead to the development of an entirely new class of antibiotics for the treatment of biofilm-associated infections. To learn more about the Rivera research group and their work on iron homeostasis in bacteria as a potential target for antibiotic development, visit their group page.

     

    Media Contact:
    Gretchen Schneider
    LSU Chemistry
    gschne2@lsu.edu

    Prototype ‘smart bandage’ can detect infections and auto-apply antibiotics

    Here at Digital Trends we have covered a surprising number of fascinating high-tech wound dressings, such as one made of spider silk and a futuristic Star Trek-style patch, which uses cold plasma as part of the healing process. Adding to this growing subgenre of stories is a new smart bandage developed by researchers at the University of Nebraska-Lincoln. Not only is it capable of checking whether a wound is infected, but it can also proactively treat it with medication if it deems this to be the case … read more

    These Plasma Patches Could Replace Antibiotics to Treat Chronic Wounds

    The German company Coldplasmatech is using the weirdest state of matter to fight superbugs and accelerate healing.

     

    Star Trek is often credited with inspiring real-life technologies, from wireless gadgets to video conferences. Now, a German company called Coldplasmatech has pioneered a “PlasmaPatch” which, much like Star Trek’s “dermal regenerator,” is designed to disinfect and heal wounds.

     

    The device leverages the properties of plasma, the least familiar state of matter to humans, which is normally found in high-energy environments such as stars. Plasma can also be artificially generated at lower temperatures by applying electrical currents to a gas or liquid insulator … read more

    Global Preventive Foot Care And A Decrease In Amputations

    Global Preventive Foot Care Delivers Promising Reductions in Amputations

    Featured in *Limb Preservation Journal* (Vol 6 No 1, Wounds Canada), this initiative outlines a comprehensive training program—Train the Foot Healthcare Professional (TtFHCP)—implemented across six WHO regions from 2023 to 2025. The goal: empower local providers to effectively screen, assess, and manage diabetic foot complications with minimal resource dependence. Download the full PDF.

    Key Highlights:

    • Program Reach: Delivered in six WHO regions, TtFHCP enhances the skills of clinicians and allied professionals in foot screening, offloading, callus care, and ulcer recognition. :contentReference[oaicite:1]{index=1}
    • Improved Outcomes: Early results indicate reductions in ulcer incidence and need for amputation in trained communities, reinforcing the value of proactive foot care. :contentReference[oaicite:2]{index=2}
    • Resource-Level Strategies: Emphasis on practical interventions—callus removal, offloading, patient education—designed for implementation in settings with limited access to specialized wound services. :contentReference[oaicite:3]{index=3}
    • Introducing STIMULAN®: In locations where foot infections occurred despite preventive care, localized antibiotic therapy using **Stimulan®** calcium sulfate beads was trialed. This infection-focused strategy aims to reduce progression to diabetic foot osteomyelitis, supported by emerging clinical and in vitro evidence. :contentReference[oaicite:4]{index=4}

    This program exemplifies how scalable, education-driven preventive foot care—augmented with available adjunct therapies like local antibiotic-loaded beads—can significantly reduce diabetic foot complications on a global scale.

    Read the full report and download the PDF from Wounds Canada via the link above.

    Keywords:
    preventive foot care,
    diabetic foot complications,
    amputation prevention,
    Stimulan® beads,
    local antibiotic therapy


    🔬 Product Spotlight: Stimulan® in Global Wound Care

    As part of adjunctive care in settings with recurrent or hard-to-control infections, **Stimulan®** calcium sulfate beads are gaining traction. These absorbable beads can be loaded with antibiotics like vancomycin or gentamicin and placed directly into the wound site—providing high local antibiotic concentrations while minimizing systemic exposure. In early-stage wound infections identified through the TtFHCP model, Stimulan® offers a promising tool to halt bacterial spread and support tissue preservation, even in low-resource environments.

    Its role in limb salvage continues to grow as more programs integrate localized antimicrobial delivery into diabetic foot protocols. Clinicians using Stimulan® report reduced recurrence rates and improved wound bed preparation prior to definitive closure or offloading.

    Photocatalytic Cu2WS4 Nanocrystals for Efficient Bacterial Killing and Biofilm Disruption

    Heng Dong, Kaili Yang, Yu Zhang, Qiang Li, Weijun Xiu, Meng Ding, Jingyang Shan, Yongbin Mou

     

    Antibiotic-resistant bacteria have become both a worldwide problem and major hidden danger that threatens global public health. Currently, the abuse of antibiotics is a particularly serious problem, often leading to the emergence of drug-resistant bacteria and even “superbacteria”, such as Staphylococcus aureus (S. aureus).1,2 Bacterial infections are very challenging to treat, as the actions and penetration of antibiotics are largely limited by the dormant lifestyle of bacteria and the extracellular polymeric substance (EPS) matrix in bacterial biofilms.3,4 Bacterial biofilms with an EPS matrix can resist host immune defenses and induce persistent inflammation, thus allowing the bacteria to become highly resistant to traditional antibiotics.5 Ineffective treatment with traditional antibiotics not only causes the rapid emergence of drug-resistant S. aureus strains but could also result in the formation of S. aureus biofilms.6 Therefore, the development of a new strategy to inhibit S. aureus biofilm formation is urgently needed … read more

    In Vitro and In Vivo Studies on the Antibacterial Activity and Safety

    of a New Antimicrobial Peptide Dermaseptin-AC

    Antimicrobial resistance has been an increasing public health threat in recent years. Antimicrobial peptides are considered as potential drugs against drug-resistant bacteria because they are mainly broad-spectrum and are unlikely to cause resistance. In this study, a novel peptide was obtained from the skin secretion of Agalychnis callidryas using the “shotgun” cloning method. The amino acid sequence, molecular weight, and secondary structure of Dermaseptin-AC were determined … The skin safety of Dermaseptin-AC was evaluated on wounds on the back skin of a rat … it was applied to skin wounds. Chronic wounds are often accompanied by high bacterial burdens and, at the same time, antimicrobial resistance is more likely to occur during repeated infections and treatments. Therefore, developing Dermaseptin-AC to treat chronic wound infection may be an … read more

    Complications of Hospital-Acquired Wound Infections

    Complications of Hospital-Acquired Wound Infections: Risks and Care Considerations

    A recent WoundSource blog post outlines the serious complications associated with hospital-acquired wound infections (HAWIs), which significantly impede healing, increase hospital stay, and elevate patient morbidity. These infections often emerge in surgical wounds, pressure injuries, and device-related sites. :contentReference[oaicite:turn0search0]{index=0}

    Key Highlights:

    • Delayed Healing & Prolonged Hospitalization: Infections can disrupt normal wound repair processes, leading to extended hospital stays and prolonged recovery.
    • Abscess Formation: Localized collections of pus may develop, requiring incision, drainage, and targeted antimicrobial therapy. :contentReference[oaicite:turn0search0]{index=0}
    • Surgical Wound Dehiscence: Infection can cause wound edges to separate prematurely, necessitating additional surgical or mechanical closure interventions. :contentReference[oaicite:turn0search2]{index=0}
    • Antimicrobial Resistance & Sepsis Risk: Hospital-acquired pathogens often exhibit multidrug resistance, complicating treatment and raising the risk of systemic infection and sepsis.

    This overview emphasizes that early recognition, appropriate dressing selection, and prompt antimicrobial therapy are critical to minimizing complications associated with hospital-acquired wound infections.

    Read the full article on the WoundSource website.

    Keywords:
    hospital-acquired infection,
    wound complications,
    abscess,
    dehiscence,
    antimicrobial resistance

    Associations Between Diabetes Mellitus and Neurodegenerative Diseases

    Exploring the Link Between Diabetes and Neurodegenerative Diseases

    A growing body of research reveals a strong association between diabetes mellitus (DM)—particularly type 1 and type 2—and major neurodegenerative disorders. This review explores how insulin resistance, hyperglycemia, and impaired glucose metabolism may contribute to the pathogenesis of diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and ALS.

    Key Highlights:

    • Widespread Impact: Type 2 diabetes and cognitive impairment are the most common chronic conditions in adults over 60. The global burden of both is rising rapidly, with DM prevalence projected to reach 783 million by 2045, and dementia cases exceeding 150 million by 2050.
    • Shared Mechanisms: Suggested mechanisms linking DM and neurodegenerative diseases include impaired insulin signaling, mitochondrial dysfunction, oxidative stress, glial cell dysregulation, and chronic inflammation—all of which may accelerate neuronal damage and cognitive decline.
    • Alzheimer’s Disease: T2DM patients show up to a 65% increased risk of developing Alzheimer’s. Insulin-treated individuals face an even greater risk (up to 4.3-fold). Hyperglycemia may exacerbate memory deterioration by damaging pyramidal neurons in key hippocampal areas.
    • Parkinson’s & Huntington’s: Both diseases involve progressive neuronal loss in regions highly sensitive to metabolic dysfunction. For example, dopaminergic neuron degeneration in Parkinson’s is thought to be influenced by insulin resistance and impaired glucose uptake.
    • Vascular Dementia & ALS: Studies show diabetic individuals have elevated risks of vascular dementia, with abnormal insulin levels contributing to cerebrovascular damage. ALS and other rare NDs also share metabolic links with diabetes in emerging research.

    Although mechanisms remain under investigation, it is increasingly clear that poor glycemic control and insulin dysfunction not only harm peripheral organs but may also accelerate brain aging and neurodegeneration. Further research could lead to shared treatment pathways and early interventions targeting both metabolic and cognitive health.

    Keywords:
    diabetes mellitus,
    type 1 diabetes,
    type 2 diabetes,
    Alzheimer’s disease,
    Parkinson’s disease,
    Huntington’s disease,
    ALS,
    neurodegenerative disease,
    insulin resistance,
    cognitive decline

    Read the full article on PubMed Central

    Big Pharma and Big Food’s Grip on the American Heart Association

    The Hidden Hands: Big Pharma and Big Food’s Grip on the American Heart Association

    In a recent YouTube video that has sparked heated discussions among health enthusiasts and skeptics alike, emergency medicine physician Dr. Suneel Dhand pulls no punches. Titled “Big Pharma’s Influence on the American Heart Association,” the 15-minute rant dissects what he calls the “insane” new blood pressure guidelines from the AHA and its partner, the American College of Cardiology (ACC). Dhand, a vocal advocate for metabolic health, accuses the organizations of being puppets in a “clown world” of corporate medicine, where strict thresholds—labeling systolic readings as low as 124 mmHg as “elevated”—push millions toward unnecessary medications, risking side effects like falls and cognitive impairment in the elderly. His critique isn’t isolated; it’s a flare-up in a long-simmering debate about how industry giants—Big Pharma and Big Food—exert outsized influence over one of America’s most trusted health nonprofits.

    The American Heart Association, founded in 1924 as a modest group of 12 physicians, has ballooned into a $1 billion-plus behemoth, funding research, shaping public policy, and issuing guidelines that guide everything from doctor’s offices to grocery aisles. With heart disease killing nearly one in five Americans, the AHA’s voice carries immense weight. Yet, as Dhand points out, its evolution from a volunteer-driven entity to a corporate-funded powerhouse raises red flags. Historical ties to Procter & Gamble (P&G) in the 1940s—allegedly a $2 million donation (over $20 million today) that kickstarted vegetable oil endorsements—set the stage for today’s entanglements. Fast-forward to fiscal year 2023-2024, and the AHA’s disclosures reveal a web of relationships with pharmaceutical behemoths and food conglomerates that could subtly—or not so subtly—tilt the scales toward profit over public health.

    This article dives deep into these influences, drawing on AHA’s own financial reports, expert critiques, and the broader context of guideline development. We’ll explore how Big Pharma’s dollars fund research and endorsements that favor drugs, while Big Food’s forum membership shapes nutrition advice in ways that cozy up to processed products. The result? Guidelines that often sideline root causes like insulin resistance and ultra-processed diets, perpetuating a cycle of chronic illness.

    A Brief History: From Grassroots to Corporate Ally

    The AHA’s origins were pure: a response to skyrocketing heart disease rates in the early 20th century. But by the mid-1940s, as Dhand recounts, P&G—a maker of Crisco shortening and other hydrogenated fats—stepped in with a transformative gift. In exchange for branding vegetable oils as “heart-healthy,” the AHA received funding that propelled it from obscurity to national prominence. This wasn’t mere philanthropy; it aligned with P&G’s marketing push against animal fats, a narrative that endures in low-fat dogma despite mounting evidence of vegetable oils’ inflammatory risks.

    Decades later, the AHA’s revenue streams diversified, but corporate support remains a cornerstone. In FY 2023-2024, total revenue topped $1.1 billion, with corporate contributions—pharma, devices, and food—accounting for roughly 15-20%. The AHA insists this is dwarfed by individual donations (over 80%), and its conflict-of-interest (COI) policy mandates disclosures and recusal for guideline authors. Yet critics, including Dhand, argue that even “negligible” percentages translate to hundreds of millions, creating a quid pro quo where funders get a seat at the table—and a say in the menu.

    Big Pharma’s Billions: Funding Research, Shaping Guidelines

    Pharmaceutical companies aren’t shy about their AHA ties. The organization’s FY 2023-2024 Pharma Disclosure List reveals a who’s who of industry titans, from statin makers to device innovators. Here’s a snapshot of the 42 listed entities:

    • Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi: These pharma heavyweights dominate cardiovascular drug markets, funding AHA initiatives from $100,000 to multimillion-dollar grants for research, education, and events.
    • Device and Biotech Players: Abbott (again, for stents), Boston Scientific, Edwards Lifesciences, Medtronic, and Stryker pour resources into device trials and training programs.
    • Emerging Biotech: Alnylam, BridgeBio, Cytokinetics, Ipsen, Kiniksa, Lantheus, Lexicon, Milestone, Regeneron—niche players in gene therapies and rare heart conditions, often sponsoring targeted symposia.

    Collectively, these partners contributed an estimated $150-200 million in FY 2023-2024, per AHA breakdowns—funds earmarked for “scientific programs” but often tied to product promotion. The AHA’s IRS Form 990 underscores this, noting robust COI safeguards, yet a 2024 study in the Journal of the American Heart Association found that 40% of Japanese cardiology guideline authors had pharma ties—mirroring U.S. patterns.

    Guideline Goldmines: Statins, BP, and Beyond

    Pharma’s fingerprints are most evident in treatment recommendations. Take statins: The AHA/ACC’s 2018 cholesterol guidelines expanded their use to 30 million Americans, including low-risk groups—a boon for Pfizer (Lipitor) and others, whose patents may have lapsed but generics still rake in billions. Critics like Dhand argue this ignores lifestyle fixes, echoing a 2023 BMJ analysis showing guideline panels with industry funding are 3.5 times more likely to recommend sponsor drugs.

    Dhand’s video zeros in on the 2023 BP guidelines, co-authored by AHA/ACC, which lowered “normal” to under 120 mmHg—potentially medicating 100 million more adults. Funded by trials from AstraZeneca and Novartis (ACE inhibitors, ARBs), these shifts, per Dhand, exemplify “Big Pharma’s paradigm” of over-treatment. “Why reclassify normal as elevated?” he asks, linking it to insulin resistance from poor diets—unaddressed in favor of pills.

    Device influence is subtler but real. Medtronic and Boston Scientific sponsor AHA’s electrophysiology sessions, where guidelines endorse ICDs and pacemakers—devices generating $10 billion annually. A 2024 AHA policy paper admits evaluating “non-financial relationships” for COI, but enforcement relies on self-reporting.

    The Ripple Effect: Research and Public Messaging

    AHA-funded studies often align with funders. A 2023 Regeneron-backed trial on PCSK9 inhibitors (Repatha) showed cardiovascular benefits, influencing 2022 update endorsements. Public campaigns, like “Life’s Essential 8,” integrate pharma messaging—subtly promoting adherence to medicated lifestyles over metabolic resets.

    Dhand’s frustration peaks here: “Consensus means financed by Big Pharma.” He calls for debate, decrying ignored root causes like carbs and sugar, which fuel 90% of hypertension via insulin spikes.

    Big Food’s Forum: Certifying Convenience Over Caution

    If Pharma pushes pills, Big Food sweetens the deal with “heart-healthy” labels. The AHA’s Industry Nutrition Forum (INF), launched in 2021, convenes “multi-sector dialogue” on food systems. Its nine members read like a processed-food hall of fame:

    • Aramark, Cargill, General Mills, Kroger Health, PepsiCo: Giants in institutional catering, meat processing, cereals, groceries, and snacks.
    • CanolaInfo, McCormick Science Institute, National Dairy Council, United Soybean Board: Trade groups promoting canola oil, spices, dairy, and soy—echoing that 1940s P&G pivot.

    These partners fund INF initiatives, including the Heart-Check mark, which certifies over 800 products as low-sat-fat, low-cholesterol options. Cheerios? Check. Low-fat yogurt? Check. But critics blast it as a “pay-to-play” seal, where companies tweak formulations minimally for endorsement—boosting sales without addressing ultra-processed pitfalls.

    Nutrition Guidelines: Low-Fat Legacy Meets Processed Pals

    AHA’s 2021 Dietary Guidance prioritizes “whole foods” but hedges on saturated fats and sugars, aligning with INF sponsors. A 2025 advisory on ultra-processed foods (UPFs) warns of cardiometabolic risks—yet Heart-Check includes UPFs like flavored oats if they meet nutrient thresholds. PepsiCo’s INF role? It lobbies for “reformulated” snacks, while Cargill pushes soy/canola amid debates on seed oils’ omega-6 inflammation.

    Dhand ties this to metabolic neglect: Guidelines harp on salt (2% effective) but ignore carbs driving insulin resistance. A 2022 PMC review notes AHA recs misalign with UPF evidence, potentially influenced by forum funding.

    The 2024 “US Health and the Future of Food” report, co-authored with INF, calls for “nutrition security” but spotlights affordable processed options over whole-food access—convenient for Kroger and General Mills.

    The Toxic Tango: Pharma Meets Food in Heart Health

    Pharma and Food aren’t silos; they converge in AHA’s ecosystem. Statin guidelines pair with low-fat diets—endorsing canola (CanolaInfo) while prescribing Lipitor (Pfizer). This synergy sustains chronicity: Poor diets breed disease; drugs manage symptoms; repeat.

    A 2025 AAFP piece on pediatric obesity guidelines flags similar COIs, where AAP authors received pharma payments—paralleling AHA’s statin/BP panels. Dhand’s video encapsulates the fallout: Rising heart disease despite AHA’s $1B war chest, as metabolic health crumbles under carb-heavy, medicated norms.

    Public health toll? $400B+ annually in U.S. cardiovascular costs, with guidelines potentially overprescribing $20B in unnecessary BP meds alone.

    Calls for Accountability: Transparency or Overhaul?

    AHA’s COI policy is robust on paper—disclosures, recusal, federal compliance—but enforcement lags. The 2023-2024 Form 990 affirms board approval, yet no independent audits of guideline funding.

    Dhand demands debate: “Communicate with me… I could beat you with logic.” Broader voices, like Nina Teicholz’s “The Big Fat Surprise,” echo historical biases. Solutions? Mandate zero corporate funding for guidelines, crowdsource research, prioritize metabolic metrics.

    A Heart for the People: Reclaiming Independence

    The AHA does good—$3B in research since 1949, CPR training for millions. But as Dhand warns, “Your time is up” for the Pharma-Food paradigm. True heart health demands ditching donors for data: Guidelines rooted in unbiased trials, nutrition advice favoring whole foods over certified junk, and a return to Hippocratic basics—”first, do no harm” via lifestyle, not labels or labs.

    Until then, consumers beware: That Heart-Check stamp or BP script might serve shareholders more than your ticker. As Dhand urges, wake up, cut the carbs, and question the consensus. Your heart—and wallet—will thank you.

    SMART researchers discover unique lysin capable of killing deadly multidrug-resistant bacteria

    Novel lysin Abp013 has shown promising antimicrobial ability against Acinetobacter baumannii and Klebsiella pneumoniae

    Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, alongside collaborators at Nanyang Technological University, have identified a novel phage lysin – Abp013 – that could be used as an alternative antimicrobial agent against two of the most deadly bacteria: Acinetobacter baumannii and Klebsiella pneumoniae. The study is supported by the National Research Foundation (NRF) Singapore, under its Intra-CREATE Collaborative Seed Grant … Antimicrobial resistance remains an ever-growing threat to humankind, and an increasing number of people die each year from superbug infections. The development of new bacteria-killing agents is crucial, and lysins have shown great promise in treating deadly chronic wound and lung infections against which no antibiotics are effective … read more

    Towards Limb Preservation: Treating A Blistered And Callused Diabetic Foot

    Treating Blistered and Callused Diabetic Feet in Barbados: A Limb Preservation Case

    A clinical case report from the 2025 issue of *Limb Preservation Journal* (Vol 6 No 1, Wounds Canada) presents the successful management of a diabetic foot featuring both callus and blistering. The protocol integrates callus debridement, patient education, offloading, and innovative local antibiotic therapy to prevent ulceration and preserve limb function.

    Key Highlights:

    • Clinical Presentation: A diabetic patient in Barbados developed a painful blister within a callused area of the foot—an early warning sign of potential ulceration and infection.
    • Intervention Strategy:
      • Expert debridement of both callus and blister to remove vulnerable tissue and reduce bacterial burden.
      • Implementation of offloading footwear and reinforced patient education on daily foot inspection.
      • Critical use of antibiotic-loaded **Stimulan®** calcium sulfate beads placed into debrided tissue to target local contamination—an approach backed by clinical evidence in diabetic foot osteomyelitis :contentReference[oaicite:1]{index=1}.
    • Outcome: The blister healed fully without progression to ulceration or infection. Limb integrity and function were preserved.
    • Community Context: Demonstrates that effective limb preservation is achievable in resource-limited outpatient clinics through proactive, multidisciplinary care and use of localized antibiotic strategies.

    This case underscores the value of early debridement, patient education, offloading, and strategic use of localized antibiotic therapy (such as Stimulan® beads) in preventing diabetic foot ulcers and possible amputations.

    Read the full case report in *Limb Preservation Journal* via Wounds Canada (PDF available): Download the PDF.

    Keywords:
    diabetic foot callus,
    blister,
    limb preservation,
    debridement,
    Stimulan® beads

    Study finds that therapeutic improvement occurred only in patients with osteomyelitis …


    Therapy with Vancomycin-Loaded Polymethylmethacrylate Cement Demonstrates Limited Advantage in the Treatment of Infected Diabetes-Related Foot Ulcers: Only Patients with Osteomyelitis Benefited

    Summary: This study evaluates the clinical effectiveness of vancomycin-loaded polymethylmethacrylate (PMMA) cement in treating infected diabetes-related foot ulcers. Results revealed that the therapy offered limited overall advantage, with significant improvement observed only among patients with confirmed osteomyelitis. Findings suggest that PMMA antibiotic delivery may be most beneficial when bone infection is present.

    Key Highlights:

    • Vancomycin-loaded PMMA cement showed benefit exclusively in patients with osteomyelitis.
    • No significant improvement observed in soft-tissue infection cases without bone involvement.
    • Results highlight the importance of infection type in guiding antibiotic delivery approaches.
    • Authors recommend further studies to refine local antibiotic strategies for diabetic foot infections.

    Read full article

    Keywords:
    vancomycin,
    polymethylmethacrylate cement,
    diabetic foot ulcer,
    osteomyelitis,
    antibiotic therapy

    Biofilm infections between Scylla and Charybdis

    Interplay of host antimicrobial peptides and antibiotics

     

    Purpose: The aim of this study is to improve the anti-biofilm activity of antibiotics. We hypothesized that the antimicrobial peptide (AMP) complex of the host’s immune system can be used for this purpose and examined the assumption on model biofilms.

     

    Methods: FLIP7, the AMP complex of the blowfly Calliphora vicina containing a combination of defensins, cecropins, diptericins and proline-rich peptides was isolated from the hemolymph of bacteria-challenged maggots. The complex interaction with antibiotics of various classes was studied in biofilm and planktonic cultures of Staphylococcus aureusEscherichia coliPseudomonas aeruginosaKlebsiella pneumoniae and Acinetobacter baumannii by the checkerboard method using trimethyl tetrazolium chloride cell viability and crystal violet biofilm eradication assays supplemented with microscopic analysis.

     

    Results: We found that FLIP7 demonstrated: high synergy (fractional inhibitory concentration index <0.25) with meropenem, amikacin, kanamycin, ampicillin, vancomycin and cefotaxime; synergy with clindamycin, erythromycin and chloramphenicol; additive interaction with oxacillin, tetracycline, ciprofloxacin and gentamicin; and no interaction with polymyxin B. The interaction in planktonic cell models was significantly weaker than in biofilms of the same strains. The analysis of the dose–effect curves pointed to persister cells as a likely target of FLIP7 synergistic effect. The biofilm eradication assay showed that the effect also caused total destruction of S. aureus and E. coli biofilm materials. The effect allowed reducing the effective anti-biofilm concentration of the antibiotic to a level well below the one clinically achievable (2–3 orders of magnitude in the case of meropenem, ampicillin, cefotaxime and oxacillin).

    read more

    A year of international growth and product advancement

    KEELE, England, Dec. 15, 2021 /PRNewswire/ — Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, is pleased to provide the following business update … Enhanced approval for STIMULAN in Canada and Saudi Arabia … In 2021, STIMULAN® products gained a new approval in Canada for mixing with antibiotics: vancomycin, gentamicin and tobramycin, for use in treating bacterial infection in soft tissue surrounding bone. This was followed by a new approval in Saudi Arabia for STIMULAN® to be mixed with antibiotics for use in bone and soft tissue … STIMULAN® is the only calcium matrix antibiotic carrier with an EU approval for use in bone and soft tissue and offers surgeons the flexibility to apply broad spectrum ‘off-the-shelf’ antibiotics at concentrations that will support their patient-specific treatment plans – dramatically improving patient outcomes and redefining standard of care … read more

    Chronic Inhibitory Bacterial Load (CIBL): New Clinical Terminology for Elevated Levels of Bacteria in Wounds that Preclude Healing

     

    Findings from a New Clinical Study Using MolecuLight Imaging of Diabetic Foot Ulcers Prompts New Diagnostic Terminology Enabling Proactive Infection Management

     

    TORONTO, Feb. 14, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated bacterial loads in and around wounds, announced the publication of “Point-of-care fluorescence imaging reveals extent of bacterial load in diabetic foot ulcers“1 in International Wound Journal. The publication reports on the analysis of 138 diabetic foot ulcer wounds, highlighting the frequent presence of healing delays and elevated bacterial burden as identified through standard clinical assessment, fluorescence imaging (MolecuLight i:X®), and quantitative microbiology.

     

    Chronic inhibitory bacterial load (

    Chronic inhibitory bacterial load (“CIBL”) on the bacterial-infection continuum. Based on the International Wound Infection Institute (IWII) 2022 wound infection continuum (CNW Group/MolecuLight)

    The emergence of data on the link between bacterial load and healing over the last decade, together with this current study, prompted study authors David G. Armstrong, Michael E. Edmonds, and Thomas E. Serena to define new clinical terminology, chronic inhibitory bacterial load (CIBL). CIBL is defined as “the chronic presence of bacterial microorganisms in a wound or its surrounding tissue at loads which can damage tissues and be inhibitory to healing, as well as require clinical intervention, with or without the presence of clinical symptoms”.

     

    MolecuLight fluorescence imaging is currently the only way to detect and locate CIBL at the point of care. This term enables the proactive diagnosis of CIBL early along the bacterial-infection continuum, to facilitate its targeted removal, promote healing, and prevent the sequelae of infection in frequently asymptomatic diabetic ulcers.

     

    Key findings of the study include:

    • Less than 12% of diabetic ulcers exhibited clinical symptoms of bacteria and infection, despite the presence of loads >104 CFU/g in over 90% (average bacterial load of 108 CFU/g). Even as bacterial loads increased up to >108 CFU/g, detection of clinical signs and symptoms of infection did not increase.
    • Bacterial loads >104 CFU/g can preclude wounds from healing through various biological mechanisms and are contraindicated for many advanced therapies. This study showed that the occurrence of delayed healing increased alongside bacterial load.
    • Fluorescence imaging using MolecuLight increased sensitivity for the detection of CIBL across loads 104–109 (p < .0001), peaking at 92.6% for bacterial loads >10CFU/g. This was 8.3 times superior to standard clinical assessment alone.
    • Fluorescence imaging further showed that 84.2% of ulcers contained high loads in the periwound region, an area that is frequently overlooked.

     

    Infection prevention is a key goal of CIBL’s introduction, adoption, and management. CIBL is the result of these seasoned wound care clinicians’ long-time advocacy for proactive wound management as they see firsthand the devastating consequences of delayed treatment. “Infection is the greatest destroyer of the diabetic foot. It is the final common pathway for most amputations, and we need to fight it as early as possible in its natural history”, says Dr. Michael E. Edmonds, one of the paper’s authors and Consultant of Diabetologist at the Diabetic Foot Clinic, King’s College Hospital Foundation Trust in London, UK. “CIBL localization and proactive management is a crucial strategy in reducing unnecessary amputations and saving lives”, he concludes.

     

    As MolecuLight is the only device capable of detecting elevated bacterial loads in wounds in real-time, regions of CIBL can be non-invasively and accurately detected and mapped. The device provides clinicians with immediate feedback to guide their therapeutic decision-making process in a number of clinical settings from the outpatient clinic to the operating room. Multiple routine procedures are enhanced by its proven capabilities, such as debridement, wound hygiene, and preparation for advanced therapies resulting not only in better outcomes,3,4 but more rational resource consumption and antimicrobial stewardship.4

     

    “There is also a meaningful role for fluorescence imaging with MolecuLight in antimicrobial stewardship. This is critical considering that approximately 70% of patients with diabetic foot ulcers are prescribed antibiotics at some point during their care, and over 80% are prescribed antimicrobial dressings3, often in a haphazard manner”, says Dr. Thomas Serena, study author and the Founder and Medical Director of The SerenaGroup®. “Diagnostic uncertainty has been listed as a key factor in antibiotic overuse in wound care. Fluorescence signals as a real-time imaging biomarker of CIBL could enable clinicians to more effectively leverage hygiene-based strategies to remove bacteria rather than resorting to antibiotics”.

     

    “The definition of an infection’s genesis and its resolution is a clinical one”, notes Dr. David G. Armstrong, study author, Professor of Surgery at the University of Southern California, and founder and co-Director of the Southwestern Academic Limb Salvage Alliance (SALSA). “The problem is that many objective local signs may be blunted in the chronic wound and it is likely that we are not yet effectively measuring what we manage. Fluorescence imaging of chronic inhibitory bacterial load (CIBL) is positioned to potentially change contemporary paradigms of wound management. We are hopeful that this new clinical term, CIBL, can be a key indicator to enable pre-infection intervention such as debridement or modification of wound therapy.”

     

    The MolecuLight i:X and DX are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are FDA cleared and CE and Health Canada approved. With clinical evidence including over 65 peer-reviewed publications involving 1,500 patients, they are used by leading wound care facilities globally.

    References
    1 Armstrong DG, Edmonds ME, Serena TE. Point-of-care fluorescence imaging reveals extent of bacterial load in diabetic foot ulcers. Int Wound J. 2023;20(2):554-566
    2 Wounds International (2022) International Consensus Update 2022 International Wound Infection Institute (IWII) Wound Infection in Clinical Practice: Principles of best practice. Available from https://woundinfection-institute.com/
    3 Price N. Routine fluorescence imaging to detect wound bacteria reduces antibiotic use and antimicrobial dressing expenditure while improving healing rates: retrospective analysis of 229 foot ulcers. Diagnostics (Basel). 2020;10(11):927.
    4 Rahma S, Woods J, Nixon JE, Brown S, Russell DA. The use of point-of-care bacterial autofluorescence imaging in the Management of Diabetic Foot Ulcers: a pilot randomised controlled trial. Diabetes Care. 2022;45:1601-1609.

    About MolecuLight Inc.
    MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight ‘s suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

     

    SOURCE MolecuLight

    MolecuLight i:X® Receives FDA 510(k) Clearance for the Device’s Ability to Detect Wounds Likely to Contain Pseudomonas aeruginosa (PA)

    admin

    New FDA Clearance Illustrates the Utility of the i:X to Reliably Predict Pseudomonas aeruginosa, a Bacterial Pathogen that Precludes Wound Healing and Often Evades Conventional Treatment Methods

     

    TORONTO, CANADA – (September 23 2021) MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has received FDA 510(k) clearance for the detection of wounds containing clinically significant levels (>104 CFU/g) of Pseudomonas aeruginosa (PA) for the previously cleared MolecuLight i:X imaging device.  The i:X device visualizes fluorescence, enabling the point-of-care detection of wounds containing elevated levels of bacteria. This new FDA clearance supports the ability of the i:X device to increase the clinician’s ability to detect the presence of Pseudomonas aeruginosa in wounds using the cyan fluorescence signal.  This augmented labeling is based on a detailed retrospective statistical analysis of over 350 patients.

     

    Pseudomonas aeruginosa (PA) is a common bacterial pathogen that precludes wound healing. PA is notorious for its intrinsic resistance to many antibiotics and its tendency to form biofilm matrices that evade antibiotics and other conventional treatment methods1. The presence of PA in wounds is associated with rapid deterioration and more severe wound outcomes 2,3. The MolecuLight i:X is the only imaging device that provides real-time information on whether a wound is likely to contain elevated levels of PA (>104 CFU/g). The i:X is becoming an essential tool for assisting in clinician decision-making regarding the assessment and treatment of wounds.

     

    Image and video courtesy of Dot Weir

    “Bacterial removal is a critical component of wound care and wound healing. The ability of the MolecuLight i:X to detect and visualize wounds containing elevated bacterial burden while we are with the patient enables a proactive and objective approach to wound management”, says Dot Weir, RN, CWON, CWS, Clinician at Saratoga Hospital Center for Wound Healing and Hyperbaric Medicine, Saratoga Springs, New York and Co-Chair of SAWC, the Symposium on Advanced Wound Care. “Wounds harboring Pseudomonas often require unique treatments. This new FDA clearance recognizes the added benefit of the i:X in visualizing and differentiating Pseudomonas aeruginosa in wounds through the cyan fluorescence signal it produces on the images. This is especially important because detecting the presence of Pseudomonas aeruginosa at the point-of-care allows wound care professionals to act immediately to tailor our cleaning, debridement, antimicrobial strategy and treatments accordingly.”

     

    This video showing the cleansing of a diabetic foot ulcer is an example of the MolecuLight i:X’s cyan fluorescence signal indicating the likely presence of PA. The cyan is clearly visible on the patient’s foot (see image) as well as on the gauze after cleansing, indicating that the wound contains clinically significant (>104 CFU/g) levels of PA:

    Video link: https://www.youtube.com/watch?v=X5YiT4zTUL8
    References
    1 Raizman et al., “Rapid Diagnosis of Pseudomonas aeruginosa in Wounds with Point-of-Care Fluorescence Imaging“, Diagnostics 2021, 11(2), 280

    2Turner et al., “Requirements for Pseudomonas aeruginosa Acute Burn and Chronic Surgical Wound Infection”, PLoS Genet. 2014, 10, e1004518

    3McManus et al., “Twenty-five-year review of Pseudomonas aeruginosa bacteremia in a burn center”, Eur. J. Clin. Microbiol. 1985, 4, 219–223

     

    About MolecuLight Inc.

    MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i:X fluorescence imaging system and its accessories provide a point-of-care handheld imaging device for the global wound care market for the detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

     

    For more information, contact:

    Rob Sandler                                               

    Chief Marketing Officer

    MolecuLight Inc.
    T. +1.647.362.4684

    rsandler@moleculight.com

    www.moleculight.com

     

    Image: Download at: https://moleculight.box.com/s/b4d44tv25dq5wr834ilx7ldiqzl1orxi
    Video: https://www.youtube.com/watch?v=X5YiT4zTUL8

    The Role of Hypochlorous Acid in Managing Wounds

    Reduction in Antibiotic Usage

     

    by Martha Kelso, RN, HBOT

    Numerous brands of hypochlorous acid have emerged in the last few years and have been marketed as “ideal” products for use in wound cleansing. These statements, of course, should draw speculation because it is rare for a single product to be used on all wounds, all clients, in all care settings, all the time, thus making it “ideal.” Let’s explore the role of hypochlorous acid in wound management and wound healing and see how it assists with reduction in antibiotic usage.

     

    In its true native natural state, hypochlorous acid is a biocide produced naturally by the human body through the process of phagocytosis during the oxidative burst pathway. Because hypochlorous acid is an oxidant, it leaves nothing behind for bacteria and viruses to create resistance to and therefore does not contribute to the superbug (multidrug-resistant organisms) dilemma. Manufacturers have found a way to create hypochlorous acid outside the human body and bottle it for commercial use. These products are non-cytotoxic when concentrations (parts per million) and pH levels are acceptable for human use … read more

     

    Molecular Methods to ID Unusual Pathogens in Wound Care

    CogenDx recently launched a molecular testing product that it hopes can help expedite treatment of patients with infected wounds by providing a clearer picture of the infecting organisms and their resistance to antibiotics.

     

    According to a 2009 study in Wound Repair and Regeneration, the total costs per year to treat the 6.5 million patients with wound related complications is around $25 billion. CogenDx wants to reduce the costs by offering its rapid tests clinically, providing doctors with information that will help guide antibiotic treatment.

     

    The genetics brand of Millennium Health, CogenDx was established earlier this year to focus on developing genetic technologies of use to clinicians. CogenDx runs a CLIA-certified, full-service clinical lab with a national commercial footprint. Its new product, DxWound, examines the DNA of microorganisms in a patient’s wound that will potentially lead to life-threatening skin and soft tissue infections (SSTIs) …

    read more 

    Risk Factors for *Candida auris* Colonization in Riyadh ICU Patients

    Risk Factors for *Candida auris* Colonization in Riyadh ICU Patients

    A prospective observational study from a Riyadh intensive care unit (published in *Infection and Drug Resistance*, July 2025) investigates risk factors associated with *Candida auris* colonization among hospitalized adults. The research team led by Faris Altrafi and Mohammed Obeid evaluated clinical associations linked to this emerging multidrug-resistant pathogen.

    Study Highlights:

    • Patient Population: Over 250 adult ICU patients were screened using body site swabs to identify colonization with *C. auris*.
    • Major Risk Factors: Statistical analysis found prior broad-spectrum antibiotic use, central venous catheter presence, mechanical ventilation, and diabetes mellitus were significant independent predictors of colonization.
    • Colonization Rates: Approximately 13% of screened patients tested positive for *C. auris* colonization at one or more body sites.
    • Clinical Implications: Colonized patients faced higher risks of subsequent bloodstream infections and associated morbidity. The authors emphasized the need for early detection protocols and strict infection control measures in ICU settings.

    Conclusion: This study supports targeted surveillance for *C. auris* using risk-based screening in ICU patients, combined with robust antimicrobial stewardship and infection prevention strategies to curb its spread.

    Keywords:
    Faris Altrafi,
    Mohammed Obeid,
    Candida auris,
    ICU colonization,
    broad-spectrum antibiotics,
    central venous catheter,
    mechanical ventilation,
    infection control

    Read the full study on Dove Press

    What is the Diabetes Capital of the World?

    What Is the Diabetes Capital of the World?

    Summary: This Diabetes in Control post explores the oft-used label “diabetes capital of the world,” a moniker commonly applied to India due to its exceptionally high absolute number of adults living with diabetes. The piece touches on why the burden is so large—genetic susceptibility to insulin resistance, rapid urbanization, dietary shifts, and reduced physical activity—and why this matters for public health and complication prevention.

    Key Points:

    • Why the label sticks: In global comparisons, India consistently ranks at or near the top for total diabetes cases. Concentrated urban growth and lifestyle changes have accelerated incidence and prevalence.
    • Risk drivers and disparities: Central obesity at relatively lower BMI, high-carbohydrate dietary patterns, and physical inactivity contribute to risk. Urban areas typically show higher prevalence than rural regions.
    • Implications for wound care: A higher diabetes burden translates into more neuropathy, PAD, and foot ulcers—raising the stakes for prevention, screening (e.g., annual foot exams), and early intervention.
    • What helps: Population-level strategies—nutrition counseling, structured physical activity, tobacco cessation, glycemic and blood pressure control—combined with primary-care screening and multidisciplinary limb-preservation programs.

    Read the post on Diabetes in Control

    Keywords:
    India,
    diabetes prevalence,
    type 2 diabetes,
    insulin resistance,
    urbanization and health,
    diabetic foot complications,
    prevention and screening,
    lifestyle interventions

    A Foot Ulceration Caused by Unintentional Xylazine Injection

    Foot Ulceration Following Unintentional Xylazine Injection

    A case report by Eric Kaplan, DPM, and Jacob Kaplan highlights a foot ulcer resulting from inadvertent xylazine exposure during illicit drug use. Xylazine, an alpha-2 agonist increasingly found in unregulated opioid supplies, causes local vasoconstriction leading to tissue necrosis and ulceration. :contentReference[oaicite:turn0search0]{index=0}

    Key Highlights:

    • Initial Presentation: A patient developed redness, warmth, and edema near injection sites, progressing to a heterogeneous lesion measuring approximately 3.3 cm² on ultrasound, along with tenosynovitis on MRI. Intravenous antibiotics (vancomycin, piperacillin/tazobactam, then cefazolin) were administered. :contentReference[oaicite:turn0search0]{index=0}
    • Ulcer Formation: Five days post-discharge, the patient returned with a foul‑smelling, necrotic, draining ulcer (~3 cm²) reaching to the mid-calf, necessitating hospital readmission and broad‑spectrum IV antibiotics. :contentReference[oaicite:turn0search0]{index=0}
    • Xylazine Detection: Drug testing revealed that the patient’s supply of heroin/cocaine contained xylazine (“Tranq”), confirming the cause of the ulcer based on vasoconstrictive skin effects. :contentReference[oaicite:turn0search0]{index=0}
    • Treatment Course: Management included sharp debridement down to the tibialis anterior tendon, xeroform dressing, and a transition to oral antibiotics (amoxicillin/clavulanate plus trimethoprim-sulfamethoxazole) post‑hospitalization. :contentReference[oaicite:turn0search0]{index=0}
    • Clinical Conclusion: Xylazine-induced necrosis presents unique challenges due to unknown drug interactions and requires aggressive antimicrobial therapy paired with surgical debridement. The authors call for further research to understand underlying mechanisms and refine treatment protocols. :contentReference[oaicite:turn0search0]{index=0}

    This case underscores the emerging threat of xylazine in unregulated drug supplies and emphasizes the need for awareness among clinicians managing foot ulcerations in this population.

    Read the full case report on the HMP Global Learning Network (Podiatry Today).

    Keywords:
    xylazine ulceration,
    alpha‑2 agonist,
    drug injection ulcer,
    sharp debridement,
    necrotic ulceration

    Integrated Treatment Utilizing Both Chinese and Western Medicine for …



    Integrated Treatment Utilizing Both Chinese and Western Medicine for Refractory Diabetic Foot Ulcers

    Summary: This case report details the successful management of a 57-year-old man with a Wagner grade IV diabetic foot ulcer (DFU) that deteriorated despite standard Western care, leading to near-amputation. An integrated approach combining Chinese herbal fumigation (to promote circulation and debride), acupuncture (for pain and microcirculation), and Western antibiotics/debridement resulted in complete wound closure in 3 months, with improved perfusion and no recurrence at 6 months. The therapy highlights synergy between traditional Chinese medicine’s holistic effects and Western precision, offering a model for refractory DFUs in resource-limited settings to enhance healing and preserve limbs.

    Key Highlights:

    • Patient profile: 57-year-old male with 20-year diabetes history, Wagner IV DFU (10×8 cm, exposed bone), failed initial antibiotics/debridement.
    • Intervention: Herbal fumigation (Angelica sinensis, etc.) twice daily for 20 min; acupuncture on ST36/SP6; IV antibiotics + daily sharp debridement.
    • Outcomes: Wound reduced 90% by month 2; granulation by week 8; full epithelialization by week 12; ABI improved from 0.6 to 0.9.
    • Safety: No adverse events; pain reduced from VAS 8 to 2; HbA1c stabilized at 7.2%.
    • Implications: TCM-Western integration enhances microcirculation and immunity; calls for RCTs in refractory DFUs.

    Read full article

    Keywords: integrated medicine, diabetic foot ulcer, Chinese herbal, acupuncture, refractory DFU

    Study: Antiobitics, probiotics together eradicate bacteria that infect wounds

    By combining antibiotics and probiotics, researchers have developed a one-two punch to eradicate two strains of drug-resistant bacteria that often infect wounds, according to a preclinical study … MIT researchers encapsulated probiotic bacteria in a protective shell of alginate, which is a biocompatible material that prevents the probiotics from being killed by the antibiotic. The findings were published Wednesday in the journal Advanced Materials … Probiotics, which are good live bacteria and yeasts, help send food through the digestive system by affecting nerves that control gut movement. Probiotics come from supplements, as well as foods that are prepared by bacterial fermentation, including yogurt, kefir, sauerkraut, tempeh and kimchi … read more

    related: Probiotics and antibiotics create a killer combination

    AmpliPhi Biosciences Announces Updated Positive Clinical Results

         for its Expanded Access Program

     

    • 21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program
    • Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 and have been generally well tolerated, with no serious adverse events attributable to bacteriophage treatment
    • 84% of patients achieved treatment success at the end of therapy

     

    AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing single-patient expanded access program. 84% of patients achieved treatment success (physician’s assessment) at the end of therapy, defined as complete resolution or significant improvement of baseline signs and symptoms.

     

    AmpliPhi has now provided its investigational bacteriophage therapeutics for a total of 21 patients, at 7 hospitals, with serious or life-threatening infections not responding to antibiotic therapy. These patients were treated with AB-SA01 or AB-PA01 under single-patient expanded access programs in the U.S. (Emergency INDs per the U.S. Food and Drug Administration) or Australia (Special Access Scheme per the Australian Therapeutic Goods Administration). The following analysis updates the data previously announced by the company on January 3, 2018 … read more

    Consensus on the Diagnosis and Treatment of Adult Necrotizing Fasciitis

    Consensus on the Diagnosis and Treatment of Adult Necrotizing Fasciitis

    A 2024 expert consensus published in the Chinese Medical Journal provides comprehensive guidance on the diagnosis and treatment of adult necrotizing fasciitis (NF), a rapidly progressive soft tissue infection with high mortality. The statement, developed by leading Chinese clinicians, aims to improve early recognition and standardize treatment protocols across medical centers.

    Consensus Highlights:

    • Clinical Recognition: NF should be suspected in patients with rapidly worsening pain, skin discoloration, bullae, and systemic toxicity—especially when pain is disproportionate to exam findings.
    • Laboratory and Imaging Clues: Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score, elevated CRP, and CT/MRI can support early diagnosis, but clinical judgment remains paramount.
    • Surgical Emergency: Early, aggressive surgical debridement is emphasized as the most critical component of treatment. Repeated exploration may be required.
    • Antibiotic Therapy: Broad-spectrum intravenous antibiotics should be started promptly. Recommended regimens include carbapenems or beta-lactam/beta-lactamase inhibitor combinations, with coverage for MRSA and anaerobes as indicated.
    • Supportive and Adjunctive Measures: Hemodynamic stabilization, organ support, nutritional support, and optionally hyperbaric oxygen therapy are addressed as key components of a multidisciplinary approach.

    Conclusion: The consensus provides standardized criteria for early recognition and coordinated management of necrotizing fasciitis. Timely diagnosis, surgical debridement, and appropriate supportive care are essential to reducing mortality in this severe infection.

    Keywords: necrotizing fasciitis, LRINEC score, surgical debridement, broad-spectrum antibiotics, Chinese Medical Journal, hyperbaric oxygen

    Read the full consensus statement on PubMed Central

    Simple and Effective: 2% Citric Acid Ointment for Wound-Bed Preparation in Chronic, Infected Wounds

    Simple and Effective: 2% Citric Acid Ointment for Wound-Bed Preparation in Chronic, Infected Wounds

    Summary: A case series from India (MIMSR Medical College, Latur) reports on 24 chronic wounds that failed conventional therapy for more than three weeks. Application of 2% citric acid ointment once daily led to healthy granulation tissue in **all cases** (3 to 20 applications), even with antibiotic-resistant bacteria present. The approach offers a low-cost, accessible option for wound bed preparation when standard treatments fall short.

    Key Highlights:

    • Wounds included large raw areas and were resistant to standard treatments (various antiseptics, topical antimicrobials) for over three weeks.
    • Cultures identified multiple organisms: most common Staph aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella, etc.; many were multidrug resistant.
    • No systemic antibiotics were used unless systemic symptoms (fever, toxemia) present; local citric acid alone controlled infection and induced granulation.
    • Healthy granulation suitable for grafting or continued healing observed in all patients after 3 to 20 topical applications. No local toxicity reported.
    • Authors note limitations including small sample size, observational design, absence of control; however results suggest potent efficacy of citric acid ointment in challenging wounds.

    Read the full article in *Wound Management & Prevention*

    Keywords:
    citric acid ointment,
    wound bed preparation,
    chronic infected wounds,
    MIMSR Medical College,
    antibiotic resistant organisms

    Osteomyelitis in Pressure Ulcers



    Osteomyelitis in Pressure Ulcers

    Summary:** This best practice statement (BPS) from Wounds UK addresses osteomyelitis in pressure ulcers, affecting 20-30% of deep cases, with guidelines for diagnosis (MRI preferred, 90% sensitivity), treatment (6-12 weeks antibiotics, debridement for exposed bone), and prevention (offloading, nutrition). It emphasizes MDT care for 70% healing rates, reducing amputation risks, and calls for training to recognize symptoms like sinus tracts in pressure ulcers.

    Key Highlights:

    • Diagnosis: MRI for bone edema; probe-to-bone test 80% accurate; biopsy for culture.
    • Treatment: IV antibiotics (vancomycin for MRSA); surgical debridement for 50% faster resolution.
    • Prevention: Weekly pressure relief; nutrition (albumin >3g/dL); offloading 80% compliance.
    • Outcomes: 70% healing with MDT; 20% amputation if untreated.
    • Implications: BPS for pressure ulcer protocols; training for GPs/nurses.

    Read full article

    Keywords: osteomyelitis, pressure ulcers, MRI diagnosis, antibiotic therapy, debridement

    AiCuris Announces Expansion of its Collaboration with Lysando with a Focus on Diabetic Foot Infections

    AiCuris Anti-infective Cures AG, a leading company in the discovery and development of drugs against infectious diseases, and the biotechnology company Lysando AG with its Regensburg-based subsidiary Lysando GmbH, today announced the expansion of their existing long-term collaboration for the development and optimization of Artilysin(R)-based drug candidates for the topical treatment of infected, chronic wounds such as diabetic foot infections.

    AiCuris and Lysando joined forces in 2019 to drive the fight against antimicrobial resistance, with innovative approaches based on Lysando’s Artilysin(R) technology platform, a new class of phage-lysine derived artificial designer molecules with a novel mode of action and the potential to replace conventional antibiotics. Under the terms of the agreement … read more

    Beating Biofilm Is Key to Fighting Surgical Infections

    Health care is at a perilous crossroads. “[D]eaths from drug-resistant infections are set to skyrocket to over 10 million per year worldwide and could cost the global economy as much as $100 trillion by 2050,” a STATISTICA article reports. The same concerning fact is stressed by United States public health officials, who agree that “antimicrobial resistant pathogens (AMR) threaten everyone”.Both reports suggest a grim future of consequences from bacterial resistance, with U.S. officials believing AMR is occurring at a rate of more than 2.8 million antibiotic resistant infections in the U.S. each year, ending in a heavy economic price and over 35,000 deaths annually. The Centers for Disease Control and Prevention (CDC) believes “no one can completely avoid the risk of resistant infections, with some people at greater risk than others.” Eye-opening research suggests at least 80% of these infections are biofilm related … read more

    A Review: Matrix Metallopeptidase-9 Nanoparticles Targeted for the Treatment of Diabetic Foot Ulcers

    Diabetes foot ulcers are a leading cause of death in diabetic individuals. There are very few medicines and treatments that have received regulatory clearance for this indication, and numerous compounds from various pharmacological classes are now in various stages of clinical studies for diabetic foot ulcers treatment. Multiple risk factors contribute to diabetic foot ulcers, including neuropathy, peripheral artery disease, infection, gender, cigarette smoking, and age. The present difficulties in diabetic foot ulcers treatment are related to bacterial resistance to currently utilized antibiotics. Inhibition of the quorum sensing (QS) system and targeting matrix metallopeptidase-9 (MMP-9) are promising. This study focuses on the difficulties of existing treatment, current treatment technique, and novel pharmacological targets for diabetic foot ulcer. The electronic data base search diabetic for literature on foot ulcers treatment was carried out using Science Direct, PubMed, Google-Scholar, Springer Link, Scopus, and Wiley up to 2021. Becaplermin, a medication that targets MMP-9, glyceryl trinitrate, which inhibits the bacterial quorum sensing system, probiotic therapy, and nano technological solutions are just a few of the novel pharmaceuticals being developed for diabetic foot ulcers … read more

    The role of non-medicated dressings for the management of wound infection

    Author(s): Thomas Bjarnsholt, Val Edwards-Jones, Matthew Malone, Karen Ousey, Mark Rippon, Alan Rogers, Samantha Westgate, Sabine Eming, Isabelle Fromantin, Astrid Probst, Hans Smola, Hui-Mei Yang, Jiun-Ting Yeh, Steven Percival

     

    Every wound type has the potential to develop serious infection, which in some cases can lead to chronicity, bone infections, long-term disabilities or even death. Bacteria within a wound will exist in either planktonic or biofilm forms, with treatment mostly by use of topical antimicrobials or antibiotics. Alarmingly, there is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance in many common bacterial pathogens and the misuse of antimicrobial agents … read more

    The Role of Probiotics in Healing Burns and Skin Wounds

    The Role of Probiotics in Healing Burns and Skin Wounds: An Integrative Review in Regenerative Medicine

    Summary: In an open-access review published in Life (2025, Vol. 15, Issue 9), Lenuta Ambrose, Ciprian Adrian Dinu, Gabriela Gurau, Nicoleta-Maricica Maftei, Madalina Nicoleta Matei, Maria-Andrada Hincu, Marius Radu, and Mihaela-Cezarina Mehedinti examine the evolving evidence supporting use of probiotics and postbiotics in burn care and skin wound healing. The review connects mechanistic insights—anti-inflammatory, immunomodulatory, antimicrobial, regenerative—with translational and pilot clinical outcomes, emphasizing safety, strain selection, and formulation options (topical, systemic) in different wound contexts.

    Key Highlights:

    • Probiotics are being investigated not only for gut health but also topically in gels, biofilms, and impregnated dressings, showing promise in reducing bacterial colonization, accelerating re-epithelialization, and promoting angiogenesis.
    • Postbiotics—non-living bioactive compounds produced by probiotic organisms (like peptides, short-chain fatty acids, polysaccharides)—offer similar regenerative benefits with potentially fewer risks.
    • The gut–skin axis is considered: systemic health, microbiota balance, and immune modulation are recognized as contributing to outcomes in burn and wound care.
    • Preclinical models (animal and in vitro) and early clinical studies show positive outcomes, but heterogeneity in strains, dosage, mode of delivery, and timing remain major barriers to standardization.
    • In the context of antimicrobial resistance, probiotics/postbiotics are seen as potential adjunct or alternative therapies, helping reduce dependency on systemic antibiotics.

    Read the full review in Life

    Keywords:
    probiotics,
    postbiotics,
    burn healing,
    skin wounds,
    regenerative medicine,
    immunomodulation,
    Lenuta Ambrose,
    Ciprian Adrian Dinu,
    Gabriela Gurau,
    Nicoleta-Maricica Maftei,
    Madalina Nicoleta Matei,
    Maria-Andrada Hincu,
    Marius Radu,
    Mihaela-Cezarina Mehedinti

    Evidence Review & Consensus: Dialkylcarbamoyl Chloride (DACC)–Coated Wound Dressings

    Evidence Review & Consensus: Dialkylcarbamoyl Chloride (DACC)–Coated Wound Dressings

    Summary: A Wounds International expert consensus document evaluates the clinical role of DACC-coated wound dressings, which bind microorganisms through hydrophobic interactions rather than releasing active antimicrobial agents. This mode of action reduces resistance risk and preserves host tissue, offering a unique option for wounds at risk of infection.

    Key Highlights:

    • Mechanism: DACC attracts and irreversibly binds hydrophobic microbes, physically removing them when the dressing is changed, rather than killing them chemically.
    • Evidence base: Systematic reviews and clinical studies support effectiveness in reducing bioburden and promoting healing in diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and burns.
    • Safety: No cytotoxicity; suitable for fragile tissue. Dressings are biocompatible and safe across a wide range of wound types and patient populations.
    • Consensus: The panel positions DACC dressings as a valuable first-line tool for infection prevention and adjunctive therapy in wounds with high microbial burden or delayed healing.
    • Health economics: By reducing infection rates and antibiotic use, DACC dressings may contribute to lower overall treatment costs and improved antimicrobial stewardship.

    Read the full consensus document on Wounds International

    Keywords:
    DACC wound dressing,
    antimicrobial stewardship,
    bioburden control,
    diabetic foot ulcer,
    venous leg ulcer,
    pressure ulcer

    Topical Pravibismane Shows Promise for Diabetic Foot Infections



    Phase 1b Results: Topical Pravibismane Shows Promise for Diabetic Foot Infections

    Summary: This phase 1b randomized, multi-center, double-blind, placebo-controlled trial assessed topical pravibismane—a novel broad-spectrum anti-infective targeting biofilm-associated pathogens—as an adjunct to standard care for moderate to severe diabetic foot ulcer (DFU) infections in 53 patients over 4 weeks. Primarily evaluating safety, the study also captured efficacy signals, revealing nearly 3-fold greater wound size reduction, lower amputation rates, and microbiological clearance of key pathogens compared to placebo. Well-tolerated across doses with no significant safety issues, pravibismane addresses antimicrobial resistance and biofilm challenges, potentially reducing reliance on systemic antibiotics and supporting faster wound closure in this high-risk population.

    Key Highlights:

    • Trial design: Double-blind, placebo-controlled; topical application over 4 weeks; primary endpoint safety/tolerability; secondary: wound reduction, amputations, microbiology.
    • Efficacy: ~3x greater ulcer size reduction vs. placebo; reduced lower extremity amputations; effective against biofilm-forming bacteria in DFUs.
    • Safety: Well-tolerated with no significant concerns; supports advancement to larger trials.
    • Expert quote (Benjamin Lipsky, MD): “We are pleased with the safety results and signals of clinical efficacy, which we believe warrant further clinical development… There is currently a major unmet need for new, easy-to-apply drug agents with multiple modes of activity to treat infection.”
    • Expert quote (David Armstrong, DPM, PhD): “We are encouraged by the clinical efficacy signals… We need new agents that promote faster closing of infected wounds because we are currently dependent on an expensive, time-consuming, two-pronged approach.”
    • Future: Sponsored by Microbion; data published in International Wound Journal (April 3, 2024); plans for further development in DFI treatment.

    Read full article

    Keywords: topical pravibismane, diabetic foot ulcer infection, biofilm targeting, wound size reduction, amputation prevention, Benjamin Lipsky, David Armstrong, Microbion

    Dual-Species Biofilm Model: Advancing Antibiofilm Testing for Wound Care



    Dual-Species Biofilm Model: Advancing Antibiofilm Testing for Wound Care

    Summary: This study introduces a biorelevant in vitro dual-species biofilm model using an electrospun gelatin-glucose (Gel-Gluc) matrix to mimic chronic wound environments and test antibiofilm wound dressings. Focusing on common wound pathogens like *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*, the model supports robust biofilm growth (up to 10^8 CFU/matrix after 24 hours) and enables evaluation of electrospun polycaprolactone (PCL) dressings loaded with chloramphenicol (CAM) or ciprofloxacin (CIP). PCL-CIP effectively prevented biofilm formation and treated established biofilms, particularly against Gram-negative species, while PCL-CAM was bacteriostatic. The model’s reproducibility and visualization tools (confocal microscopy, selective agars) highlight its utility for developing targeted therapies against polybacterial infections in chronic wounds, including diabetic foot ulcers.

    Key Highlights:

    • Dual-species biofilms (*S. aureus* + *E. coli* or *P. aeruginosa*, *E. coli* + *P. aeruginosa*) reached 10^7–10^8 CFU/matrix in 24 hours on Gel-Gluc, with Gram-negative dominance after 48 hours.
    • PCL-CIP prevented biofilms (undetectable bacteria) and reduced established ones (1.8–3.9 log CFU decrease), outperforming PCL-CAM, which only inhibited growth.
    • Optimization: Homogenization over sonication improved bacterial recovery; confocal/SEM imaging confirmed interspecies microcolonies and spatial distribution.
    • Challenges: *S. aureus* survival in *P. aeruginosa* co-cultures due to exoproducts, mimicking real-world resistance in chronic wounds.
    • Implications: Model aids development of localized antibiotic dressings to combat biofilms in 80% of chronic wounds, reducing amputation risks in diabetic cases.

    Read full article

    Keywords: dual-species biofilm, antibiofilm dressings, chronic wound model, electrospun PCL, polybacterial infections, Kelli Randmäe, Kairi Lorenz, Marta Putrinš

    First Report of *Cystobasidium slooffiae* in Human Wounds from China



    First Report of *Cystobasidium slooffiae* in Human Wounds from China: Molecular Identification and Clinical Insights

    Summary: First Chinese cases of *C. slooffiae* isolated from wound infections in 2 immunocompromised patients: a 15-year-old trauma patient with persistent sinus tract (healed after debridement/antibiotics) and a 67-year-old with non-healing calf ulcers (ongoing). Yeast showed pink-orange colonies, Gram-positive budding cells; identified via ITS/18S rDNA sequencing. High MICs to echinocandins (>8 μg/mL) and fluconazole (32-64 μg/mL), low to isavuconazole/amphotericin B (0.75-1/0.5 μg/mL). Erg11 analysis confirmed distinct clade; highlights need for molecular ID and alternative antifungals in opportunistic wound infections.

    Key Highlights:

    • Cases: Trauma wound (healed Jan 2022); chronic ulcers in diabetes/autoimmune (ongoing).
    • Micro: Orange colonies on SDA; budding cells; MALDI-TOF failed; ITS confirmed.
    • Susceptibility: Echinocandins/fluconazole resistant; isavuconazole/amphotericin susceptible.
    • Erg11: Distinct from Rhodotorulaceae; no mutations for azole resistance.
    • Implications: Emerging pathogen; use molecular diagnostics, avoid empiric echinocandins.

    Read case report

    Keywords: Cystobasidium slooffiae, wound infections, China, antifungal susceptibility, echinocandins, Jingjing Huang, Lijing Guo, Ge Zhang

    Study of 236 patients reveals utility of MolecuLight i:X® in detection and management of wound-related cellulitis

    Published results describe use of point-of-care imaging for the early detection and proactive management of wound-related cellulitis

     

    TORONTOOct. 12, 2021 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication in International Wound Journalof an independent prospective observational study examining the impact of incorporating fluorescence imaging into standard care for the diagnosis and management of wound-related cellulitis. Dr. Charles Andersen, a surgeon at the Madigan Army Medical Center, led this study on wound-related cellulitis, defined as an invasion of bacteria from chronic wounds into the adjacent dermis.

    “The results of this study show how MolecuLight point-of-care imaging presents an intriguing solution to revealing extension of bacteria into tissue, reducing misdiagnosis of wound-associated cellulitis, and enabling more proactive early treatment, particularly in patients lacking obvious symptoms”, says Dr. Charles A. Andersen, Chief, Vascular/ Endovascular and Limb Preservation Surgery Service (Emeritus), Chief Wound Care Service and Medical Director Wound Care Clinic at Madigan Army Medical Center, Tacoma, WA. “Given that at least 30% of cellulitis cases are misdiagnosed,6,5 the addition of consistent and objective information provided by fluorescence scans can significantly reduce the uncertainty associated with diagnosis of wound-related cellulitis. In addition, the use of fluorescence imaging to support earlier detection and proactive management of wound-related cellulitis can limit progression of infection and avoid the need for intravenous antibiotics and the high costs associated with inpatient admission”.

    An example case of wound-related cellulitis from the study is shown (above) where the wound does not appear to have cellulitis or elevated bacterial burden upon assessment with standard-of-care clinical signs and symptoms (left). In contrast, when imaged with the MolecuLight i:(right), an irregular pattern of red (bacterial) fluorescence extending beyond the wound bed and periwound is visible, and could not be removed with vigorous cleansing, indicating that the bacteria are located subsurface. This pattern of red fluorescence, demonstrating invasive extension of bacteria into surrounding tissues, was consistent in all wounds in the study where wound-related cellulitis was diagnosed.

    Dr. Andersen will present the findings of this publication in a talk titled, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging at the upcoming clinical conference, SAWC (Symposium on Advanced Wound Care) Fall 2021 on Sunday, October 31, 2021 at 9:00 am at Caesars Palace in Las Vegas, Nevada.

    References

    1

    Andersen, C.A. et al, “Diagnosis and Treatment of the Invasive Extension of Bacteria (Cellulitis) from Chronic Wounds Utilizing Point-of-Care Fluorescence Imaging“, International Wound Journal 2021: 1-13

    2

    Lazzarini L et al, J Infect. 2005;51(5):383-389.

    3

    Raff AB et al, JAMA. 2016;316(3): 325-337.

    4

    Pasternack MS. Mandell, Douglas, & Bennett’s Principles & Practice of Infectious Diseases. Vol 1; Phil., PA: Churchill Livingstone/Elsevier; 2010:1289-1312.

    5

    Weng QY et al, JAMA Dermatol. 2017;153(2):141-146.

    6

    Levell NJ et al, Br J Dermatol. 2011;164(6):1326-1328.

    About MolecuLight Inc.

    MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s first commercially released device, the MolecuLight i:X fluorescence imaging system and its accessories provide a point-of-care handheld imaging device for the global wound care market for the detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

    Image:
    Download at: https://moleculight.box.com/s/oab22c1vi8ud1j8oymylbfogp2lg12bk

    SOURCE MolecuLight

    Related Links

    www.moleculight.com

    Effects of Simultaneous versus Staged VAC Placement in the Treatment of Deep Neck Multiple-Space Infections at a …

    Tertiary Hospital Over a Four-Year Period in China

    Deep neck infections (DNIs) are a group of serious bacterial infections occurring in the potential spaces and fascia of the neck. The incidence of DNIs is not clear. Although many studies have shown that the incidence of DNIs has decreased due to the use of antibiotics and improvements in sanitary conditions, reports also indicate an increased incidence of DNIs in the last 10 years. Deep neck multiple-space infections (DNMIs) are the most serious among all types of DNIs and often spread further to cause mediastinal infections, invade the carotid sheath, and possibly compromise the airway, resulting in life-threatening conditions.

    Treatments for DNMIs include life-supporting measures, surgical drainage, and appropriate use of antibiotics. Among these treatments, surgical drainage is key. Although traditional extensive surgical drainage is effective for treating DNMIs, some limitations remain for this approach, ie, drainage depends on gravity, the locations for the drainage tube and incision are limited, dressing changes and wound irrigation more than once a day may increase patient suffering, and secondary wound infection may occur. In recent years, vacuum-assisted closure (VAC)

    Bacterial Biofilm Destruction: A Focused Review On The Recent Use of Phage-Based Strategies With Other Antibiofilm Agents

    Biofilms are bacterial communities that live in association with biotic or abiotic surfaces and enclosed in an extracellular polymeric substance. Their formation on both biotic and abiotic surfaces, including human tissue and medical device surfaces, pose a major threat causing chronic infections. In addition, current antibiotics and antiseptic agents have shown limited ability to completely remove biofilms. In this review, the authors provide an overview on the formation of bacterial biofilms and its characteristics, burden and evolution with phages. Moreover, the most recent possible use of phages and phage-derived enzymes to combat bacteria in biofilm structures is elucidated. From the emerging results, it can be concluded that despite successful use of phages and phage-derived products in destroying biofilms, they are mostly not adequate to eradicate all bacterial cells. Nevertheless, a combined therapy with the use of phages and/or phage-derived products with other antimicrobial agents including antibiotics, nanoparticles, and antimicrobial peptides may be effective approaches to remove biofilms from medical device surfaces and to treat their associated infections in humans … read more

    AmpliPhi Biosciences Will Utilize NIAID Preclinical Services to Advance

    Development of Its Targeted Therapeutic Candidate for the Treatment of Resistant Staphylococcus Aureus

     

    SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it will utilize the Therapeutic Development Services funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to conduct further preclinical studies of AB-SA01. The Therapeutic Development Services program funds the provision of preclinical services for selected companies and researchers in order to advance development of promising interventional agents.

     

    “We are pleased and encouraged by the support from the NIAID and its commitment to studying the role of bacteriophage in combating infectious diseases,” said Paul C. Grint, M.D., CEO of AmpliPhi Biosciences. “This service will help support the development of bacteriophages as a much needed treatment for antibiotic-resistant infections.”

     

    AB-SA01 is a 3-phage investigational therapeutic being developed for treatment of serious and drug-resistant Staphylococcus aureus (S. aureus) infections. In preclinical studies, AB-SA01 demonstrated broad activity against more than 96% of global S. aureus clinical isolates, including multidrug-resistant forms. AB-SA01 has completed two Phase 1 studies and has also been administered to patients under compassionate use guidelines in the U.S. and Australia for treatment of serious and life-threatening S. aureus infections … read more

    Wound Healing Sped Up by Patient’s Own Platelets

    The University of Cincinnati is reporting that a team of clinicians under David Hom, MD, an otolaryngologist, completed a study that demonstrated that a gel containing a patient’s own platelets (autologous platelet gel or APG) is more effective in promoting skin wound healing than a control antibiotic ointment.

    It is believed to be one of the earliest preliminary studies comparing the effectiveness of APG on skin wounds in healthy humans.
    Four male and four female volunteers aged 21-58 received five full-thickness skin punch wounds (4 mm diameter) on each thigh. APG was applied topically to the punch sites (one to two times) on one thigh and antibiotic ointment to the other, and the wounds were monitored for six months … read more

    Manipulating the microbiome alters regenerative outcomes in

    Xenopus laevis tadpoles via lipopolysaccharide signaling

    Phoebe A. Chapman, Campbell B. Gilbert, Thomas J. Devine, Daniel T. Hudson, Joanna Ward, Xochitl C. Morgan, Caroline W. Beck

     

    Xenopus laevis tadpoles can regenerate functional tails, containing the spinal cord, notochord, muscle, fin, blood vessels and nerves, except for a brief refractory period at around 1 week of age. At this stage, amputation of the tadpole’s tail may either result in scarless wound healing or the activation of a regeneration programme, which replaces the lost tissues. We recently demonstrated a link between bacterial lipopolysaccharides and successful tail regeneration in refractory stage tadpoles and proposed that this could result from lipopolysaccharides binding to Toll-like receptor 4 (TLR4). Here, we have used 16S rRNA sequencing to show that the tadpole skin microbiome is highly variable between sibships and that the community can be altered by raising embryos in the antibiotic gentamicin. Six Gram-negative genera, including Delftia and Chryseobacterium, were over-represented in tadpoles that underwent tail regeneration. Lipopolysaccharides purified from a commensal Chryseobacterium spp. XDS4, an exogenous Delftia spp. or Escherichia coli, could significantly increase the number of antibiotic-raised tadpoles that attempted regeneration. Conversely, the quality of regeneration was impaired in native-raised tadpoles exposed to the antagonistic lipopolysaccharide of Rhodobacter sphaeroides. Editing TLR4 using CRISPR/Cas9 also reduced regeneration quality, but not quantity, at the level of the cohort. However, we found that the editing level of individual tadpoles was a poor predictor of regenerative outcome. In conclusion, our results suggest that variable regeneration in refractory stage tadpoles depends at least in part on the skin microbiome and lipopolysaccharide signalling, but that signalling via TLR4 cannot account for all of this effect … from Wiley


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Piperacillin-tazobactam-Induced Pneumonitis: A Clinical Case Study

    William Urbas, DPM, FACFAS, Deep N. Shah, DPM MBA, and Alex Pilkinton, DPM

     

    This case study involves a 46-year-old male patient admitted with a localized necrotizing soft tissue infection of the right foot that developed an unusual and rare delayed hypersensitivity pneumonitis from the antibiotic Piperacillin-tazobactam … Drug hypersensitivity reactions present in multiple ways and have various presentations in timing. Piperacillin-tazobactam is a fourth-generation penicillin antibiotic combining a penicillin molecule (piperacillin) with a beta-lactamase inhibitor (tazobactam). Piperacillin-tazobactam is US Food and Drug Administration (FDA)-approved for 30-minute intravenous infusion at 2.25g, 3.375g, or 4.5g doses to help cover a broad spectrum of … read more


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)

    Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022

     

    SARASOTA, Fla., April 5, 2022 /PRNewswire/ — Lakewood-Amedex, Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins®, announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU). More than 34 million adults in the United States have diabetes mellitus (Source: CDC), and complications of DFU are responsible for about 85% of the non-traumatic lower extremity amputations per year, creating a tremendous morbidity, mortality, and financial burden on the healthcare system.

     

    The Phase 2 study is a randomized, multi-center, double-blind, placebo-controlled, dose-escalating study to evaluate the safety and tolerability of topically applied Bisphosphocin Nu-3 gel on Type I or II diabetes mellitus patients with chronic DFU. During all clinic visits, the patients’ ulcers will be examined for any changes in the area and depth of the ulcer and microbiological control will be assessed.

     

    Steve Parkinson, President & CEO of Lakewood-Amedex, said, “We are very pleased to be embarking upon our second clinical trial in treating DFUs. In our previous experience evaluating Nu-3 for the treatment of patients with infected diabetic foot ulcers, Nu-3 was well-tolerated with no reported adverse events related to treatment. While this previous dose-escalating study was not powered to generate statistically significant efficacy data, it did demonstrate an encouraging efficacy trend. Patients treated with 2% Nu-3 solution for seven days had a 65.5% reduction in ulcer area versus a 29.9% reduction in the placebo arm, as measured 14 days after treatment began. In addition, 62.5% of patients treated with 2% Nu-3 saw a reduction in the microbiological load, versus 20% in the placebo. Now our Phase 2 dose-escalating study will build on the foundation of the previous clinical trials by using a longer treatment duration of 28 days, a higher concentration of 5% followed by 10% Nu-3, as well as an improved Nu-3 gel formulation, all of which we expect will offer a better delivery of Nu-3 and treatment of nonhealing wounds. The impact of both topical and systemic infections remains a tremendous burden on the healthcare system. We believe our commitment to further developing our proprietary, antimicrobial Bisphosphocins technology platform with efficient, localized treatment of serious infections, often caused by antibiotic-resistant pathogens, both gram-positive and gram-negative, will enable healthcare providers to more safely and effectively address a host of bacterial infections that are currently proving challenging using conventional approaches.”

     

    “Dr. Felix Sigal, who is one of the most distinguished specialists in the field of diabetic limb salvage, is on staff at both the Hollywood Presbyterian Medical Center and the California Hospital Medical Center. He focuses on wound care and diabetic limb salvage, while pursuing his interest in clinical research to enable better treatment options for his patients. We are pleased to report that Dr. Sigal has now enrolled the first patient in this Phase 2 study evaluating the use of Nu-3 gel in the treatment of diabetic foot ulcers,” said Sumita Paul, MD, MPH, MBA, Chief Medical Officer & Senior Vice President of Research & Development at Lakewood-Amedex Inc. “There will be 12 patients treated with the Nu-3 gel in each of the two cohorts and with a smaller placebo treated group.”

     

    About Lakewood-Amedex, Inc.

    Lakewood-Amedex is a privately held, clinical stage pharmaceutical company developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins. The company’s products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets. The company’s lead therapeutic candidates are novel synthetic broad-spectrum antimicrobials proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and all fungal strains tested. Nu-3 has already completed a Phase 2a clinical trial in patients with infected diabetic foot ulcers. For more information, https://lakewoodamedex.com.

     

    This press release contains forward-looking statements that can be identified by terminology such as “expects,” “potential,” “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

     

    Contacts
    Tiberend Strategic Advisors, Inc.

     

    Investors
    Lisa Sher
    lsher@tiberend.com

     

    Media
    Dave Schemelia
    dschemelia@tiberend.com

     

    SOURCE Lakewood-Amedex Inc.

     

    This article was originally published here

    Risk Factors for Multidrug-Resistant Organisms Infection in Diabetic Foot Ulcer

    Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes.1 Epidemiological investigation found that the global prevalence of DFU is 6.3%, and what is more troublesome is that DFU also has a high recurrence rate.3 Cohort studies have shown that DFU have a high mortality rate in both developed and developing countries, with a 5-year mortality rate of up to 42%. With high morbidity and mortality, DFU has been the main cause of nontraumatic lower-limb amputations. We have developed a model for predicting the risk of early DFU, which may potentially guide early intervention. Hyperglycemia impair immune cells activity in eliminating pathogens, while severe infection can cause stress hyperglycemia. The interaction of the two ways has resulted in a rapid development of diabetic foot infection (DFI) and sometimes a necrotizing abscess can be developed in just 6 days. Early empiric antibiotic treatment is necessary due to the long culture time of microorganisms and the lack of basic microbiology laboratories. But Multidrug-resistant organisms (MDROs) infection is easy to make antibiotic treatment failure, increasing the difficulty of diabetic foot treatment … read more

    Exploring the Benefits of Metal Ions in Phage Cocktail for the Treatment of

    Methicillin-Resistant Staphylococcus aureus (MRSA) Infection

     

    Xinxin Li, Yibao Chen, Shuang Wang, Xiaochao Duan, Fenqiang Zhang, Aizhen Guo, Pan Tao, Huanchun Chen, Xiangmin Li, Ping Qian

     

    The Gram-positive Staphylococcus aureus, an important zoonotic pathogen caused bacteremia, endocarditis, and tissue infection in humans and animals, are listed as a “high priority” pathogen by the World Health Organization (WHO). It is estimated that in the absence of new antibiotic alternatives, by 2050, antibiotic-resistant pathogens will cause around 10 million deaths worldwide. The emergence of methicillin-resistant S. aureus (MRSA) and vancomycin-resistant S. aureus (VRSA) have brought challenges to clinical treatment … Bacteriophages (phages), first discovered in the early 20th century, are the most abundant organism in the world … read more

    Implant Salvage in Patients With Severe Post-Fracture Fixation Surgical Site Infection

    Using Negative Pressure Wound Therapy With Intramedullary and Subcutaneous Antibiotic Perfusion

     

    Surgical site infection (SSI) after fracture fixation is associated with higher-grade Gustilo-Anderson open fractures (ie, type III).1,2 Patients with SSI that has progressed to deep infection or osteomyelitis must undergo multiple surgeries and may experience permanent dysfunction at the fracture site. Radical surgical debridement, orthopedic implant removal, and systemic antibiotic administration are generally performed to control SSIs. Orthopedic implant removal is considered to be an efficacious procedure. For example, 28% to 79% of orthopedic implants are removed after foot, ankle, or lower leg fracture surgery.3,4 After orthopedic implant removal, postoperative SSI rates are reportedly 0% to 20%.3-5 The standard-of-care therapeutic regimen is insufficient in the management of SSI after fracture fixation. Some studies have reported the use of negative pressure wound therapy with instillation and dwell time … read more

    Implant Salvage in Patients With Severe Post-Fracture Fixation Surgical Site Infection

    Using Negative Pressure Wound Therapy With Intramedullary and Subcutaneous Antibiotic Perfusion

     

    Keisuke Shimbo, Tatsuhiko Saiki, Haruka Kawamoto, Isao Koshima

     

    Surgical site infection (SSI) after fracture fixation is associated with higher-grade Gustilo-Anderson open fractures (ie, type III).1,2 Patients with SSI that has progressed to deep infection or osteomyelitis must undergo multiple surgeries and may experience permanent dysfunction at the fracture site. Radical surgical debridement, orthopedic implant removal, and systemic antibiotic administration are generally performed to control SSIs. Orthopedic implant removal is considered to be an efficacious procedure. For example, 28% to 79% of orthopedic implants are removed after foot, ankle, or lower leg fracture surgery.3,4 After orthopedic implant removal, postoperative SSI rates are reportedly 0% to 20%.3-5 The standard-of-care therapeutic regimen is insufficient in the management of SSI after fracture fixation. Some studies have reported the use of negative pressure wound therapy … read more

    Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

    admin
    • Poster highlights pravibismane’s MIC activity in testing against aerobic and anaerobic pathogens isolated from diabetic foot infection patients
    • Pravibismane demonstrated potent, broad-spectrum activity against a wide range
      of pathogens, including MRSA, MSSA, and P. aeruginosa

    BOZEMAN, Mont., May 10, 2023 /PRNewswire/ – Microbion Corporation today announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands. The poster highlights pravibismane’s activity versus comparator antibiotics against pathogens isolated from diabetic foot infection (DFI) patients in an earlier Phase 1b clinical study.

    Poster Details:
    Representative image (CNW Group/Microbion Corporation)

    Representative image (CNW Group/Microbion Corporation)

    Title: Broad-Spectrum, Potent Activity of Pravibismane Versus Comparators Against Diabetic Foot Ulcer Infection Patient Isolates Collected in a Phase 1b Study

    Presenter: Dr. Jeff Millard, CSO

    Poster Highlights:
    • Most common pathogens isolated from DFI subjects (N = 44) at baseline were: methicillin-susceptible Staphylococcus aureus [MSSA (25%)]; methicillin-resistant Staphylococcus aureus [MRSA (18.2%)]; Enterococcus faecalis (13.6%); and Pseudomonas aeruginosa (11.4%).
    • Mean pravibismane minimum inhibitory concentration (MIC) (µg/mL) for S. aureus MSSA was 0.21, S. aureus MRSA was 0.17, E. faecalis was 2.53, and P. aeruginosa was 1.43.
    • Mean pravibismane MICs for 12 of the 13 anaerobic bacteria was ≤1 µg/mL, including against Finegoldia magna and Anaerococcus spp.
    • Pravibismane exhibited similar or lower MIC relative to a panel of comparator antibiotics, including (but not limited to) levofloxacin, linezolid, clindamycin, and piperacillin-tazobactam, against Gram-positive and Gram-negative, susceptible and resistant, aerobes and anaerobes.

    "We are pleased that pravibismane demonstrated extremely potent MIC activity against clinical DFI isolates, which was in line with in vitro AST microbial pre-clinical studies," said Dr. Jeff Millard, CSO of Microbion Corp. "Diabetic foot infections are often infected by several different bacterial species concurrently, which may change over the chronicity of the wound, from predominantly aerobic to anaerobic. We believe pravibismane’s potent broad-spectrum activity is potentially a key treatment advantage since a single agent could eradicate both aerobic and anaerobic bacteria, thereby decreasing the need for multiple systemic therapies."

    Bacterial cultures for this study were grown from swabs collected at the wound bed at baseline visit and antimicrobial susceptibility testing (AST) was performed on isolated pathogens. Pathogen isolation and AST was performed at Investigational Health Management Associates (IHMA, IL), using the Clinical & Laboratory Standards Institute (CLSI) standard methods.

    Topical pravibismane has received QIDP and Fast Track drug designation from the US FDA for the adjunctive treatment of moderate and severe diabetic foot ulcer infections. Topical pravbismane is currently enrolling in a Phase 2 clinical study to further evaluate its safety and efficacy in subjects suffering from moderate infections associated with chronic diabetic foot ulcers.

    About Microbion

    Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.

    For more information visit: www.microbioncorp.com.

    Safe Harbor Statement

    Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    SOURCE Microbion Corporation

    Rare ‘Flesh-Eating’ Bacterium Spreads North as Oceans Warm

    Rare ‘Flesh-Eating’ Bacterium Spreads North as Oceans Warm

    Summary: Vibrio vulnificus, a rare but deadly marine bacterium, is gradually expanding its reach northward along the U.S. coast as ocean temperatures rise. Historically concentrated in Gulf of Mexico waters, the bacterium has begun appearing more frequently in the Pacific Coast and increasingly along the Eastern shoreline. WoundCareAdvisor notes that between 150 and 200 U.S. cases are reported annually, with about 20% resulting in death, and approximately 7% of cases in 2019 occurring on the Pacific Coast.

    Key Insights:

    • Cases remain rare (150–200/year), but with rising ocean temperatures and changing salinity, the geographical range of infections is expanding :contentReference[oaicite:1]{index=1}.
    • Vibrio vulnificus requires warm, brackish waters to thrive—conditions now extending further north due to climate-driven ocean warming :contentReference[oaicite:2]{index=2}.
    • Infections are highly fatal; early antibiotic treatment is critical, and clinicians in expanding risk zones should remain vigilant for necrotizing wound infections :contentReference[oaicite:3]{index=3}.

    Importance: As ocean warming continues, clinicians in previously unaffected regions must become aware of Vibrio vulnificus as a potential cause of severe wound infections. Early recognition and rapid antibiotic intervention are vital to prevent tissue necrosis and systemic complications.

    Keywords:
    Vibrio vulnificus,
    flesh-eating bacteria,
    ocean warming,
    necrotizing fasciitis,
    climate change and infections

    Choice of Primary Repair in Animal Bite Wounds: A Novel Management Strategy



    Choice of Primary Repair in Animal Bite Wounds: A Novel Management Strategy

    Summary: This article introduces a novel management strategy for animal bite wounds, primarily from dogs and cats, which pose significant risks especially to children due to potential infections from oral bacteria. Challenging the standard practice of surgical debridement followed by delayed primary closure, the study evaluates criteria for safe primary repair, demonstrating reduced infection rates, better cosmetic results, and shorter healing times in low-risk cases like facial bites with thorough irrigation and antibiotics.

    Key Highlights:

    • Animal bites often lead to polymicrobial infections; primary repair is feasible in clean, low-risk wounds after aggressive debridement and prophylactic antibiotics.
    • Facial bites in children benefit most from primary closure to prevent scarring and functional impairment.
    • Prospective evaluation shows infection rates under 2% with the novel protocol, compared to 5-10% in delayed closure.
    • Emphasizes multidisciplinary assessment including wound location, depth, and patient factors for decision-making.
    • Calls for updated guidelines to incorporate this strategy, reducing unnecessary delays in healing.

    Read full article

    Keywords:
    animal bite wounds,
    primary repair,
    delayed closure,
    wound infection prevention,
    pediatric wound management

    Debridement and ALBC in DFUs: Alleviating Pain and Improving Psychological Status



    Debridement and ALBC in DFUs: Alleviating Pain and Improving Psychological Status

    Summary: This retrospective study of 103 diabetic foot ulcer (DFU) patients examines the impact of debridement combined with antibiotic-loaded bone cement (ALBC) on pain and psychological status. Using Brief Pain Inventory (BPI) and Hospital Anxiety and Depression Scale (HADS), it found significant reductions in pain severity and impact scores (p<0.001), as well as anxiety and depression scores (p<0.001), particularly in patients with baseline symptoms. The treatment promoted wound healing in 69.9% of cases through infection control and granulation tissue formation, highlighting its role in comprehensive DFU management that addresses both physical and mental health.

    Key Highlights:

    • ALBC reduced pain scores in the pain group (n=61) from baseline, though they remained higher than in the numbness group (n=42), linking higher BMI and Wagner grade III to pain.
    • Anxiety scores decreased across groups (n=67 anxiety, n=36 non-anxiety), with fewer moderate/severe cases post-treatment, independent of pain relief.
    • Depression scores improved significantly (n=16 depression, n=87 non-depression), correlating with better wound progression and reduced exudate.
    • 69.9% of wounds showed healing with induced membrane and granulation tissue, minimizing enlargement and supporting fewer interventions.
    • Baseline psychological distress predicted greater improvements after adjusting for confounders like age and ulcer grade, advocating for integrated care.

    Read full article

    Keywords:
    diabetic foot ulcers,
    debridement,
    antibiotic loaded bone cement,
    pain management,
    psychological health

    Buruli Ulcer: Understanding the Silent Flesh-Eating Disease



    Buruli Ulcer: Understanding the Silent Flesh-Eating Disease

    Summary: This article explores Buruli ulcer, a debilitating neglected tropical disease (NTD) caused by the bacterium Mycobacterium ulcerans, often dubbed the “silent flesh-eating disease” due to its painless destruction of skin and soft tissues. Prevalent in West Africa, including Nigeria, it affects over 3,000 cases annually worldwide, leading to severe ulcers that can cause permanent disability if untreated. The piece emphasizes early detection, a combination of antibiotics (rifampicin and clarithromycin), and surgical debridement for wound care, alongside prevention through insect repellent, protective clothing, and community surveillance to curb outbreaks in contaminated aquatic environments.

    Key Highlights:

    • Transmission occurs via contact with contaminated water or mud, possibly through insect vectors like water bugs; no person-to-person spread.
    • Symptoms start as painless nodules or plaques, progressing to large ulcers with undermined edges, often on legs or arms, mimicking other skin conditions.
    • Diagnosis involves clinical assessment, PCR testing, or swab cultures; early intervention prevents progression to bone involvement or secondary infections.
    • Treatment combines 8-week oral antibiotics with wound dressings and surgery for extensive cases; WHO recommends rifampicin-clarithromycin regimen for 100% cure if caught early.
    • Prevention focuses on avoiding stagnant water, using DEET repellents, and early reporting; Nigeria reported 1,200 cases in 2023, underscoring need for awareness in rural areas.

    Read full article

    Keywords: buruli ulcer, flesh-eating disease, mycobacterium ulcerans, neglected tropical disease, wound debridement

    Microneedle patch penetrates biofilms to treat chronic wounds

    Chronic wounds such as diabetic foot ulcers can be very difficult to treat, partially because of antibiotic-resistant “biofilms” that form over the affected tissue. A new type of microneedle patch, however, has been shown to deliver medication through such films … Bacterial bioflms are made up of colonies of bacteria that stick together by building up a slimy polymer matrix. Unfortunately, topically applied antibiotics and other medications have difficulty penetrating that matrix, so they can’t reach the infected tissue underneath … read more

    AmpliPhi Biosciences Announces Presentation of Positive Clinical

    Data From its Expanded Access Program for Serious S. aureus Infections at IDWeek 2018 Conference

    AmpliPhi Biosciences Corporation (NYSE American:APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the presentation of clinical case series data from the company’s ongoing expanded access program for its investigational bacteriophage therapeutic, AB-SA01 targeting Staphylococcus aureus (S. aureus), at the IDWeek 2018 conference in San Francisco … Prof. Jonathan Iredell, Senior Staff Infectious Diseases Physician at the Westmead Hospital in Sydney, Director of Centre for Infectious Diseases and Microbiology at the Westmead Institute of Medical Research and Professor of Medicine and Microbiology at the University of Sydney, gave a presentation “Adjunctive bacteriophage therapy for severe Staphylococcal sepsis,” including data on 13 patients suffering from severe S. aureus infections, who were treated with AB-SA01 as an adjunct to antibiotics at the Westmead Hospital in 2017-2018. The potential treatment of S. aureus bacteremia with AB-SA01 was also the subject of the Company’s recent Type B meeting with the FDA. The treatment was conducted under emergency protocols per the Australian Therapeutic Goods Administration’s (TGA) Special Access Scheme (SAS) … read more

    Superbug-Resistant Bandages

    A staple of the news headlines in the UK over the past couple of years has been the periodic outbreak of so-called ‘Superbug’ infections in hospitals, when antibiotic-resistant strains of bacteria cause a high proportion of secondary infections in patients. Although the majority of such infections are relatively mild, they can develop into potentially fatal conditions including sepsis, toxic shock syndrome and necrotizing pneumonia. To keep things in context, the Superbug (or methicillin-resistant Staphylococcus aureus (MRSA)), for all its virulence, is simply the latest and most advanced version of a problem that spans human history – how to effectively combat bacterial infections that develop in wounds or injuries. Such infections were nearly always fatal before the development and wide-scale use of antibiotics; for example, in a military context, secondary infection and disease accounted for a far greater number of casualties than outright combat (at higher than a 2:1 ratio in the US Civil War) in the nineteenth century. In the ongoing medical arms race between diseases and treatment, then, MRSA is the next evolution on the side of the diseases, and a challenge that scientists and medics are working to meet … read more

    Diabetes UK commits £2.6 million to new research

    • New funding will be split between 14 new research projects and five new PhD grants
    • New research includes projects investigating whether medieval remedies can be used to treat foot ulcers, and if sleep disturbances can predict Type 2 diabetes

    Diabetes UK has committed to invest £2.6 million in 19 brand new projects which aim to make life-changing improvements in diabetes care, and reduce people’s risk of Type 2 diabetes.

     

    The funding will be given to projects looking into Type 1, Type 2 and gestational diabetes. In one of these projects, Dr Freya Harrison, from the University of Warwick, will be using medieval remedies to find new sources of antibiotics. She has already discovered a combination that can kill antibiotic-resistant bacteria in the lab. Dr Harrison will study this remedy further to investigate how it works and if it could be used to treat infected foot ulcers in the future.

     

    There are more than 20 leg, foot and toe amputations each day due to diabetes, four out of five of which could be prevented. This research hopes to reduce the number of diabetes-related amputations and cases of sepsis, by treating foot ulcer infections more effectively.

     

    Dr Martin Rutter, from the University of Manchester, has also been awarded Diabetes UK funding to find out if sleep problems can help predict who might be at risk of Type 2 diabetes. He will also look at whether sleep patterns in people with Type 2 diabetes can affect their blood glucose control, and their risk of serious diabetes-related complications, such as amputation, heart disease and blindness … read more

    Amniotic membrane can be a valid source for wound healing

    Abstract

    Amniotic membrane (AM) can promote proper epithelialization with suppression of excessive fibrosis by creating a supportive milieu for regeneration of chronic ulcer bed.

    Objective

    The objective of this study is to investigate whether AM scaffold can modulate the healing of a wound by promoting tissue reconstruction rather than promoting scar tissue formation.

    Subjects and methods

    AM was obtained and prepared and then applied to patients with chronic leg ulcers who were randomly divided into two different groups. Group I (control group) included eleven patients in whom ulcers were treated with conventional wound dressings that were changed daily for 8 weeks. Group II (study group) included 14 patients in whom the AM was placed in contact with the ulcer and held in place with a secondary dressing, which was changed daily. Follow-up was done to detect healing rate and detection of ulcer size, assessment of pain, and to take ulcer images (days 0, 7, 14, 21, 30, 45, and 60).

    Results

    In group I, all ulcers showed no reduction in their size, and ulcer floor remained the same. Healthy granulations were present in two ulcers (18.2%) and absent in nine ulcers (81.8%). There was no improvement of pain level in the eleven ulcers. In group II, complete healing of 14 ulcers occurred in 14–60 days with a mean of 33.3±14.7; healing rate range was 0.064–2.22 and the mean 0.896±0.646 cm2/day. Healthy granulations were present in 13 ulcers (92.9%) and absent in one ulcer (7.1%). Three ulcers (21.4%) were of mild severity (grade 1 ulcers) while eleven ulcers (78.6%) were of moderate severity (grade 2 ulcers). The healing rate was faster in ulcers of mild severity (1.7±0.438 cm2/day) in comparison to ulcers of moderate severity (0.673±0.498 cm2/day). Eleven cases (78.6%) showed improvement in their pain level on a scale from 0 to 10.

    Conclusion

    AM graft can be of value in wound healing. Further studies are needed to confirm these findings.

    Keywords: amniotic membrane, ulcer, placenta, cesarean section

    Introduction

    Amniotic membrane (AM) is an attractive method of grafting for wounds as it has unique properties, including anti-inflammatory effects, bacteriostatic, wound protection, decreased scarring, and pain reduction properties, as well as epithelialization initialization capacities. Furthermore, AM is widely available and less costly than other bioengineered skin substitutes. Human AM was used for 2,308 ophthalmologic reconstructions in Germany 2008. Its special success in ophthalmology may be due to the immune privileged properties of the AM.

     

    The anti-inflammatory property of AM seems to be a result of production of anti-inflammatory proteins and reduction of expression of transforming growth factor B and pro-inflammatory cytokines, such as interleukin. Also, AM produces B defensins, elastase inhibitors, elastin, and lactoferrin that contribute to its anti-inflammatory and antimicrobial effects. The reduction in scarring after application of AM to wounds might be due to the anti-inflammatory effects, acceleration of epithelialization, and inhibition of fibrosis. Accelerated reepithelialization was also demonstrated by Maral et al after covering split thickness skin graft with AM in rats. Loeffelbein et al demonstrated accelerated formation of basement membrane in wounds treated with AM that might be due to the release of growth factors. One of the most important properties of AM as a skin substitute is pain relieving which may be due to diminished inflammation, better hydration of wound bed, and protection of exposed nerve endings. AM expresses few antigens, which accounts for its good tolerability and the absence of rejection reactions. AM expresses many neurotrophic and angiogenic factors: endothelin-2 and -3, vascular endothelial growth factor, vascular endothelial growth factor-B, Tie-2 angiopoietin receptor, ephrin-A2, ephrin receptors A2, B1, B3, B4, B5, neuropilin-2, nerve growth factor receptor, and semaphorin-F19 as well as erythropoietin and its receptor that contribute to healing of wounds. Some studies demonstrated the effectiveness of AM graft for healing of wounds. Mermet et al put an AM graft for 15 chronic leg ulcers and healing occurred in all patients. Pesteil et al used cryopreserved AM in eight patients with resistant vascular ulcers. Tolerance to the graft was excellent with healing of six out of eight patients with significant improved pain. Alsina-Gibert and Pedregosa-Fauste used AM for four refractory ulcers with a mean 81.93% reduction of ulcer size after 16 weeks. Litwiniuk et al suggested the potential role of matrix metalloproteinase inhibitors present in radiation-sterilized amnion dressing in healing of 23 out of 25 patients with chronic venous ulcers. Sheikh et al used dehydrated amnion to provoke healing of chronic wounds in four patients and healed wounds did not recur on long-term follow-up. A similar study was done by Zelen et al who used dehydrated AM in diabetic foot ulcers with complete healing of 37 out of 40 ulcers. With respect to the low cost, wide availability, and easy preparation, AM can be an ideal graft for chronic refractory ulcers.

    Subjects and methods

    Study design

    This was an experimental, comparative, and randomized clinical trial.

    Description of patients and collection of data

    This study was performed to test a technique for the treatment of chronic nonhealing wounds using AM to express its effect on the rate of healing of such nonhealing ulcers. Patients were recruited from the outpatient clinics or the inpatient wards of the Department of General Surgery, Faculty of Medicine, Cairo University and Department of Vascular Surgery, Faculty of Medicine, Assiut University from June 2012 to June 2015. Each patient signed an informed consent after accepting to be enrolled in the study. Ethical aspects whether substantial or procedural have been implicated in this study and approval was obtained from the Faculty of Medicine, Ethical Committee of Cairo University (30-9-2012).

     

    Patients were then randomly divided into two different groups. Group I (the control group) included eleven patients with eleven chronic leg ulcers in whom ulcers were treated with conventional wound dressings that were changed daily for 8 weeks. Group II (the study group) included 14 patients with 14 chronic leg ulcers. The AM was placed in contact with the ulcer and held in place with a secondary dressing, which was changed daily. Inclusion criteria were presence of leg ulcers for more than 3 months with no improvement despite standard treatment and age between 26 and 43 years. Exclusion criteria were ulcers with ongoing active infection and presence of diabetes. Full history taking and clinical assessment were done with special reference to previous treatment and surgery, diagnosed diabetes and/or hypertension, causes, types, and duration of ulcers present.

     

    The follow-up during treatment period includes assessment of ulcer healing and pain. Ulcer healing was assessed using the percentage of the healed wound area and healing rate. Using ImageJ program (Rasband, W.S., ImageJ, US National Institutes of Health, Bethesda, Maryland, USA), the wound areas were analyzed and a percentage of the healed wound area was calculated, in respect to the original wound area and the final wound area after 2 weeks and at the end of 2 months according to the formula:

     

    Percentage of healed wound area=Original wound areaFinal wound areaOriginal wound area×100
    The healing rate was then determined, in respect to the original wound area, and the final wound area reached according to the formula:
    Healing rate=Original wound area-Final wound areaTime cons uumed to reach final wound area

    The wound area is calculated by the formula for determining the area of an ellipse ((length × width) × π/4). Results of measured ulcer area size were used for follow-up, and ulcers were categorized with respect to surface area, exudate, and type of wound tissue. A comparison of total measurements over time provided an indicator of improvement or deterioration in ulcer healing. Pain was assessed using a visual analog scale, where 0 represented no pain and 10 represented the worst pain. Each patient has a special file in which all the data were present. Then, merging of data of all patients was done before statistical analysis.

    AM isolation, preservation, grafting, and follow-up of patients

    Human AM was prepared from placentae obtained from scheduled delivery by cesarean section following a noncomplicated pregnancy. Exclusion criteria were symptoms of infection in the newborn, delivery before 34 weeks gestation, and membrane rupture more than 12 hours before delivery. The donors gave written informed consent for the donation and use of the AM. One placenta can provide four to five AM tissue fragments 5 cm in diameter.

     

    Preparation was performed in a classified (class D) room with a microbiological safety workstation (class A). The placenta was washed with physiological saline and left in contact with an antibiotic solution in its collection container until preparation within 2 hours of the cesarean delivery. The entire membrane structure was immersed in a sterile packing container. The AM is mixed with antibiotics and antifungal in the container. The AM was then cut into different sizes and AM tissue fragments were obtained (Figure 1). For cryopreservation of AM, a cryoprotective agent was added (Roswell Park Memorial Institute medium [RPMI] and glycerol), and then stored in a temperature of −80°C with each piece of the AM stored in a separate container. Three AM samples are collected for bacteriological examination. The placenta rinse fluid (8–10 mL) was used to inoculate two vials of aerobic and anaerobic organisms for bacteriological testing. The placenta was also prepared for a pathological evaluation. On the day of the cesarean section, test tubes containing blood from the mother were collected for the following serology tests: HIV-1 and -2, Ag p24, HCV, HTLV; syphilis: VDRL-TPHA; and HBV: HBs antigen-HBc antibody. Final validation of the AM was performed after a repeat serology test by testing again the donor woman after 120 days. Before use, the AM can be transported to hospital and stored on dry ice up to 24 hours and conserved up to 2 hours in normal saline at room temperature after thawing before utilization.

    An external file that holds a picture, illustration, etc. Object name is ijwh-8-225Fig1.jpg

    Figure 1

    Preparation of amniotic membrane pieces.

    The preparation of the ulcers includes cleaning and mechanical debridement with a scalpel. The membrane preservation solution was removed by washing with physiological saline and the membrane was applied directly onto the ulcer bed (Figure 2). The graft was then covered with vaseline dressing (Figure 3). Patients were confined to bed for 2 hours and then allowed to do moderate activity for the next 5 days.

    An external file that holds a picture, illustration, etc. Object name is ijwh-8-225Fig2.jpg

    Figure 2

    Amniotic membrane application over two leg ulcers.

    Notes: Two leg ulcers in one patient (A); application of amniotic membrane over the leg ulcers (B and C); image of the patient after amniotic membrane grafting (D).

    An external file that holds a picture, illustration, etc. Object name is ijwh-8-225Fig3.jpg

    Figure 3

    Vaseline dressing is added over amniotic membrane and then covered with dressing.

     

    Notes: Application of vaseline dressing (A and B); application of gauze dressing after vaseline (C); gauze wrapping at the end (D).

     

    Follow-up was done to detect healing rate and detection of ulcer size, assessment of pain, and to take ulcer images (days 0, 7, 14, 21, 30, 45, and 60). Statistical analyses of all data were performed with SPSS software version 15.0 for Windows (SPSS Inc, Chicago, IL, USA). A two-sided value of P<0.05 was considered statistically significant for all analyses. Continuous variables are presented as mean ± standard deviation (SD).

    Results

    Demographic data of the sample

    All patients were males between 26 and 43 years. In group I, there were a total of eleven leg ulcers. Age ranged from 26 to 43 years with a mean value 34.45±7.03. Nine ulcers (81.8%) were venous ulcers, while two ulcers (18.2%) were traumatic ulcers. In group II, there were a total number of 14 leg ulcers. Age ranged from 26 to 43 years with a mean value 32.86±6.94. Twelve ulcers (85.7%) were venous ulcers, while two ulcers (14.3%) were traumatic ulcers. All patients of groups I and II were nondiabetics, with no history of smoking, hypertension, or any other medical condition.

    Results of the study

    Only conventional treatment was performed for the control group. Chronicity of leg ulcers varied from 24 to 60 months. The ulcer area at the beginning of the study was 4.8±0.65 cm2 (mean ± SD). Mean percentage of healing rate was 0%, and all ulcers in this group showed no reduction in their size (Tables 1and ​and 2), and ulcer floor remained the same. Healthy granulations were present in two ulcers (18.2%) and absent in nine ulcers (81.8%). There is no improvement of pain level in the eleven ulcers (Table 3).

    Table 1

    Chronicity of leg ulcers, reduction in ulcer size with treatment, and healing rate

    Parameters of healing Group I Group II
    Chronicity of leg ulcer (range) 24–60 months 24–84 months
    Chronicity of leg ulcer (mean + SD) 45.82+14.01 months 50.57+16.43 months
    Reduction of ulcer size with treatment 0% 100% reduction in size
    Reduction of ulcer size with treatment (mean + SD) 0.0+0.0 100.0+0.0
    Healing rate cm2/day (range) 0.0–0.0 0.064–2.22
    Healing rate cm2/day (mean + SD) 0.0+0.0 0.896±0.646

    Abbreviation: SD, standard deviation.

    Table 2

    Percentage of healed ulcers

    Ulcer healing Group I Group II
    No healing 11 100% 0 0%
    Complete healing 0 0% 14 100%
    Incomplete healing 0 0% 0 0%

    Notes: Group I included patients without amniotic membrane application; while Group II included patients with amniotic membrane application.

    Table 3

    Pain level improved or remained the same from day 0 till the end of study

    Pain level Group I Group II
    No pain 0 0.0% 3 21.4%
    Improved 0 0.0% 11 78.6%
    The same 11 100% 0 0.0%

    In the study group, the AM was directly applied on leg ulcers. This group included 14 leg ulcers. Chronicity of leg ulcers varied from 24 to 84 months. The ulcer area at the start of the study was 5.1±0.48 cm2 (mean ± SD). Results obtained from the study group showed complete healing of 14 ulcers in 14–60 days with a mean of 33.3±14.7; healing rate range was 0.064–2.22 and mean 0.896±0.646 cm2/day with a 100% reduction in ulcer size. Ulcer floor improved in all ulcers. Healthy granulations were present in 13 ulcers (92.9%) and absent in one ulcer (7.1%). Three ulcers (21.4%) were of mild severity (grade 1 ulcers) while eleven ulcers (78.6%) were of moderate severity (grade 2 ulcers). The healing rate was faster in ulcers of mild severity (1.7±0.438 cm2/day) in comparison to ulcers of moderate severity (0.673±0.498 cm2/day). Eleven cases (78.6%) showed improvement in their pain level on a scale from 1 to 10. Three patients had no pain (Tables 1​1–3; Figure 4). AM graft was taken in four cases (28.6%), while AM was not taken in ten cases (71.4%) in the days following the graft application. In these ten cases, the ulcers also showed complete healing on follow-up. Reduction in ulcer size shows significant difference between group I (control group) in comparison to group II (P=0.001) in which we used AM alone.

    An external file that holds a picture, illustration, etc. Object name is ijwh-8-225Fig4.jpg

    Figure 4

    Healing of two leg ulcers after amniotic membrane application.

    Notes: Two leg ulcers in one patient (A); application of amniotic membrane on the two ulcers (B); reduction in size of both ulcers (C); complete healing of the upper ulcer and 70% reduction in the size of the lower one on follow up (D).

    Discussion

    Chronic leg ulcers are defined as a defect in the skin, below the level of the knee and above the foot, persisting for 6 weeks or more. A previous study found that ~60%–80% of chronic leg ulcers had a venous component, 10%–30% was associated with arterial insufficiency, and other factors included diabetes mellitus and rheumatoid disease. Arterial and venous insufficiency combined in 10%–20% of cases.

     

    Chronic leg ulcers often heal poorly if there is no revascularization. Different lines of treatment are based on optimized local wound care: cleansing, debridement and dressings, compression therapy, and skin grafting. AM graft can be used as placental tissues contain a large quantity of growth factors. Furthermore, AM downregulates transforming growth factor (TGF)-β and its receptor expression by fibroblasts and in doing so it reduces the risk of fibrosis. Therefore, an AM scaffold can modulate the healing of a wound by promoting tissue reconstruction rather than promoting scar tissue formation.

     

    AM is a natural scaffold, which is the supporting matrix upon which cells and tissues grow, and so it is considered an important component of tissue repair with multiple clinical applications. In addition, the AM has other biological properties important for tissue repair, including anti-inflammatory, antimicrobial, antifibrosis, antiscarring, and low immunogenicity as previously discussed. AM may thus be regarded as a bio-therapeutic product composed of a single layer of epithelial cells that lie on a basement membrane and of a nonvascular collagenous stroma. These three components give AM its beneficial properties, including antiadhesive effects, bacteriostatic properties, wound protection, pain reduction, and epithelialization effects.

     

    The AM epithelial cells reside on the inner layer of the AM, while amniotic mesenchymal stromal cells form the outer layer.

     

    Results obtained from our study group showed complete healing of 14 ulcers in 14–60 days with a mean of 33.3±14.7; healing rate range was 0.064–2.22 and mean 0.896±0.646 cm2/day with a 100% reduction in ulcer size. Ulcer floor improved in all ulcers. Healthy granulations were present in 13 ulcers (92.9%) and absent in one ulcer (7.1%). Three ulcers (21.4%) were of mild severity (grade 1 ulcers) while eleven ulcers (78.6%) were of moderate severity (grade 2 ulcers). Eleven cases (78.6%) showed improvement in their pain level on a scale from 1 to 10. AM graft was taken in four cases (28.6%), while AM was not taken in ten cases (71.4%).

     

    The current study results were supported by the results of Mermet et al in a prospective pilot study, in which they evaluated the safety, feasibility, and the effects on healing of AM graft in 15 patients with chronic venous leg ulcers. The percentage of granulation tissue increased significantly (from 17% on day 0 to 69% on day 14, P<0.0001), along with a significant decrease of fibrinous slough (from 36% at day 0 to 16% at day 14, P<0.001). There was significant reduction in ulcer size and pain level as well. Also, Alsina-Gibert and Pedregosa-Fauste performed AM transplantation for four refractory vascular ulcers. Complete wound reepithelialization was achieved for one ulcer by week 8; in the other three cases, there was a 50% reduction in size compared to baseline. At week 16, the mean reduction in wound size for the four ulcers was 81.93%. The corresponding reduction in pain intensity was 86.6%. No adverse effects were observed.

     

    To our knowledge, this is the first study to prove the possible efficacy of AM in treating nonvascular (traumatic) refractory wounds (two cases in this study) in addition to efficacy in treating vascular refractory ulcers (12 cases in this study) that was shown by previous similar studies. The limitation of this study is the small number that needs further studies to support it.

    Conclusion

    AM graft can be an ideal choice instead of tissue-engineered skin equivalents to be used in wound healing. In addition to being an excellent scaffold, it has unique biological properties that are important for tissue repair, including anti-inflammatory, antimicrobial, antifibrosis, antiscarring, as well as a reasonable cost and low immunogenicity. Furthermore, presence of its own progenitor cells help in tissue repair.

    Recommendations and implications to practice

    Further studies should be done to support this study results. Comparing AM with alternative allogeneic or autologous skin substitutes in a randomized study will be worthwhile to determine the best therapeutic option and establish the potential of using AM in the treatment of leg ulcers. Routine preparation and preservation of AM will be of great value in tissue repair programs and implementation of biotherapy especially in developing countries due to its efficacy and low cost.

    Footnotes

    Disclosure

    The authors report no conflicts of interest in this work.

    References

    1. Meller D, Pauklin M, Thomasen H, Westekemper H, Steuhl K-P. Amniotic membrane transplantation in the human eye. Dtsch Ärztebl Int. 2011;108:243–248. [PMC free article] [PubMed]
    2. Kubo M, Sonoda Y, Muramatsu R, Usui M. Immunogenicity of human amniotic membrane in experimental xenotransplantation. Invest Ophthalmol Vis Sci. 2001;42:1539–1546. [PubMed]
    3. Tseng S, Li D, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999;179(3):325–335. [PubMed]
    4. Hao Y, Ma D, Hwang D, Kim W, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. Cornea. 2000;19(3):348–352. [PubMed]
    5. Šplíchal I, Trebichavský I. Cytokines and other important inflammatory mediators in gestation and bacterial intraamniotic infections. Folia Microbiologica. 2001;46(4):345–351. [PubMed]
    6. Kanyshkova T, Buneva V, Nevinsky G. Lactoferrin and its biological functions. Biochemistry (Moscow) 2001;66(1):1–7. [PubMed]
    7. Lo V, Pope E. Amniotic membrane use in dermatology. Int J Dermatol. 2009;48(9):935–940. [PubMed]
    8. Kim J, Kim J, Na B, Jeong J, Song S. Amniotic membrane patching promotes healing and inhibits proteinase activity on wound healing following acute corneal alkali burn. Exp Eye Res. 2000;70(3):329–337. [PubMed]
    9. Maral T, Borman H, Arslan H, Demirhan B, Akinbingol G, Haberal M. Effectiveness of human amnion preserved long-term in glycerol as a temporary biological dressing. Burns. 1999;25:625–635. [PubMed]
    10. Loeffelbein D, Rohleder N, Eddicks M, et al. Evaluation of human amniotic membrane as a wound dressing for split-thickness skin-graft donor sites. Biomed Res Int. 2014;2014:572183. [PMC free article][PubMed]
    11. Singh R, Chouhan U, Purohit S, et al. Radiation processed amniotic membranes in the treatment of nonhealing ulcers of different etiologies. Cell Tissue Bank. 2004;5:129–134. [PubMed]
    12. Marvin K, Keelan J, Eykholt R, Sato T, Mitchell M. Expression of angiogenic and neuotrophic factors in the human amnion and chorio-decidua. Am J Obstet Gynecol. 2002;187:728–734. [PubMed]
    13. Toda A, Okabe M, Yoshida T, Nikaido T. The potential of amniotic membrane/amnion-derived cells for regeneration of various tissues. J Pharmacol Sci. 2007;105:215–228. [PubMed]
    14. Mermet I, Pottier N, Sainthillier JM, et al. Use of amniotic membrane transplantation in the treatment of venous leg ulcers. Wound Repair Regen. 2007;15:459–464. [PubMed]
    15. Pesteil F, Oujaou-Faïz K, Drouet M, et al. Cryopreserved amniotic membranes use in resistant vascular ulcers. J Mal Vasc. 2007;32(4–5):201–209. [PubMed]
    16. Alsina-Gibert M, Pedregosa-Fauste S. Amniotic membrane transplantation in the treatment of chronic lower limb ulcers. Actas Dermosifiliogr. 2012;103(7):608–613. [PubMed]
    17. Litwiniuk M, Bikowska B, Niderla-Bielińska J, et al. Potential role of metalloproteinase inhibitors from radiation sterilized amnion dressings in the healing of venous leg ulcers. Mol Med Rep. 2012;6(4):723–728. [PubMed]
    18. Sheikh E, Sheikh E, Fetterolf D. Use of dehydrated human amniotic membrane allografts to promote healing in patients with refractory non healing wounds. Int Wound J. 2014;11(6):711–717. [PubMed]
    19. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated humanamnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014;11(2):122–128. [PMC free article] [PubMed]
    20. Stacey M, Burnand K, Layer G, Pattison M, Browse NL. Measurement of the healing of venous ulcers. Aust N Z J Surg. 1991;61(11):844–848. [PubMed]
    21. Nelzén O, Bergqvist D, Lindhagen A. Leg ulcer etiology – a cross sectional population study. J Vasc Surg. 1991;14(4):557–564. [PubMed]
    22. Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophthalmol. 1999;83:399–402. [PMC free article] [PubMed]
    23. Gomes J, Romano A, Santos M, Dua H. Amniotic membrane use in ophthalmology. Curr Opin Ophthalmol. 2005;16:233–240. [PubMed]
    24. Alio JL, Abad M, Scorsetti DH. Preparation, indications and results of human amniotic member transplantation for ocular surface disorders. Expert Rev Med Devices. 2005;2:153–160. [PubMed]
    25. Mamede A, Carvalho M, Abrantes A, Laranjo M, Maia C, Bothelho M. Amniotic membrane; from structure and functions to clinical applications. Cell Tissue Res. 2012;349:2447–458. [PubMed]

    Articles from International Journal of Women’s Health are provided courtesy of Dove Press

    Automating wound care in hospitals

    Chronic wounds are a global medical problem closely linked to diabetes. Every year, two per cent of the US population suffers chronic wounds, many resulting in amputation because they do not heal naturally and are typically infected with antibiotic-resistant bacteria. Consequently, conventional treatment methods such as antibiotics are often not an option. However, start-up VulCur Medtech has now developed an automated laser solution writes the Technical University of Denmark in this press release … While competitors are focusing on surface treatment, VulCur MedTech’s treatment goes deeper, cleaning the wounds from the inside out using an automated laser device that kills bacteria while avoiding human cells … read more

    MolecuLight Featured in Unprecedented 32 Presentations and Posters at World Union of …

    Wound Healing Societies (WUWHS) 2022 Conference
    NEWS PROVIDED BY

    MolecuLight
    Mar 01, 2022, 06:13 ET

     

    Wide-Spread Clinical Evidence using the MolecuLight i:X Platform Reveals its Significant Global Adoption and Proven Utility in Wound Care

     

    TORONTO and ABU DHABI, United Arab Emirates, March 1, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that its MolecuLight wound imaging platform is featured in an unprecedented 32 presentations and posters at at the World Union of Wound Healing Societies (WUWHS) 2022 Annual Conference, being hosted from March 1 – 5, 2022 in Abu Dhabi, United Arab Emirates. Held every 4 years, WUWHS is the largest global wound care conference with over 6,500 wound care professionals expected to attend in-person as well as virtually this week.

     

    “We are humbled by the number of clinicians globally that have made our MolecuLight point-of-care device an invaluable tool in their wound care practices,” says Anil Amlani, MolecuLight’s CEO. “The impressive collection of 32 talks and posters from so many facilities across 6 countries shows how the MolecuLight imaging device is becoming a new standard-of-care in wound care. This clinical evidence is echoed in the 55+ peer-reviewed publications that include data collected from over 1,400 patients, showing the significant benefit of the MolecuLight i:X® and DX™ to clinical wound assessment and practice.”

     

    “The evidence is definitive. The MolecuLight imaging platform is a “must have” device for wound care clinics. The abundance of published clinical evidence showing improvements in bioburden detection, better clinical decision making, and improved outcomes is clear validation for its medical necessity,” says Dr. Thomas Serena, the Founder and Medical Director of The SerenaGroup® and author and presenter of 15+ talks and posters featuring MolecuLight at WUWHS 2022. “There is real clinical benefit for using the MolecuLight alongside a broad range of wound care procedures, in all wound care settings. Evidence now proves that clinical signs and symptoms under perform and contribute to haphazard prescribing of antimicrobials and antibiotics. Used concurrently, information from MolecuLight images is flagging at risk wounds earlier. This leads to improved wound management, reduced antibiotic overprescribing, fewer infection complications, and faster healing.”

     

    The collection of 16 presentations and 16 posters featuring the MolecuLight imaging devices show how the devices inform clinical decision-making through the real-time detection of elevated bacterial burden in wounds. They span the wound care continuum, including detection of bacteria within biofilm, wound cleansing and hygiene, antimicrobial stewardship, and impact on detecting surgical site infections. They also include health economic benefits and wound healing results accelerated by RCT-accelerated findings. The results being presented illustrate the significant clinical improvements to wound care outcomes provided by the MolecuLight platform.

     

    A selection of the clinical posters and presentation featuring the MolecuLight i:X from World Union of Wound Healing Societies (WUWHS) 2022 Annual Conference 2022 are as follows:

    (a)  Select Clinical Posters citing the MolecuLight point-of-care device include:

    • Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging
      Kylie Sandy-Hodgetts et al., School of Biomedical Sciences, Pathology and Laboratory Science, University of Western AustraliaPerth, Australia
      Download poster

    • The use of an advanced fluorescence imaging system to target wound debridement, decrease bioburden, improve healing rates, and provide positive revenues in an outpatient wound care setting
      Windy Cole, DPM et al., Kent State University College of Podiatric Medicine. Kent OH
      Download poster

    • RCT Evaluating Impact of Routine Fluorescence Imaging of Bacteria on DFU Healing Rates
      Alisha Oropallo, MD et al., Northwell Comprehensive Wound Health Center and Hyperbarics, Lake Success NY
      Download poster

    • Wound Assessment Paradigm Shift: A 350-Patient Multisite Clinical Trial Incorporating Bacterial Fluorescence Imaging into Standard of Care
      Thomas Serena MD FACS MAPWCA FACHM et al., SerenaGroup Research Foundation, Cambridge, Massachusetts, USA
      Download poster

    (b) Select Clinical Presentations citing the MolecuLight point-of-care device include:

    • Early detection of wound infection: advances in diagnostics
      Dr. Thomas Serena
      (Tuesday, March 1, 20228:40 AM – 8:50 AM as part of Society Meeting – International Surgical Wound
      Complications Advisory Panel (ISWCAP)), Hall 4 (Part B)

    • Wound hygiene: which cleansing agents and techniques are most effective?
      Session #FC 05B – ID 205/(N)
      Alisha OropalloMD
      (Wednesday, March 2, 202204:00 PM – 06:00 PM) Capital Suite 5

    • Tissue saving approach by guided debridement with fluorescence imaging – or how to treat a sternal surgical site infection with pseudomonas aeruginosa
      FC 78 – ID 275
      Heinrich Rotering, MD
      (Wednesday, March 2, 202202:15 PM – 03:30 PM), Capital Suite 7

    • Optical detection of bacteria: changing the paradigm
      Dr. Thomas Serena
      (Saturday, March 5, 202208:20 AM – 8:40 AM as part of Focus Session (FS) 17: Wound imaging), Hall 4 (Part B)

    The complete listing of the 32 presentations & posters is available here.

    In additional to the clinical posters and presentations at WUWHS 2022, the MolecuLight i: and DX™ imaging devices will be available for demonstration in the MolecuLight booth #A-06 in the Exhibit Hall at the Abu Dhabi National Exhibition Centre (ADNEC) in Abu Dhabi, UAE.

    The MolecuLight i:X® and DX™ imaging systems are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are FDA cleared and CE and Health Canada Approved. With over 2,000 systems sold, they are commercially available and used by leading wound care facilities globally.

    About MolecuLight Inc.
    MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence wound imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

    www.moleculight.com

    Management of an open crush fracture to the foot from a lawnmower injury: A case report

    Management of an Open Crush Fracture to the Foot from a Lawnmower Injury: Case Report

    This case report from *The Foot & Ankle Online Journal* (December 2020) details the clinical journey of a patient sustaining a high-energy open crush fracture to the mid- and forefoot—caused by a lawnmower. The report highlights key steps in surgical, infection-control, and rehabilitation management within an evidence-based framework.

    Case Overview:

    • Injury Description: The patient presented with an open fracture involving multiple metatarsals and cuneiforms, with accompanying soft-tissue loss and heel pad damage—characteristic of high-energy lawnmower trauma.
    • Initial Management Steps: Following Advanced Trauma Life Support principles, the patient underwent emergent irrigation and debridement, broad-spectrum intravenous antibiotics within one hour, tetanus prophylaxis, and limb stabilization with Kirschner-wires and external fixation.
    • Surgical Reconstruction: Multiple staged procedures addressed wound cleaning, fracture alignment, and repair of soft tissue avulsions, using a combination of hardware and meticulous technique to preserve tissue viability and prevent infection.
    • Infection Prevention Strategy: Aggressive decontamination, serial debridement, and appropriate antimicrobial coverage for both anaerobic and aerobic pathogens—including Pseudomonas and Staph aureus—were employed to reduce osteomyelitis risk.
    • Rehabilitation Approach: A structured physiotherapy program was initiated early, focusing on range-of-motion, strengthening, edema control, and gradual weight-bearing to restore function and reduce stiffness.

    Clinical Takeaways:

    • High-risk open crush injuries require immediate, protocol-driven intervention to minimize complications like infection and non-union.
    • Staged surgical treatment—balancing infection control, mechanical stability, and soft tissue preservation—is essential for optimal outcomes.
    • Early rehabilitation plays a key role in functional recovery and reducing long-term morbidity.

    This illustrative case underscores the critical value of a multidisciplinary, evidence-based approach when managing severe foot trauma from lawnmower injuries.

    Keywords: open fracture, crush injury, lawnmower trauma, debridement, Kirschner‑wire fixation, antibiotic prophylaxis, physiotherapy rehabilitation

    Read the full case report on FAOJ

    Management of Wounds in the Russo-Ukrainian War



    Management of Wounds in the Russo-Ukrainian War: Challenges and Clinical Experiences from the Superhumans Center

    Summary: This retrospective review of 2,000 war-related wounds at Superhumans Center (Kyiv) highlights challenges like delayed evacuation (average 72 hours), contamination (90%), and infection (60%), leading to 40% amputations. Protocols emphasize serial debridement, NPWT, and vascular reconstruction, achieving 85% limb salvage in transported cases. Lessons include antibiotic stewardship and telemedicine for remote triage.

    Key Highlights:

    • Challenges: 72h delay, 90% contamination, 60% infection, 40% amputation.
    • Protocols: Serial debridement (within 6h), NPWT, antibiotics per IDSA.
    • Outcomes: 85% salvage in treated; telemedicine cut transport time 30%.
    • Innovations: 3D-printed prosthetics post-amputation.
    • Authors: O. A. Vorobiov, A. V. Chepurnyi, V. O. Shkurupiy et al.

    Read full review

    Keywords: war wounds, Russo-Ukrainian, Superhumans Center, debridement, limb salvage, O A Vorobiov, A V Chepurnyi, V O Shkurupiy

    Probiotics accelerate wound healing in patients with diabetic foot ulcer

    Patients with diabetic foot ulcer (DFU) who were given probiotic supplements for 12 weeks had faster wound healing and improved glycemic control compared with similar patients on placebo, according to researchers who recently published their results in Diabetes/Metabolism Research and Reviews.

    ADMIN2-Probiotics pick up the pace

    Diabetic foot ulcers healed faster in patients given probiotics.

    “Due to the increasing global antimicrobial drug resistance issues, the idea of probiotic consumption is interesting and pertinent because probiotics have the ability to strengthen the immune system, have anti-inflammatory effects, and therefore, could increase the wound healing process,” wrote lead co-author Zatollah Asemi, PhD … read more

    The role of non-medicated dressings for the management of wound infection

    There is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance. This position document looks at current treatment approaches to identifying and treating biofilm in wounds, focusing on the mechanism of action and role of non-medicated wound dressings (NMWDs) within antimicrobial stewardship practices and evidence that supports their effectiveness … Download

    The Predictive Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio Levels of Diabetic Peripheral Neuropathy

    As defective insulin secretion or impaired biological function, chronic hyperglycemia can cause damage to various tissues and systems, especially eyes, kidneys, blood vessels and nerves.1 Most diabetes patients can be divided into two types. Type 1 diabetes mellitus (T1DM), due to the absolute lack of insulin secretion, can usually be identified by serological evidence and genetic markers of islet autoimmunity. Abnormal inflammation and immune responses are associated with the development of T1DM. Recent study have shown that innate immunity and inflammatory mediators play an important and wide-ranging roles, possibly inhibiting β-cell function,2 promoting subsequent apoptotic processes, and leading to insulin resistance in surrounding tissues … read more

    T-Natural Killers and Interferon Gamma/Interleukin 4 in Augmentation of Infection in Foot Ulcer in Type 2 Diabetes

    Epidemiology studies have shown that diabetes has the highest incidence of any chronic disease worldwide and is a huge threat to human health. Diabetes is clinically divided into types I and II.1 The prevalence of type II diabetes mellitus (T2DM) increases with age across all regions and income groups.2 Still, the prevalence is increasing in young age groups due to unhealthy life routines present since childhood … Insulin resistance (IR) associates with T2DM. Diabetes-related foot complications are important causes for disability worldwide. More than one-third of patients with diabetes worldwide will develop diabetic foot ulcer (DFU), which can progress to diabetic foot infection (DFI), and gangrene, consuming most of the healthcare costs dedicated for patients with diabetes. Around 17% of DFI will require amputation. Studies showed that patients with diabetes fear amputation more than death. The DFI patients will demand extensive debridement … continue

    Vitamin D deficiency increases risk for diabetic foot ulcer

    Adults with diabetes and severe vitamin D deficiency are three times more likely to develop a diabetic foot ulcer than similar patients with sufficient vitamin D levels, according to findings from a meta-analysis published in Nutrition & Diabetes … “Vitamin D has been suggested to play an important role in many chronic diseases, such as diabetes,” Yimin Chai, MD, PhD, professor in the department of orthopedic surgery at Shanghai Jiao Tong University, China, and colleagues wrote. “Low serum vitamin D levels are associated with insulin resistance, impaired beta-cell function and the development of [diabetes]. There is also ongoing interest in the association between lower level of vitamin D and diabetic complications.” … read more

    World first 3D printed feet

    It’s gory, sticky and undoubtedly on the nose, but a blend of icing sugar, chicken stock and flexible resin is proving to be the just the right recipe for creating realistic foot ulcers as part of a world-first podiatric training initiative at the University of South Australia … Concocted by UniSA’s Dr Helen Banwell and Dr Ryan Causby the gooey mixture is being added to newly printed 3-dimensional feet and is designed to mimic infected and non-infected diabetic foot wounds …The 3D printed feet are created with wound-like cavities in place. Made from thermoplastic polyurethane (a plastic with many properties, including elasticity, transparency, and resistance to oil, grease … read more

    Scientists design ‘smart’ wound healing technique

    New research, published in the journal Advanced Materials, paves the way for “a new generation of materials that actively work with tissues to drive [wound] healing.” … As more and more surgical procedures are performed in the United States, the number of surgical site infections is also on the rise … Chronic wounds that do not heal — such as those that occur in diabetes — often host a wide range of bacteria in the form of a biofilm … Such biofilm bacteria are often very resilient to treatment, and antimicrobial resistance only increases the possibility that these wounds become infected … read more

    As obesity rate rises, ‘double diabetes’ looms large

    An October report from the CDC’s National Center for Health Statistics revealed a startling increase in the prevalence of obesity in the U.S., with rates now approaching 20% in children and 40% in adults for 2015-2016 … The growing epidemic has not spared those with type 1 diabetes. Today, obesity prevalence is as high or higher among patients with type 1 diabetes as in the general population. According to 2015 data from the T1D Exchange Clinic Registry, nearly 40% of children and adolescents with the disease also have overweight or obesity, putting them at increased risk for insulin resistance, hypertension and dyslipidemia — all the hallmarks of not type 1, but type 2 diabetes … read more

    Joint EPUAP & EWMA Pressure Ulcer prevention & patient safety

         advocacy project

     

    The European Pressure Ulcer Advisory Panel (EPUAP) and EWMA are collaborating on a joint engagement in the PU prevention and patient safety agendas at the European level as well as at the national level in selected European countries.

    Five articles by the joint EPUAP-EWMA initiative have now been published. The articles are available for download here:

    The role of pressure ulcer prevention in the fight against antimicrobial resistance

    EWMA & EPUAP added-value to OECD efforts

    Diabetic Control & Pressure Ulcers: fighting fatal complications and
    improving quality of life

    Patient safety across Europe: the perspective of pressure ulcers.

    The time to invest in patient safety and pressure ulcer prevention is now!

     

    Patient safety has for some years been high on the European Commission health care agenda. At the EU level as well as at national levels of many European nations, considerable investments have been made by health care authorities to establish organisations and programmes addressing the patient safety agenda.

     

    Looking at the patient safety agenda from a wound care perspective, the topic of Pressure Ulcer (PU) prevention has always been central due to the fact that most PU’s are preventable if the patient is managed correctly by health care staff … read more

    Oxygen therapies for wound healing: EWMA findings and recommendations

    For wounds to heal, it is essential that macro- and microcirculation is restored in the surrounding tissue (Niinikoski et al, 1991; Gottrup, 2004a). One of the most urgent requirements is oxygen, as it is critically important for the reconstruction of new vessels and connective tissue, and also enables resistance to infection … View PDF

    Wound healing work presented at the RCP Innovation in

         Medicine Conference 2018 by Neem Biotech

     

    Neem Biotech, a South Wales based R&D pharmaceutical biotech working in the field of novel antimicrobial drug development, and the Welsh Wound Innovation Centre recently attended the Royal College of Physicians’ Innovation in Medicine Conference 2018 where Neem presented their data around wound-relevant biofilms.

     

    The promising laboratory data presented reinforces the role of quorum sensing inhibition in virulence factor regulation and biofilm disruption, with implications for management of antimicrobial resistance.

     

    Dr Graham Dixon, Neem’s CEO and Prof Keith Harding … read more

    SomaGenics Awarded Multi-Year Funding for Hepatitis Delta Virus Therapeutic Program

    SANTA CRUZ, Calif., July 30, 2018 /PRNewswire/ — SomaGenics, Inc. announces the award of a three-year, $2.9 million NIH grant in support of its Hepatitis Delta Virus (HDV) therapeutic program under Principal Investigator and SomaGenics CEO Brian H. Johnston, Ph.D. This Phase II grant, from the NIH’s Small Business Innovation Research (SBIR) program, continues the development of SomaGenics’ novel RNA interference (RNAi)-based approach under a Phase I SBIR grant and will fund late-stage preclinical studies and preparations for clinical trials.

     

    HDV infection, which requires concurrent or prior infection with the hepatitis B virus, results in the most severe form of viral hepatitis, and no HDV-specific therapy exists. Chronic HDV has a 20% mortality rate and its incidence is rising globally. The establishment of U.S.–based Hepatitis Delta Connect (hepconnect.org), a public outreach program, highlights recent efforts to increase patient and physician awareness about the pressing need for HDV screening and treatment.

     

    SomaGenics’ HDV therapeutic is a novel treatment modality simultaneously targeting the virus at multiple stages of its life cycle using the Company’s proprietary synthetic short hairpin RNA (sshRNA®) technology. “Current clinical treatments suffer from multiple problems including limited efficacy, high relapse rate and toxicity,” according to Anne Dallas, Ph.D., Principal Scientist.

     

    To date, the Company has demonstrated efficacy of its sshRNA® HDV therapeutic in cell culture models and will use the new NIH funding to support efficacy studies in animal models as well as to optimize the Company’s novel delivery platform. “Our combination, multi-target approach reduces the likelihood of treatment resistance and targets non-host entities, lowering the chance of toxicity. We are excited that SomaGenics’ therapeutic may have the potential to cure HDV patients,” explains Dr. Dallas.

     

    Somagenics’ sshRNAs® are highly potent RNAi triggers, with IC50’s in the low picomolar range. sshRNAs® have distinct advantages over the more familiar siRNAs, including the fact that they consist of single chemical entities, simplifying their production and purification, and their lack of off-target effects from “passenger” strand retention. sshRNAs® are suitable for use in many indications in addition to HDV, with therapeutics currently in development for chronic wound healing including diabetic foot ulcers.

    SomaGenics, Inc. is a privately held company with offices and laboratories located in Santa Cruz, California. The Company specializes in developing novel RNA-centered approaches to address unmet life science research and medical needs. Core competencies include RNA molecules as therapeutic agents, drug targets and biomarkers as well as the development of innovative kits for RNA analysis.

     

    For information on SomaGenics’ HDV program or the sshRNA® platform, please contact Anne Scholz, VP Business Development, 831-426-7700 x20, 199087@email4pr.com

     

    SOURCE SomaGenics, Inc.

    Press Release from PRNewswire

    How to Assess Wounds for Tunneling and Undermining

    by Laurie Swezey RN, BSN, CWOCN, CWS, FACCWS

    As part of a thorough wound assessment, in addition to noting location and measuring size, the entire wound bed should be probed for the presence of tunneling and/or undermining. If you are unsure what tunneling and undermining are and how to recognize these phenomena, here’s an explanation of these terms and how to assess wounds for their presence.

    Tunneling Wounds

    Tunneling is caused by destruction of the fascial planes which results in a narrow passageway. Tunneling results in dead space that has the potential for abscess formation. To measure tunneling, a probe is gently inserted into the passageway until resistance is felt. The distance from the tip of the probe to the point at which the probe is level with the wound edge represents the depth of the tunnel. Clock terms are often used to describe the position of the tunnel within the wound bed. This is helpful in identifying and remeasuring tunnel depth at a later time in order to assess progress of wound healing. Tunneling can occur in any wound, but it occurs most commonly in surgical wounds and wounds occurring from a neuropathic cause … read more

    Amazon, health care and the first American chaebol

    Abe Kasbo, CEO, Verasoni Worldwide.

    Abe Kasbo, CEO, Verasoni Worldwide.

    Amazon’s recent landmark partnership with Berkshire Hathaway and JPMorgan Chase is yet another example of how certain sectors continue to underestimate Amazon’s imagination, never mind business prowess. I honestly believe some businesses, though fully capable, simply do not know how to respond to Amazon, and therefore don’t even try. Or they may want to try, but are afraid to fail. Amazon has led the way in industries where there’s prodigious inertia, like retail, entertainment, grocery and now health care.

     

    The announcement, which is short on details, spurred a sell-off in some of health care’s most popular stocks like CVS, Cardinal Health, Walgreen and United Healthcare, among others. If the Whole Foods acquisition wasn’t a wakeup call, this particular venture into health care is a shot across the bow to every industry in America. It seems the financial markets were nervous that Amazon and partners will do what no American government could achieve to date: get better control of health care costs and deliver efficiencies and results where they matter. The cornerstone of the announcement, in my estimation, is the intention by this coalition to deliver health care “free from profit-making incentives.” American health care’s long resistance to price transparency seems to be have been dealt a blow with this announcement and that is a good thing for patients, and for health care providers, who can now compete on price, experience and outcomes … read more

    The role of non-medicated dressings for the management of wound infection

    There is growing concern regarding the treatment of infection, caused by the rise of antimicrobial resistance. This position document looks at current treatment approaches to identifying and treating biofilm in wounds, focusing on the mechanism of action and role of non-medicated wound dressings (NMWDs) within antimicrobial stewardship practices and evidence that supports their effectiveness … read more

    Silver in Wound Care: Clinical Outcomes | webinar

    Thursday, January 27, 2022

    Health care professionals should consider silver nanoparticle dressings to decrease healing times and improve the quality of life of their patients.

    Registrants attending this session will learn:

    • The history of silver usage
    • The problem of antimicrobial resistance
    • Indications and contraindications for the use of medicinal silver
    • Variations of medical silver in dressings and their clinical outcomes

    read more

    Effects of physical activity as an adjunct treatment on healing outcomes and

    recurrence of venous leg ulcers: A scoping review
    Healing time is protracted and ulcer recurrence is common in patients with venous leg ulcers. Although compression is the mainstay treatment, many patients do not heal timely. Physical activity may be a clinically effective adjunct treatment to compression to improve healing outcomes. This scoping review provides a broad overview of the effect of physical activity as an adjunct treatment to compression on wound healing and recurrence. We followed the six-step framework developed by Arksey and O’Malley. We searched electronic databases and trial registration websites for relevant studies and ongoing trials. Two authors independently screened and selected articles. Findings were presented in a descriptive statistical narrative summary. We consulted and presented our findings to the wound consumer group to ensure the relevance of our study. Physical activity interventions in 12 out of the 16 eligible studies consisted of only one component, eight studies were resistance exercises … read more

    Is Comedy a Prerequisite to a Successful Medical Career?

    Milton Packer explores the innumerable reasons why laughter is essential to medicine
    Like everyone else, I have been reading the distressing headlines about the Ukraine. The most important figure in the current conflict may be Vladimir Putin. But the most fascinating person is Volodymyr Zelenskyy (anglicized Zelensky) … A long-standing advocate of Ukrainian-Russia harmony, Zelenskyy was elected in a landslide as the President of the Ukraine in 2019. Although he initially underestimated the extent of Putin’s ambitions, Zelenskyy has become the central symbol for the Ukrainian resistance. Most people expected Zelenskyy would abdicate, fleeing the country to save his own life … read more

    TELA Bio Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

    Company expands product portfolio with focus on addressing surgical site infections in plastic reconstructive surgery

     

    MALVERN, Pa., March 03, 2022 (GLOBE NEWSWIRE) — TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today announced the commercial launch of its SiteGuard No Rinse Antimicrobial Solution for use in plastic reconstructive surgery.
     
    SiteGuard utilizes Next Science’s proprietary XBIO® Technology that supports surgical site and post-operative infection control by addressing the biofilms that make bacteria more resistant to traditional antimicrobial agents, disinfectants, and host immune defenses. XBIO Technology deconstructs biofilm, destroys the bacteria enveloped in the solution, and defends against bacterial recolonization. There is no known bacterial resistance to XBIO Technology, and the no-rinse delivery allows the solution to provide over five hours of ongoing protection against bacterial biofilms with exceptional rates of pathogen removal.
     
    “SiteGuard is a complementary technology that we believe enhances our mission to deliver a portfolio of next-generation soft-tissue solutions that are both clinically effective and economically impactful,” said Antony Koblish, President and CEO of TELA Bio. “Early test market experience with SiteGuard has been encouraging, and we look forward to broadening awareness and usage of the technology nationwide.” … read more

    A Narrative Review of Cadexomer Iodine Ointment Versus Povidone Iodine Ointment

    Several iodine formulations have been used for wound care for ages, but still there exist a number of controversial issues regarding their uses in the present era. Many published studies are available for both povidone iodine (PI) and cadexomer iodine (CI) with conflicting outcomes due to different preparations used and different study types. PI has a broad spectrum of activity including antiseptic properties, anti-inflammatory properties, low cytotoxicity, and good tolerability with the absence of associated resistance. CI is an immobilized iodine molecule in a hydrophilic modified-starch polymer bead with the dual property of cleansing the wound by absorbing the exudate and bactericidal effect by sustained release of iodine molecules over the infected wound. The preparations comprising PI and CI improve wound healing and minimize the bacterial infestation or contamination in various chronic wounds, burns, and ulcers. This review narrates the comparison of CI and PI for the management of wounds in the context of biofilm reduction, wound size reduction, and granulation tissue promotion … read more

    A previously uncharacterized gene, PA2146, contributes to biofilm formation and drug tolerance across the ɣ-Proteobacteria

    Matthew F. Kaleta, Olga E. Petrova, Claudia Zampaloni, Fernando Garcia-Alcalde, Matthew Parker & Karin Sauer

     

    Bacteria preferentially grow as biofilm communities in diverse settings including the natural environment, industrial systems, and the medical sphere1,2,3. Growth within biofilms offers protection from adverse conditions, such as defense from protozoan grazing in the marine environments, resistance to antimicrobial agents during decontamination of industrial and medical equipment, and evasion of host immune responses during infections. Evidence of this protected mode of growth appears early in the fossil record (~3.25 billion years ago) and is common throughout a diverse range of organisms in both the Archaea and Bacteria lineages, suggesting biofilm growth to be an integral component of the prokaryotic life cycle8. Indeed, studies of biofilms formed by diverse prokaryotes have revealed common trends and phenotypic characteristics of biofilms, as addressed by several reviews. These common trends include cell-to-cell communication or quorum sensing (QS), the production of extracellular polymeric substances to form a protective matrix, the presence of eDNA … read more

    PREVENTION AND MANAGEMENT OF PERIWOUND SKIN COMPLICATIONS

    ISTAP Best Practice Recommendations for Prevention and Management of Periwound Skin Complications

    The International Skin Tear Advisory Panel (ISTAP) has published comprehensive guidelines to enhance the prevention and management of periwound skin complications. These recommendations emphasize the significance of periwound skin health in promoting effective wound healing and reducing associated complications. Read the full document.

    Key Highlights:

    • Definition of Periwound: The periwound is identified as the area surrounding a wound that may be affected by wound-related factors and/or underlying pathology.
    • Risks of Periwound Damage: Complications such as maceration, skin stripping, and medical adhesive-related skin injury (MARSI) can delay healing, increase infection risk, and elevate treatment costs.
    • Assessment Protocols: Regular evaluation of the periwound area should be integrated into wound assessments, focusing on skin integrity, moisture levels, and signs of infection or inflammation.
    • Management Strategies: Effective approaches include managing exudate to prevent moisture-associated skin damage (MASD), using appropriate dressings, and employing gentle cleansing techniques with pH-balanced solutions.
    • Infection Control: Implementing antimicrobial stewardship principles is crucial to prevent and manage infections without contributing to antimicrobial resistance.
    • Education and Training: Ongoing education for healthcare professionals and caregivers is essential to ensure best practices in periwound care are understood and applied consistently.

    These guidelines serve as a valuable resource for clinicians aiming to improve patient outcomes through diligent periwound care.

    Read the full document on the Wounds International website.

    Keywords:
    periwound skin care,
    moisture-associated skin damage,
    medical adhesive-related skin injury,
    wound assessment,
    antimicrobial stewardship

    WoundCareRN.com Launches to Provide Comprehensive Resources for Wound-Care Management

    WoundCareRN.com Launches to Provide Comprehensive Resources for Wound-Care Management

    Summary: WoundCareRN.com, a newly launched online platform, aims to serve as a one-stop resource hub for wound-care professionals. The site offers in-depth articles, video tutorials, continuing education modules, product comparisons, and clinical tools designed to support best practices in wound assessment, treatment protocols, and patient outcomes.

    Key Highlights:

    • The platform includes expert interviews and analyses, featuring wound-care specialists, podiatrists, vascular surgeons, and certified wound care nurses, discussing emerging issues such as antimicrobial resistance, wound dressings, and cost-effective therapies.
    • Interactive tools help clinicians with decision support: wound staging calculators, offloading device selectors, infection screening checklists, and video-guided dressing tutorials.
    • Comparative product reviews are included, with side-by-side evaluations of advanced dressings, biologics, and negative pressure wound therapy systems to assist procurement and clinical decision making.
    • Continuing education (CEU) opportunities are integrated: modules, webinars, and case-study-based learning credited for professional development in nursing and wound care specialties.
    • WoundCareRN.com also emphasizes community: user forums, peer case sharing, and a library of patient education resources to support patient engagement and self-management.

    Read the full announcement via Austin-Online

    Keywords:
    WoundCareRN,
    wound care education,
    product comparisons,
    clinical tools,
    continuing education,
    online platform

    Management of Early-Onset Type 2 Diabetes in Adults

    Management of Early-Onset Type 2 Diabetes in Adults

    Summary: A 2025 review in the Diabetes & Metabolism Journal explores strategies for managing early-onset type 2 diabetes (EOT2D) in adults. The article emphasizes the importance of early intervention, weight reduction, and preserving β-cell function to delay complications and improve long-term outcomes.

    Key Highlights:

    • Weight reduction: Lifestyle modification, structured dietary plans, and when appropriate, pharmacologic or surgical interventions are recommended to achieve sustained weight loss.
    • Preserving β-cell function: Early initiation of therapies that reduce β-cell stress and maintain tight glycemic control helps slow disease progression.
    • Therapeutic escalation: Clinicians are encouraged to move beyond metformin monotherapy sooner when patients are not meeting glycemic targets, incorporating newer agents with cardiovascular and renal benefits.
    • Risk stratification: Assess patients based on age at onset, baseline insulin resistance, comorbidities, and family history to guide individualized management.
    • Monitoring complications: Early screening for retinopathy, nephropathy, and cardiovascular disease is advised from diagnosis, alongside aggressive risk-factor management.

    Read the full review in Diabetes & Metabolism Journal

    Keywords:
    early-onset type 2 diabetes,
    weight reduction,
    β-cell preservation,
    therapeutic escalation,
    cardiovascular risk,
    diabetes complications

    Ethacridine Targets Bacterial Biofilms in Diabetic Foot Ulcers



    Ethacridine Targets Bacterial Biofilms in Diabetic Foot Ulcers: Multi-Target Mechanisms

    Summary: This study elucidates ethacridine’s antibacterial mechanisms in diabetic foot ulcers (DFUs) through integrated network pharmacology, molecular docking, molecular dynamics (MD) simulation, and clinical RT-qPCR validation. Identifying 105 overlapping targets, ethacridine modulates hub genes like AKT1 and MMP9, enriching in oxidative stress, inflammation, and bacterial response pathways (e.g., AGE–RAGE, TNF, IL-17). Docking confirmed strong MMP9 binding (−9.8 kcal/mol), with MD simulations verifying complex stability. In DFU patient tissues, RT-qPCR showed upregulated pro-healing genes (AKT1, HSP90AA1) and downregulated inflammatory/degradative ones (MMP9, MAPK8; p<0.0001). As a safe topical agent, ethacridine disrupts biofilms, mitigates inflammation, and fosters regeneration, offering a multi-functional approach to combat DFU infections and reduce amputations.

    Key Highlights:

    • Network analysis identified 105 common targets, with 10 hubs (e.g., AKT1, EGFR, MMP9) linked to oxidative stress, inflammation, and bacterial defense GO terms.
    • KEGG pathways enriched in AGE–RAGE, TNF, and IL-17 signaling, underscoring ethacridine’s role in diabetic complications and biofilm disruption.
    • Molecular docking: Binding energies < −5.0 kcal/mol, strongest for MMP9 (−9.8 kcal/mol); MD simulation: Stable complex (RMSD < 2.4 Å, ~2 H-bonds).
    • RT-qPCR in 20 DFU patients: Upregulated AKT1/HSP90AA1 (p<0.0001) for survival/angiogenesis; downregulated MMP9/MAPK8 (p<0.0001) for matrix preservation and inflammation control.
    • Implications: Topical ethacridine as affordable biofilm eradicator; future trials needed for resistance and efficacy in chronic wound management.

    Read full article

    Keywords: ethacridine, diabetic foot ulcers, bacterial biofilms, network pharmacology, molecular docking, Tianbo Li, Yuming Zhuang, Jiangning Wang

    What is the Key to Preventing Type 2 Diabetes?



    What is the Key to Preventing Type 2 Diabetes?

    Summary: This article explores the primary strategies for preventing type 2 diabetes (T2D), emphasizing that lifestyle modifications—such as modest weight loss (5-7% body weight), 150 minutes of moderate exercise, and a diet rich in fiber/low in refined carbs—can reduce incidence by up to 58% in high-risk individuals. Drawing from the Diabetes Prevention Program, it highlights prediabetes screening (A1C 5.7-6.4%) and early interventions like metformin for those over 60 or with BMI>35, tying prevention to averting complications like neuropathy and foot ulcers. With T2D affecting 38M Americans, the piece stresses sustainable changes over quick fixes, including sleep, stress management, and regular check-ups, to improve glycemic control and wound healing risks.

    Key Highlights:

    • Prediabetes: Affects 98M adults; 5-10% annual conversion to T2D without intervention.
    • Lifestyle Impact: DPP study showed 58% risk reduction with diet/exercise; 31% with metformin.
    • Diet Tips: Focus on whole foods, portion control, limit sugars; Mediterranean diet lowers risk 52%.
    • Exercise: 30 min/day aerobic + strength; reduces insulin resistance and supports neuropathy prevention.
    • Complications Link: Poor control leads to neuropathy/ulcers; prevention via A1C<7% cuts DFU risk 50%.

    Read full article

    Keywords: type 2 diabetes prevention, prediabetes, lifestyle changes, glycemic control, diabetic complications

    An Update of Phytotherapeutic Advances of Marigold in Wound Healing



    An Update of Phytotherapeutic Advances of Marigold (Calendula officinalis L.) in Wound Healing

    Summary: This update reviews Calendula officinalis (marigold) phytotherapy for wound healing, highlighting its triterpenoids and flavonoids for anti-inflammatory, antimicrobial, and proliferative effects in DFUs. Clinical trials show 25-40% faster closure with topical extracts vs controls, via collagen stimulation and biofilm disruption. Nanoformulations enhance delivery, reducing doses and resistance risks, positioning marigold as a cost-effective adjunct for chronic ulcers in resource-limited settings.

    Key Highlights:

    • Compounds: Triterpenes (faradiol) for anti-inflammatory; flavonoids for ROS scavenging.
    • DFU Efficacy: 40% granulation boost; RCTs show 25% faster epithelialization.
    • Nano-Advances: Liposomal extracts for sustained release; 30% infection reduction.
    • Safety: No AEs; suitable for diabetics with poor perfusion.
    • Future: Combination with honey for synergistic DFU therapy.

    Read full article

    Keywords: Calendula officinalis, phytotherapy, wound healing, DFUs, triterpenoids, Duraid Al-Khafaji, Abdul-Rahman Al-Khafaji, Mohammed Al-Khafaji

    DAE Launches India’s First Nitric-Oxide Wound Dressing for Diabetic Foot Ulcers



    DAE Launches India’s First Nitric-Oxide Wound Dressing for Diabetic Foot Ulcers

    Summary: The Department of Atomic Energy (DAE) launched ColoNoX, India’s first nitric-oxide (NO)-releasing wound dressing for diabetic foot ulcers (DFUs), developed by Bhabha Atomic Research Centre (BARC) and validated in Phase II/III trials. The DCGI-approved product enhances angiogenesis and antimicrobial action, accelerating healing in 70% of cases and reducing amputation risks by 40% in resource-limited settings. Affordable and locally produced, it addresses India’s 77M diabetics, with rollout via public-private partnerships for nationwide access.

    Key Highlights:

    • ColoNoX: NO from chitosan matrix promotes vascularization and kills bacteria without resistance.
    • Trials: Phase II/III show 70% faster granulation; 40% amputation reduction vs standard dressings.
    • Impact: Targets 15% DFU incidence; cost-effective for rural care.
    • Launch: DAE/BARC initiative; partnerships for distribution.
    • Quote: DAE Secretary: “Breakthrough for diabetic complications in India.”

    Read full article

    Keywords: nitric oxide dressing, diabetic foot ulcers, ColoNoX, BARC, amputation reduction

    The Efficacy and Safety of Polyhexanide Compared to Other Wound Dressings



    The Efficacy and Safety of Polyhexanide Compared to Other Wound Dressings in Patients with Various Wound Types: A Systematic Review and Meta-Analysis

    Summary: This systematic review/meta-analysis of 10 RCTs (n=1,200) demonstrates polyhexanide (PHMB) dressings significantly accelerate healing (MD -14.84 days) and reduce pain (MD 1.36) in chronic/surgical wounds vs controls (silver, saline), with superior bacterial reduction (OR 0.76) and no serious AEs. PHMB’s broad-spectrum, non-cytotoxic action makes it ideal for infected DFUs/VLUs, though long-term data needed.

    Key Highlights:

    • Healing: MD -14.84 days (p=0.08); faster vs silver/saline.
    • Bacterial Load: OR 0.76 reduction (p=0.65); odor control benefit.
    • Pain: MD 1.36 reduction (p=0.01); QoL improvements.
    • Safety: Mild AEs (pruritus); no resistance/cytotoxicity.
    • Implications: First-line for colonized wounds; further chronic data.

    Read full meta-analysis

    Keywords: polyhexanide, wound dressings, meta-analysis, healing time, bacterial reduction, Vannia Christianto Teng, Asnawi Madjid, Widya Widita

    Antimicrobial Stewardship in Wound Care: Measurement of Implementation and Outcomes



    Antimicrobial Stewardship in Wound Care: Measurement of Implementation and Outcomes

    Summary: This scoping review of 80 studies (95% surgical wounds) evaluates antimicrobial stewardship (AMS) in wound care, showing 67% de-escalation of use, 46% duration reduction, and no mortality increases. Education (40%) and audits (44%) drive outcomes like lower SSIs/AMR; cost savings in 96% of cases. Limited chronic wound data (3 studies) highlights need for more research on diagnosis and community care.

    Key Highlights:

    • AMS Interventions: De-escalation 67%; dosage changes 25%; education/audits 40-44%.
    • Outcomes: Reduced SSIs/AMR; 96% cost savings; shorter stays.
    • Safety: No negative mortality/readmission effects.
    • Gaps: Only 3 chronic wound studies; challenges in infection diagnosis.
    • Implications: Optimize prescribing; expand to chronic wounds for resistance prevention.

    Read full review

    Keywords: antimicrobial stewardship, wound care, AMR, SSI, de-escalation, Karen Ousey, Mark G Rippon, Alan A Rogers

    Rapid Detection of Biofilm in Chronic Wounds



    Rapid Detection of Biofilm in Chronic Wounds: Validation of a Point-of-Care Diagnostic Tool

    Summary: This prospective multicenter study (n=250 chronic wounds) validated a novel point-of-care biofilm detection assay using fluorescent probes for matrix polysaccharides and microbial DNA. The tool achieved 92% sensitivity and 88% specificity vs gold-standard culture/histology, with results in <15 minutes. Biofilm-positive wounds showed 3x higher non-healing rates at 12 weeks; early detection enabled targeted antimicrobials, reducing treatment duration by 25%. Implications for DFU/VLU management: Integrate into routine care to combat hidden resistance.

    Key Highlights:

    • Sensitivity/Specificity: 92%/88% vs culture; 95% for polymicrobial.
    • Outcomes: Biofilm+ wounds: 65% non-healing vs 25% negative (OR 4.2, p<0.001).
    • Method: Swab-based fluorescence; blinded assessors; 12-week follow-up.
    • Cost: <$5/test; POC compatible.
    • Authors: Smith J, Johnson A, Lee K et al.

    Read full validation study

    Keywords: biofilm detection, point of care, chronic wounds, fluorescence, non healing, J Smith, A Johnson, K Lee

    Diabetic foot ulcer treatment could kill COVID-19 virus, researchers say

    A new foot ulcer formulation developed by scientists at the University of South Australia could be used to kill the COVID-19 virus, according to new research.

    In a study published in the journal Applied Physics Letters, the team looked at the treatment of antimicrobial-resistant bacterial infections, experimenting to find an effective non-antibiotic antimicrobial strategy to combat the infections in diabetic foot ulcers.

    The authors found that enhancing cold plasma ionized gas with peracetic acid was “highly effective” at eradicating common wound pathogenic bacteria and at inactivating SARS-Cov-2 … read more

    Simple Color Change Test Identifies Wound Infections

    Researchers at the University of Bath in the UK, along with outside collaborators, have developed a simple color change test that rapidly indicates whether a wound is infected with harmful bacteria. The test works by detecting virulence factors released by the bacteria, which prompt a simple color change in a solution. The test could help clinicians to determine whether to prescribe antibiotics, and may help to avoid unnecessary prescribing. As the test can be administered at the point of care, and does not require expensive and time-consuming laboratory analysis, it may be very useful in low-resource or remote regions … read more

    Scientists report new hydrogel to protect wounds from germs

    RUDN University and Shahid Beheshti University (SBU) chemist together with colleagues from Iran created a hydrogel film for wound dressing. It protects the wound from germs and is harmless to healthy tissues. Moreover, its porous structure can hold antibiotic, which kills dangerous microorganisms and provide additional protection. The results are published in the International Journal of Biological Macromolecules.

    The main aim in treating wounds is to prevent infection. With an open wound, microbes gain direct access inside the body. This significantly complicates wound healing and can cause more serious consequences, so it is important to develop antibacterial coatings for wounds. One of the modern approaches to this is hydrogel films. Unlike traditional remedies, hydrogels mimic healthy tissue and cover the wound, protecting it from germs. They also help to cool the wound and not over-dry it. In addition, hydrogels can contain … read more

    A multi‐centre, single‐blinded randomised controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of DFUs

    Diabetic foot ulcers (DFUs) represent one of the many complications of long-standing diabetes.1 Not only are these wounds expensive to treat, with a recent systematic review showing that the mean cost was over $31 000 in 2015,2, 3 but complications, especially infection, can require prolonged antibiotic administration, deep and extensive debridement, and lower extremity amputations when these measures fail. Even relatively shallow (UT1A, Wagner 1) DFUs that do not respond to standard of care (SOC) are at risk for amputation of the affected area.2-5 This risk increases for patients who have had prior DFUs or amputations. Any product, therefore, that can prevent infection or disrupt biofilm while promoting wound healing in a moist environment is worthy of further investigation … read more

    A Preliminary Exploration of the Efficacy of Gentamicin Sponges in the Prevention and Treatment of Wound Infections

    Gentamicin sponges, implantable topical antibiotic agents, are approved for surgical implantation in 54 countries. Since 1985, more than one million patients have been treated with these sponges.1–3 However, despite having been studied for over 30 years, their effectiveness is still disputed … Han et al have found that applying gentamicin-impregnated sponges during spinal operations significantly decreases surgical-site infection (SSI).4 Chang et al have conducted a meta-analysis encompassing 15 randomized control trials and also concluded that gentamicin sponges decrease the rate of SSI.5 Schimmer et al have used a controlled, prospective, randomized double-blind study to investigate the efficacy of gentamicin sponges in sternal wound complications after heart surgery. They enrolled 720 patients and found that gentamicin sponges effectively reduce infection complications … However, several other studies have demonstrated that gentamicin-impregnated sponges cannot reduce SSI, and some researchers have even proposed that the sponges increase the risk of infection. Wouthuyzen-Bakker et al have discussed the efficacy of applying gentamicin-impregnated sponges locally during debridement in early acute periprosthetic joint infections. They found that their application does not reduce the incidence … read more

    Impact of repeated remote ischemic conditioning on diabetic foot ulcers: A proof-of-concept study

    Patients with a diabetic foot ulcer (DFU) suffer disabilities and are at increased risk for lower extremity amputation. Current standard of care includes debridement, topical antibiotics, and weight off-loading—still resulting in low rates of healing. Previous small-scale research has indicated that repeated remote ischemic conditioning (rRIC) is a novel modality that delivers significantly higher DFU healing rates. This proof-of-concept study was performed to expand the research on the utility of rRIC as an adjunctive treatment in the healing of chronic DFUs. Forty subjects (41 wounds) received rRIC treatment three times weekly in addition to standard of care for 12 weeks. Subjects that did not heal in this time frame but had a significant reduction in wound size were eligible to continue for an 8-week extension period. By the end of the extension period, 31 of the 41 DFU wounds (75.6%) in this study were determined to be healed. This compares favourably to the 25–30% standard of care average healing rate … read more

    When Should I Perform Point-of-Care Fluorescence Imaging of Wound Bioburden? Guidelines Based on Delphi Consensus

    Bacteria and biofilm plague chronic wounds, impair the healing process, and can increase the risk of infection and antibiotic overprescribing. Fluorescence imaging of bacterial burden (MolecuLight i:X) is the only point-of-care solution to visualize the presence of significant bacterial burden in wounds. This information, when added to standard of care, supports informed clinical decision making and more proactive bacterial management practices. This point-of-care imaging technology is quickly becoming a standard in wound care … View webinar start time in your timezone.

    When Should I Perform Point-of-Care Fluorescence Imaging of Wound Bioburden? (webinar)

    Bacteria and biofilm plague chronic wounds, impair the healing process, and can increase the risk of infection and antibiotic overprescribing. Fluorescence imaging of bacterial burden (MolecuLight i:X) is the only point-of-care solution to visualize the presence of significant bacterial burden in wounds. This information, when added to standard of care, supports informed clinical decision making and more proactive bacterial management practices. This point-of-care imaging technology is quickly becoming a standard in wound care … View webinar start time in your timezone

    Sustainable fabric made from tree bark could cut MRSA infection rates

    A traditional Ugandan cloth that uses tree bark to make sustainable textiles could be used to treat skin wounds after new research shows it has antimicrobial properties to fight against tough infections such as MRSA … MRSA—Methicillin-resistant Staphylococcus aureus—is an infection caused by bacteria that is resistant to many different antibiotics … continue

    Virus that Infects Bacteria Turns Immune Response Away

         from P. aeruginosa, Study Shows

     

    Pseudomonas aeruginosa, the most common bacteria found in cystic fibrosis (CF) patients, uses a virus to go unnoticed by the host immune system, a new study shows … Treatment with a vaccine designed to help the immune system detect the virus was found to significantly reduce P. aeruginosa’s ability to infect mice, suggesting it might represent a new way to treat CF patients … The study, “Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection,” was published in the journal Science … P. aeruginosa, dangerous for CF patients, is also common in diabetic ulcers, bedsores, and burn wounds. At the moment there is no approved vaccine against these bacteria, and they are increasingly becoming resistant to antibiotics …The World Health Organization categorized P. aeruginosa as one of the most dangerous pathogens to human health … “I see this every day in my clinical practice,” Paul Bollyky, MD, PhD … read more

    Electrifying wound care: Better bandages to destroy bacteria

    Bandages infused with electricity can help heal wounds faster than typical bandages or antibiotics—but for years, researchers have not really understood why … A recent study by a team at The Ohio State University is offering new clues about the science behind those bandages, and researchers say the findings could help lead to better wound treatment … The bandages belong to a class of therapies called electroceuticals, which are devices that use electrical impulses to treat medical issues such as wounds … read more

    Efficacy of Maggot Therapy on Staphylococcus aureus

         and Pseudomonas aeruginosa in Diabetic Foot Ulcers

     

    Subjects were randomly selected for the maggot-treated (treatment) or conventional treatment (control) group. Conventional treatments such as antibiotic therapy, debridement, and offloading were done for both groups, but maggot therapy (MT) was added to the protocol of the treatment group. Bacterial burden was monitored and compared for both groups using cultures … read more

    AmpliPhi receives positive feedback from FDA for its …

         AB-PA01 product targeting P.aeruginosa infections

     

    AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration (FDA) regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting … “We are delighted with the FDA’s response to our development plans for AB-PA01, AmpliPhi’s bacteriophage product candidate targeting Pseudomonas aeruginosa infections, and the FDA’s concurrence on the proposed design of two randomized controlled clinical trials, in hospital-acquired and ventilator-associated pneumonia and P. aeruginosabacteremia,” said Paul C. Grint, M.D., CEO … read more

    Texas A&M partnership developing biomedical ‘bandage’ for wounds

    University research focusing on building stimuli-responsive material that could release, absorb antibiotics

     

    Researchers at Texas A&M University and the Stevens Institute of Technology are working on the next generation of biomedical materials used to treat chronic wounds, including ulcers and wounds caused by diabetes.

     

    Svetlana Sukhishvili, A&M professor and director of the soft matter facility, and her research partner at Stevens, Hongjun Wang, have conducted experiments alongside their respective teams and combined them to form one study.

     

    “If you have diabetes, for example, your ability to heal wounds may be compromised, and ulcers may occur. What we’re trying to do is give you this bandage-like material that will be able to transform into skin that will help your body overcome the wound and to heal,” said Victoria Albright, a fourth-year doctoral student and lead researcher in the A&M Department of Materials Science and Engineering … read more

    Innovation in Wound Care

    An interview with Prof. Harding, CBE, and Dr Dixon, PhD, conducted by Alina Shrourou, BSC

     

    What is a hard-to-heal wound?

    There are many definitions of hard-to-heal. More conventionally, it’s based on underlying etiology of the wound, but in practice it’s any wound that has not healed within a timely fashion. This is often due to a lack of coordinated care. Many of those patients receive multiple courses of antibiotics and antimicrobial therapy, because clinicians aren’t sure what they’re looking at.

     

    Not all wounds are necessarily hard-to-heal from the beginning, but because of the need for improvements and coordination of care, many of those patients that are seen in clinical practice become hard-to-heal … read more

    Breakthrough Evidence on Vomaris Bioelectric Technology’s

         Impact on Wound Biofilm Infection

     

    TEMPE, Ariz.Dec. 5, 2017 /PRNewswire/ — Vomaris Innovations, Inc. announced today breakthrough results of the first controlled, preclinical in vivo evidence on the anti-biofilm impact of the Company’s bioelectric antimicrobial technology. The study found that the technology can prevent and disrupt biofilm infection and restore functional wound healing. The manuscript, “Electric Field Based Dressing Disrupts Mixed-Species Bacterial Biofilm Infection and Restores Functional Wound Healing,” was published online in the Annals of Surgery. The research was led by Chandan Sen, Ph.D., Professor of Surgery and Director of the Comprehensive Wound Center at The Ohio State University’s Wexner Medical Center.

     

    Bacteria use electrical interactions to communicate with each other in a process called quorum sensing (QS), signaling them to adhere to a wound, multiply, and encase themselves within a protective structural substance known as a biofilm. This protective biofilm barrier impedes the body’s immune defense system and renders the bacteria highly resistant to antibiotics, making biofilm infections extremely difficult to treat.

     

    Approximately 80% of infections in chronic and surgical wounds are thought to be caused by bacteria within biofilm.1,2Chronic wounds affect an estimated 6.5 million patients a year and over $25 billion is estimated to be spent annually on their treatment.3 Surgical site infections (SSIs) occur in 2% to 5% of all patients undergoing inpatient surgery and affect up to 300,000 patients a year in the U.S. alone. Annual costs of managing SSIs range from $3.5 billion to $10 billion … full press release

    Vomaris Innovations, Inc. website

    Material could offer ‘smarter’ wound healing

    A new study takes a step toward the development of smarter skin grafts that facilitate healing while minimizing infection for chronic skin wounds.

     

    “Our group has expertise in developing new polymers and functional surface assemblies for biomedical applications,” says Svetlana Sukhishvili, professor and director of the soft matter facility at Texas A&M University.

     

    “At Texas A&M we investigated how to build a stimuli-responsive polymeric material that could absorb and release antibiotics when prompted by a physiologically relevant stimuli,” explains lead researcher Victoria Albright, a graduate student materials science and engineering department … read more

    APHB: SUCCESSFUL CASE REPORTS PRESENTED FOR AB-SA01 AND AB-PA01

    Multiple Case Reports Presented for Patients Treated with AB-SA01 and AB-PA01



    On June 7, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) reported that multiple case reports on patients treated with the company’s lead bacteriophage development products, AB-SA01 and AB-PA01, were presented at the American Society of Microbiology (ASM) Annual Meeting and the 41st European Cystic Fibrosis Conference. Topline results from these cases had previously been announced by AmpliPhi with the presentations providing additional details.

    At ASM, a presentation described four cases of severe Staphylococcus aureus infection treated with AB-SA01. Three of the cases involved patients with endovascular infection and one case of severe vertebral osteomyelitis with epidural abscess. For all the patients, medical and surgical therapy options had been exhausted. Patients were treated with 3×109 plaque-forming units of AB-SA01 intravenously twice-daily for two weeks in combination with the best antibiotic therapy available. The bacteriophage therapy was well tolerated in all patients with no reports of serious adverse events … read more

    Efficacy of a New Flowable Wound Matrix in Tunneled

    and Cavity Ulcers: A Preliminary Report

     

    Abstract: Introduction. In chronic wounds the healing is stagnant, and regenerative surgery is often needed. Many engineered tissues with a conventional bidimensional sheet are ineffective for tunneling wounds, because adherence to the wound bed is not complete. An advanced wound matrix for treating wounds with irregular geometries has been developed (Integra Flowable Wound Matrix, Integra LifeScience Corp, Plainsboro, NJ).

     

    Methods and Materials. Between March 2013 and December 2013 the authors treated 18 patients (11 female) with tunneled or cavity ulcers with the advanced wound matrix at the Unit of General and Geriatric Surgery of the Second University of Naples, Naples, Italy. Two patients (11.1%) had postsurgical wounds, two (11.1%) had post-traumatic wounds, and 14 (77.8%) had neuropathic ulcers. After debridement and antibiotic therapy, the lesions were filled with the wound matrix product. Surgical wound edges were either approximated with stitches or left to heal by secondary intention and covered with wet gauze. During the first week, follow-up visits were carried out every 3 days, then once a week until complete healing was achieved. All patients underwent preoperative and postoperative ultrasonography scans and plain radiograph controls. Results. Twenty-one applications were performed. Engraftment was complete in all but 1 patient who had diabetes and graft failure. Three patients needed repeated applications to complete the filling of the lesions. Median (range) pain Visual Analog Scores—on a scale of 0 to 10, where 0 = no pain, and 10 = intolerable pain—were 6.3 (range 3-8) preoperatively and 0.5 (range 0-2) at first follow-up (P ≤ 0.001). All but 2 patients showed a progressive remodeling of the tissue gap at scheduled radiographic controls. Conclusions. To the author’s knowledge, the advanced wound matrix used in this study is the only available biomaterial for the treatment of tunneled lesions. It stimulates tissue regeneration by filling surfaces which cannot be repaired spontaneously or by using conventional biomaterials in the form of sheets. Its application is atraumatic, painless, and safe … read more

    Approval for commercialization of Heberprot-P® in Mexico

    Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing time, surgical debridement, amputation risk, and recurrences. The intralesional infiltration of Heberprot-P® may be applied in combination with Good Wound Care (GWC), revascularization, and antibiotics. This medicine is an effective solution for an unmet medical need, a first in class product, unique worldwide, for DFU treatment. It is the only therapeutic choice available for advanced and complex DFU, reluctant to healing (grades 3, 4, and 5, according to Wagner’s classification).

     

    Clinical experience derived from the intervention with Heberprot-P® in daily medical practice in Cuba was analyzed in 2013 in a study that reviewed the evolution of more than 2 000 patients as well as the pharmacovigilance of 1 788 patients, showing a 75% probability of granulation response, 61% healing rate, 71% amputation risk reduction, Bayes’ favorable factor (5.40), and complete granulation in 76% of ulcers in 5 weeks (Adv. Pharmacoepidem. 2013, 2 (2): 1000128; BMC Pharm. & Toxicol, 2013, 14: 44). The International Working Group of Diabetic Foot (IWGDF) evaluated results of the clinical trial performed with Heberprot-P® in Cuba and reported in 2009 as promising, highlighting the results obtained in only 2 weeks of treatment (Diabetes Metab Res Rev 2012; 28 (Suppl 1): 119-141).

     

    In a later systematic review, clinical trials comparing the use of growth factors with GWC (Cochrane Database of Systematic Reviews 2015, Issue 10, Art. No. CD008548), the IWGDF’s evaluation was reported on all major issues and requirements of Heberprot-P® clinical trials in Cuba. Similar criteria were expressed by the IWGDF in the guidelines on DFU healing (IWGDF Guidance, 2015: 10). A fourth study reported similar observations on the intralesional EGF infiltration method: “… a highly significant difference between groups in the prevalence of granulation tissue after just 2 weeks” (Diabetes Metab Res Rev 2016; 32 (Suppl 1): 154- 168).

     

    Results of clinical studies performed in Cuba, Russia, Turkey, Vietnam, Argentina, Mexico, and Ukraine were enough to demonstrate safety and efficacy profile of Heberprot-P®. This medicine has been used in more than 290 000 patients with diabetic foot ulcer (DFU) in Russia, Belarus, Georgia, Ukraine, Turkey, Algeria, China, Panama, Argentina, Cuba, Dominican Republic, Venezuela, Ecuador, Libya, Uruguay, Paraguay, Colombia, Guatemala, Philippines, Vietnam, Nicaragua, Saudi Arabia, Indonesia, Seychelles, Saint Lucia, Saint Vicente, Sri Lanka, Jordan, and Kuwait.

     

    A national survey of health and nutrition in Mexico reported that prevalence of diabetes is 9.4% of total population, which sums up more than 11 million people, 9.1% of adult diabetic suffers DFU, and amputation is indicated to 5.5% of adult diabetics (National Survey of Health and Nutrition, INEGI 2016). According to recent reports, lower limb amputation is the unique alternative for 45% of diabetics with advanced DFU in Mexico (Diabet. Foot. Ankle. 2017 Sep 6, 8 (1): 1367210). In a previous study, similar results were reported: 42% patients with advanced DFU required major amputation (Wound Repair & Regen. 24 (5): 923-927).
    Written by Jose A. Buxado, MSc., Assistant Researcher, CIGB.

     

    The Center for Genetic Engineering and Biotechnology of Havana is an institution devoted to research, development, manufacturing, and commercialization of products and technology derived from life science.

     

    Alyane Vazquez González, BA., Communication & Media, e-mail: alyane.vazquez@cigb.edu.cu
    . Ave 31 e/ 158 y 190, Playa, P.O. Box 6162, Habana 10600, Cuba.

     

    This release was published on openPR.

    Fresh hypothermically stored amniotic allograft in …

    the treatment of chronic nonhealing ulcers: a prospective case series

     

    Introduction Millions suffer from diffcult to heal ulcers worldwide. The incidence of chronic ulcers is increasing rapidly, fueled by an aging population, rising incidence in obesity, diabetes, and venous insuffciency. Diabetic foot ulcers (DFUs), VLUs, and nonhealing postsurgical wounds are among the most frequently encountered ulcers in wound care practice. In the United States, over 4.3 million diabetic patients will develop a DFU in their lifetime, and ~2.5 million individuals suffer from VLUs. DFUs add 1–4 $9–$13 billion to the direct yearly cost associated with diabetes itself. The annual 5 cost of VLUs is $2.5–$3.5 billion. Nonhealing surgical wounds are also commonly 6 seen in wound care clinics. Surgical wounds pose an increased risk for infection and contribute to the growing economic burden of wound care management.

     

    In recent years, several clinical trials have been conducted to investigate products derived from human amniotic membranes (HAMs) as adjunctive therapies to accelerate of different layers – the epithelium, basement membrane, and stroma – and these layers further consist of three contiguous but distinct layers – the inner compact layer, the middle fbroblast layer, and the outermost spongy layer. The HAM has been shown to have anti-infammatory, antifbrotic, antiangiogenic as well as antimicrobial properties. Research has confrmed that growth factors present in amniotic membranes can induce angiogenesis and human dermal fbroblast proliferation as well as recruit multiple stem cells relevant to wound repair and regeneration. 9,10

     

    A fresh hypothermically stored amniotic allograft (HSAM) may improve healing rates by preserving growth factors and living cells, including stem cells, as well as retaining the membrane’s native structure. HSAM is aseptically processed and stored in a proprietary hypothermic storage solution using the Allofresh™ (Organogenesis, Canton, MA, sisting of topical antimicrobials. His comorbidities consisted USA) process. 13

     

    Methods
    A case study was conducted to evaluate an HSAM (Organogenesis) in the treatment of chronic wounds. Information was collected on patient demographics, wound type, wound location, age of wound, comorbidities, previous treatments, and current treatments. All patients were informed of study procedures and consented to have their case details and any accompanying photographs published. Digital planimetry (ARANZ Medical, Christchurch, New Zealand) was used ateach visit to record the wound surface area. Previous and current treatments were recorded. Two of the patients presented with VLU and one had a postsurgical wound.

     

    The VLU patients had previously received compression, and one patient had also received negative pressure wound therapy. The one with a surgical wound had received a variety of previous therapies, including topical silver, Hydrofera Blue, and topical antibiotics. The age of the wounds for the VLUs were 2–3 weeks, while the surgical wound was 5 months. Comorbidities for the VLUs consisted of venous insuffciency, diabetes, arthritis, osteomyelitis to ulcer location, hypertension, and lymphedema. Comorbidities for the surgical wound patient consisted of arthritis and hypertension. The new treatment regimen consisted of HSAM covered with a knotted cellulose acetate fabric dressing (Adaptic ; Acelity, San Antonio, TX, USA) and appropriate standard of care, including offoading, multilayer compression, and of care, including offoading, multilayer compression, and surgical debridement.

     

    Findings
    Case 1

    A 62-year-old patient presented to the wound clinic with a postop foot wound (nondiabetic), right foot dorsum. The duration of the wound was 5 months, with previous treatments consisting of topical antimicrobials. His comorbidities consisted of arthritis and hypertension. On day 0, the wound area size measured 3.3 cm , with 50% granulation, 10% fbrin, 40% slough, and a moderate amount of light red/pink serosanguineous drainage. Moderate edema was present. A 2.5 cm × 2.5 cm HSAM was applied and fxed in place using Steri-Strips™ (McKesson Medical-Surgical, Londonderry, NH, USA). On day 21, the wound area reduced to 2.9 cm2, a 12.12% reduction. There was an increase in the percentage of granulation tissue as well. By day 42, the wound area size had reduced by 81.82% with 100% granulation, and healed on day 71 (Figure 1).

    Figure 1 Case 1 surgical wound.
    Note: (A) Day 0, 3.3 cm2 ; (B) day 71, 0 cm2.

    Case 2 
    A 57-year-old patient presented with a left lower extremity VLU on the medial malleolus. The wound had been present for 8 weeks. The treatment thus far consisted of compression and topical antimicrobials. His past medical history included chronic venous insuffciency, peripheral vascular disease, deep vein thrombosis, and hyperlipidemia. On day 0, the wound area measured 0.3 cm . HSAM (2.5 cm x 2.5 cm) was applied and held in place with Steri-Strips™ ( McKesson Medical-Surgical) and compression wrap. On day 7, the wound was completed closed with no drainage (Figure 2).

    Figure 2 Case 2 venous leg ulcer.
    Note: (A) Day 0, 0.3 cm2; (B) day 7, 0 cm2.

    Case 3
    A 70-year-old patient presented with a VLU on the medial right lower extremity. The wound had been present for 2 weeks. The medical history obtained from this patient revealed hypertension, lymphedema, type II diabetes, and chronic venous insuffciency. At the time of HSAM (2.5 cm × 2.5 cm) application, the wound area measured 1.0 cm . By day 7, the wound area was reduced to 0.4 cm , and by day 14, it achieved complete closure (Figure 3).

    Figure 3 Case 3 venous leg ulcer.
    Note: (A) Day 0, 1.0 cm2; (B) day 14, 0 cm2

    Discussion
    Prompt treatment of chronic ulcers is essential in preventing complications, reducing the cost of care, and lessening the economic burden on the health care system. In clinical studies, amniotic membranes have been shown to be effective in promoting healing in chronic wounds. Prior products consisted of dehydrated products. We postulated that fresh amniotic membrane would demonstrate even greater effect. Prior to embarking on large expensive clinical trials, we tried the fresh amniotic product on a few selected patients. Results from this study suggested that HSAM may be an effective treatment option for management of VLUs and other non-healing wounds. HSAM offers a new treatment alternative to promote healing in chronic wounds. This membrane contains numerous growth factors and cytokines. These growth factors are found to be released over an extended period and result in increased cellular migration, proliferation, and remodeling. Moreover, HSAM may reduce the long-term costs associated with the care of chronic ulcers by increasing the healing rate and lowering the risk of infection and complications This pilot case series was subsequently used to inform larger DFU and VLU trials that are ongoing at the time of this writing.

     

    Original Article – Dovepress

     

    Multi-resistant Infections: A Global Concern

    A presentation by Associate Professor Geoff Sussman on antimicrobial resistence.

     

    Resistant microorganisms (including bacteria, fungi, viruses and parasites) are able to withstand attack by antimicrobial drugs, such as antibacterial drugs (e.g., antibiotics), antifungals, antivirals, and antimalarials, so that standard treatments become ineffective and infections persist, increasing the risk of spread to others … read more (pdf)

    Researchers observe ‘paramedic’ ants treating their injured

    IVORY COAST, Africa —Researchers observed a species of insect that has its very own first responders who treat their comrades after raids on termites.

     

    The Guardian reported that African Matabele ants, which often become injured while launching raids on termites they hunt for food, are cared for by “paramedic” ants that clean their wounds, carry them home and maybe even administer antibiotics.

     

    “What we show, for first time in the animal kingdom, is a proper treatment focused on a wound,” University of Wurzburg behavioral ecologist Erik Frank said. “We have anecdotal observations of wound care in other animals, but none that have been studied scientifically.”

    full article …

    100 Years of Bedsores: How Much Have We Learned?

    ABSTRACT Just over 100 years ago, an article was published describing a plan to treat decubitus ulcers that can shed light upon medical progress and current practices. Key prevention and treatment elements included a dedicated ward, staff continuity, frequent position changes and special surfaces, cleanliness, disinfectants, and dressing changes. The necessity of resource allocation and interdisciplinary collaboration was acknowledged. This article sheds light on not only how much we have learned, but also how far we have to go.

     

    A little over 100 years ago, a Decubitus Division was established at Kings County Hospital in Brooklyn, New York, and a management plan was published in an article in The Hospital Bulletin of the Department of Public Charities of the City of New York.1 This facility was established as an almshouse for the poor and today is a major municipal hospital affiliated with SUNY Downstate College of Medicine and a level I trauma center. We can learn much by examining this century-old plan for preventing and treating bedsores. To understand components of the plan, it must be remembered that antibiotics were decades in the future, and Dakin solution was still being developed on the battlefields of Europe.2 This article uses the terms “decubitus ulcer” and “bedsore,” as the terms “pressure ulcer” and “pressure injury” were not yet in the medical vocabulary.

    read more

    Inflammation in Chronic Wounds

    Non-healing chronic wounds present a major biological, psychological, social, and financial burden on both individual patients and the broader health system. Pathologically extensive inflammation plays a major role in the disruption of the normal healing cascade. The causes of chronic wounds (venous, arterial, pressure, and diabetic ulcers) can be examined through a juxtaposition of normal healing and the rogue inflammatory response created by the common components within chronic wounds (ageing, hypoxia, ischaemia-reperfusion injury, and bacterial colonisation). Wound bed care through debridement, dressings, and antibiotics currently form the basic mode of treatment. Despite recent setbacks, pharmaceutical adjuncts form an interesting area of research.

     

    The skin forms an important and effective barrier against the environment. It plays a vital role in protection against insults such as bacteria, xenobiotics and dehydration. When a cutaneous injury occurs, the body initiates a series of complex events to re-establish this protection. Wound healing can be roughly divided into four continuous and overlapping phases: (1) haemostasis; (2) an immediate inflammatory response defined by an infiltration of cytokine-releasing leukocytes with antimicrobial functions; (3) these cytokines kick off a proliferative phase where new epithelium, blood vessels, and extracellular matrix (ECM) are laid down; (4) over a period of weeks to months, the wound contracts as the ECM is remodelled []. These highly regulated cellular, humoral and molecular processes have been described as an orchestral performance—a potential flawless interplay can lead to perfect regeneration; however, human adult wounds undergo a repair process that leads to scarring, and, in some cases, non-healing chronic wounds ….  read more

    Biofilm and Wound Healing

    Composition of Biofilm

    Biofilm is a complex microbial community containing self- and surface-attached microorganisms that are embedded in an extracellular polymeric substance.1,2 The extracellular polymeric substance is a primarily polysaccharide protective matrix synthesized and secreted by the microorganisms that attaches the biofilm firmly to a living or non-living surface. This protective covering does not allow the body’s immune system to recognize the presence of the microorganism; therefore, the bacteria evade an immune response, avoid detection by standard diagnostic techniques, and avoid destruction by standard treatments. Because of the tenacity of the attached biofilm, the microoganisms are able to resist physical forces, such shear, and are able to withstand nutrient and moisture deprivation, altered pH, and the impact of antibiotics and antiseptics. For the purposes of this discussion we break down the formation and actions of biofilms and discuss their impact on wound healing … read more

     

    The Miller-Newgent Amputation Scale

    A comprehensive scoring system to evaluate patient-centered risk factors regarding lower extremity amputation

     

    Abstract: Care of the patient with a presumed life- or limb-threatening lower extremity wound poses many challenges. The mindset regarding potential outcomes of such conditions is mostly driven by the experiences and expertise of those providing the care. This mindset generally appears as two primary actions presented to the afflicted patient: attempted resolution of the problem via medical, surgical or combination treatment, with the hope of low recurrence risk, or exacerbation and amputation—amputations at a level sufficient to, at least in the mind of the surgeon, eliminate the problem. Achieving the former outcome is dependent on a number of factors associated with both patient and caregiver. If healing is achieved, the secondary goal of prevention of recurrence may be no less arduous, with failure most likely resulting in amputation. Clearly, these considerations appear to be based more on the health professionals perception, of the patient’s physical and medical status rather than on patient-centered considerations. This article will review considerations and recommendations for lower extremity amputation, and the short- and long-term implications. Based on our research, there is clear need for a set of criteria against which to weigh not just the medical issues, but also definitive patient-centered issues when considering a lower extremity amputation. We offer a set of patient-centered, easily verified and recognized criteria that we believe addresses this need. The goal of the Miller-Newgent Amputation Scale (MENACE) is to provide a decision base from which to consider and evaluate all factors in determining the need for a lower extremity amputation. This involves identification of patient-centered issues, which are likely to produce satisfactory short- and long-term physical and quality-of-life outcomes if the amputation does proceed.

     

    Declaration of interest: The authors have no conflict of interest to declare. The lead author, as a Board Certified general surgeon with 23 years’ experience in the field of advanced wound care, has been involved in the different aspects to amputation and its considerations and a common thread my colleagues and I have identified is that the expertise of those attempting to heal and salvage limbs was largely ineffectual. More often than not, the progression of high-risk conditions mandated lower extremity amputation. The progression of technology, science and products to promote healing is thought to improve limb salvage rates; however, there has not been an appreciable reduction in amputations. The thought is that those possessing the skill, knowledge and desire to promote limb salvage (which entails greater time and effort with considerably lower compensation) are few and far between. Despite advances in medical care, the rates of lower extremity amputation are unchanged at best or are even increasing.

     

    Despite educational programmes touting the newest technologies for vascular intervention and advanced wound healing to mitigate those conditions commonly leading to amputation, there has been minimal change in the willingness of health professionals to consider limb salvage and indications for amputation have changed minimally. There is a clear need for a matrix against which to compare and contrast the clinical and non-clinical considerations for amputation. Since the patient is the one undergoing this potentially horrific procedure, it is only fair that all aspects of the procedure must be considered as an integral part of the decisionmaking process. The Miller-Newgent Amputation Scale (MENACE) scale was created to provide a patientcentred guide using simple, easily identified information that directly impacts on all aspects of the amputation decision process.

     

    Background Considerations for the intentional removal of a body part have their roots in antiquity. Matthew 5:29–30, 18:8–9 and Mark 9:43–47 are commonly recognised biblical references to amputation. Lower extremity amputation is one of the oldest known surgical practices with Hippocrates among others providing insights.

     

    In the US, 30,000–40,000 amputations are performed annually. In 2005, there were an estimated 1.6 million individuals living with the loss of a limb; by 2050, this figure is expected to rise to 3.6 million.

     

    In 1954, Silbert and Hamiovici published an article recommending that lower extremity amputation be avoided, preferring more conservative surgeries such as supracondylar amputations as opposed to mid-leg amputations. In the paper they cited the Handbook on Amputations, published in 1942 by the Council on Physical Therapy of the American Medical Association, which expressed the opinion of most surgeons, when it advised the use of supracondylar amputations and warned against mid-leg amputations: an opinion justifiable at the time before the advent of antibiotics.

     

    The Netherlands Society of Physical and Rehabilitation Medicine in October 2012 published its guideline on Amputation and Prosthetics of the Lower Extremities in which it recommended that the interventional radiologist, vascular internist and rehabilitation physician collectively identify and resolve those clinical issues before proceeding with a lower extremity amputation. Further, the guidelines state that treatment by a multidisciplinary team (MDT) involving a surgeon, anaesthesiologist, pain specialist, rehabilitation specialist, and possibly an internist is necessary for treatment of pain, cardiovascular risks, comorbidity and the co-determination of the level of amputation. The article identified many of the clinical indications for lower extremity amputation found in the literature; however, there is the same omission of any patient-centred, non-clinical concerns.

    Table 1. Estimated change in metabolic energy expenditure based on level of amputation

    Table 1. Estimated change in metabolic energy expenditure based on level of amputation

     

    Reyzelman and Kim presented their idea of acceptable considerations for partial tissue removal (digital amputation) based on presenting conditions including: osteomyelitis, septic arthritis, gas gangrene, ischaemia/ gangrene and an advancing soft tissue infection. The authors concluded that early digital amputation in the appropriate patient allowed patients a return to normal activity with minimal disability.

     

    Kalapatapu attempted to provide a compendium of indications for lower extremity amputation by providing an exhaustive listing of essentially all lower extremity morbidities. He stated:

     

       ‘Primary amputation may be the only option for
       patients without an anatomic option for
       revascularisation or those with medical risk factors that
       contraindicate revascularisation.’

     

    Recognising that the spectrum of surgical and medical skills is considerable, and that there are an almost limitless number of non-medical factors, even attempting to define specific conditions as the basis for amputations is extremely problematic and potentially precludes the surgeon and thus the patient from any consideration of limb salvage.

     

    A patient presenting with a condition prompting even the slightest consideration for lower extremity amputation likely has other issues related directly or indirectly to the presenting condition itself. It is a small leap of faith to recognise that an increase in metabolic demand places greater stress systemically on the patient with a concurrent risk of exacerbating current comorbidities as well as promoting new ones. These increased energy expenditures clearly mandate the highest scrutiny of a patient’s physical condition, both pre- and postoperatively, before undertaking any surgical consideration including lower extremity amputation. Recognising that the loss of an extremity means a dramatic change in the metabolic as well as mental status of the body, the failure to include these considerations potentially impacts on the ability of the patient to engage in activities of daily living. Estimates of the changes in metabolic energy expenditure based on the level of the amputation are shown in Table 1.

     

    However, the definitive consideration must be the effect of survival from a lower extremity amputation since this takes all factors together under a single irreversible endpoint. Survival rates for individuals with dysvascular pathology undergoing major lower extremity amputations including (above the knee amputation) AKA and BKA (below the knee amputation) have been reported as 69.7% and 34.7% at 1 and 5 years, respectively.12 Mortality was found to be significantly higher for patients who underwent AKA (50.6% and 22.5% at 1 and 5 years) as compared with BKA (74.5% and 37.8% at 1 and 5 years).

     

    Although amputation can be considered a failure of treatment, the actual considerations must be based on a number of factors, even when the initial impression is that salvage of the limb is untenable. There are still general categories of lower extremity conditions in which limb salvage is not appropriate. These would include traumatic limb loss or significant tissue deformation from motor vehicle or industrial accidents, malignancies whose location or dissemination precluded salvage, and congenital malformations precluding use of prosthetics or achieving a functional end result. Excluding the majority of these still leaves a considerable number of lower extremity conditions, in which the end result, amputation, unquestionably puts the patient at a higher risk of morbidity and mortality than before the decision to perform the procedure.

     

    At present, the decision to recommend lower extremity amputation appears to be universally based on objective medical issues. Without recognising and attending to the equally important and pervasive, nonclinical, patient-centred issues, the decision is usually made based on the surgeon’s tunnel vision. The most basic tenet becomes that of removing the problem as the key to resolving the problem. As Ertl aptly stated:

     

    ‘The only contraindication for amputation is poor
    health that impairs the patient’s ability to tolerate
    anaesthesia and surgery. However, the diseased limb is
    often at the centre of the patient’s illness, leading to a
    compromised medical status. The removal of the
    diseased limb is necessary to eliminate systemic toxins
    and save the patient’s life.’

     

    Unfortunately, the mere removal of an afflicted lower extremity under the guise of resolving the issue takes on a ‘low-hanging fruit’ mentality as it fails to address equally important patient-centred issues that often define the progress and ultimate outcome.

     

    The identification of any criteria regarding the appropriateness of a lower extremity amputation based on patient-centered, non-clinical criteria has been found to be nonexistent despite an exhaustive literature search. This covered 70 years and approximately 200 citations. Brigham and Women’s Hospital in Boston uses a Pre-Amputation Assessment Checklist that, while comprehensively identifying specific patient expectations and information, does not consider any patient-centered criteria for amputation. Therefore, the Brigham tool does not recognize the potential issues and ultimate outcomes surrounding amputation. In contrast, the MENACE SCALE and its patent-centered components focus the attention on those issues related to non-clinical outcomes when lower extremity amputation is considered.

     

    Table 2

    The MENACE scale

    It is not enough to objectively quantify only the clinical considerations for lower extremity amputation. The resulting amputation and the effect on quality-oflife must be taken into account. For that reason, there must be a combination of clinical factors together with non-clinical factors. The impact of these patientcentred, non-clinical factors cannot be overstated. The loss of all or part of a limb has a major psychological impact on the patient’s mental status. The psychological effects of amputation can be related to postoperative pain, cosmetic appearance, cultural and social effects, all potentially causing or exacerbating anxiety and depression.

     

    We believe that any initial consideration for lower extremity amputation, regardless of the presenting issues, can be based on two primary factors. Those two factors are intractable pain and functionality in the presence of a potentially life- or limb-threatening condition. While these factors may at first appear to be objective they are equally dependent on the patient’s subjective impressions of their condition.

     

    In considering the issues that ‘open the door’ to amputation, the authors felt that this process is analogous to ‘looking through a keyhole’ from which only a narrowed view is possible. We chose the term ‘keyhole criteria’ to represent this process as initial consideration regarding amputation. The two criteria (Table 2) establish a platform that forms the basis for the critical decision of amputation. These criteria move the decision from one that is based solely on the surgeon’s experience to a more germane one that encompasses considerations of the patient as a whole.

     

    Criterion 1 is significant in that there are lower extremity conditions including neurologic, musculoskeletal or other deficits where attempted preservation would offer no benefit to the patient. When these presentations are associated with debilitating pain, then this criterion would be met and consideration for an amputation at some level would be appropriate. This criterion would require that all attempts be made to mitigate the pain. Thus, an acute presentation (following traumatic accident, postoperative complications from prosthetic implantation, etc.) would arguably require some time to be allowed to pass before accepting these criteria.

     

    The issues regarding criterion 2 include preservation of the patient’s functionality and assumed morbidity and mortality of the presenting condition and that of the procedure. The goal of MENACE is to assure full consideration of all aspects of limb salvage versus amputation. Recognising that lesser procedures may provide both short- and long-term satisfactory outcomes, the issue of when to perform a lesser procedure and what that procedure may be, must be based on preservation of maximum functionality. For these reasons, attention must be directed to the patientspecific issues since information obtained provides the necessary elements required for a successful outcome. For example, the presence of distal pedal gangrenous changes in a diabetic neuropathic ulcer with a history of osteomyelitis poses a daunting problem. Not surprisingly, these findings would, in the vast majority of cases, lead to a strong recommendation for amputation. However, the usual discussion of potential complications and progression of disease state will generally lead to at least a discussion of the ‘benefits’ of simply removing the entire problem-containing lower limb. In contrast, the consideration of functionality is integral because it changes the discussion from one that obviates a potential progression of the presenting problem to one that recognises that retained maximum functionality allows ongoing quality-of-life based on retaining the limb. In simplest terms, if the extremity is still used to bear weight, provide propulsion in a wheelchair, transfer from chair to bed to commode, or even ambulate for any distance, then maintenance of that functionality takes on the highest priority. The goal becomes maximising the longevity and functionality of that extremity.

     

    The authors believe that the two keyhole criteria represent a mandatory check step for medical providers who either perform or refer to those performing lower extremity amputation. These two criteria need to be used to ascertain the appropriateness of amputation for a given patient. This represents a marked departure from the practice that the decision be based on the perception of perceived benefit of amputation.

     

    Initial evaluation of the patient’s presenting status with respect to the keyhole criteria should be undertaken. If the result is a decision to amputate, the MENACE scale assures that patient-centred factors are considered in the decision to amputate. Those factors placing the patient at risk for quality-of-life issues after surgery should be addressed well before amputation.

     

    Table 3

    The initial tool used by the authors was the 1–2 point scale to assess patient-centred factors. However, we recognised that the keyhole criteria were needed to focus the attention of the surgeon on what the authors felt were the two critical issues: pain and functionality.

     

    With the focus now placed on the patient, those factors that impact on their lives both pre- and postoperatively need to be considered. While there are an infinite number of both specific and general categories to be considered, we believe that those factors identified in Table 3 represent the most salient, recognising the interrelationship of these factors and others not specifically identified.

     

    The social status of the patient is integral to mental and physical wellbeing. Considerations must include: Who else is in the home? What will be the patient’s functional capacity both before and after the amputation? What is the expected effect on the family after amputation? Is the patient the primary breadwinner/caretaker for the family? Are there others who will be affected by the patient’s amputation status in the same environment (young children, teenagers, young adults, middle-agers)?

     

    Habitation factors must include: where does the patient live (both geographically and in terms of the actual residence)? The geographic location, including changes in elevation (mountainous, or San Francisco hills), whether there are stairs to navigate, or consistently functioning lifts, and old versus new construction (ADA, Standards for Accessible Design related to the Americans With Disabilities Act)15 are all considerations that must be addressed before amputation.

     

    Economic factors are the underpinning of what transpires with the patient and their direct family and friends. How will the patient’s economic status change after the amputation? Financial considerations are the bedrock on which much of the other issues achieve stability. Are they ready for retirement? Are they employable after amputation? Is there another breadwinner? Are they financially able to withstand loss of leg? What about the costs of treatment, prosthetics, devices? Are there accessible and available sources available to provide external financial support and can the patient access them (social security, disability insurance, etc.)? Is there adequate and sustained financial means either through a health insurance or other entity to pay for ongoing care including rehabilitation, care for any complications, medications, therapies, home health care, and if so for how long?

     

    Interpersonal support and functional issues have the potential to create effects that reverberate throughout the entire recuperative period and beyond. What other intrinsic/extrinsic factors do they have to contend with? Do they live with conditions such as a small cluttered house (hoarder), ‘bad’ neighbourhood, difficulty getting to the grocery store, doctors, and social events? Is there inter-family stress such as abusive or uncaring children or relatives?

     

    What psycho-emotional and self-perception issues are present? Do they already have body-centred issues (too fat, too skinny, too old, too sick …)? Is there a history of behavioural or mental health issues (depression, anxiety, obsessive compulsive disorder (OCD), schizophrenia, bipolar disorder, etc.)? How are they dealing with the potential amputation? Do they consider the recommendation for amputation a ‘death sentence’? Is there the opportunity to do something besides see the wound specialist all the time? How will they deal with the resultant disfigurement? The ultimate question is clearly: how important is that toe, foot, or leg to their life?

     

    An exhaustive online search of the available literature identified definitive criteria/guidelines for removal of the gallbladder, appendix and performance of caesarean sections as well as numerous other surgeries. However, regarding amputation of a lower extremity, the overwhelming majority of articles that even entertain the rationale for performing the procedure present surgeon-based clinical considerations as the primary decision criteria and mention patient-centred factors only in passing.

     

    Based on the experiences of the authors, there clearly needs to be a set of patient-centred criteria to juxtapose with the experiences of the surgeon and other providers integral to the decision-making process. We recognise that there are a myriad of compounding factors that affect provider and patient considerations that are easily overlooked and so a set of guidelines for evaluation such as the MENACE scale identifies those factors that can be easily evaluated and rectified.

     

    The MENACE scale including the keyhole criteria has been used by the primary author for 23 years in one form or another. Explanation and review of the MENACE critera has been undertaken with our patients for whom amputation was the only alternative offered before coming to our clinics. In clinical practice, numerous encounters have occurred with patients marked for amputation in which their presenting condition was clearly (and ultimately) salvageable. Based on extensive clinical use, we believe that the appropriate use of this tool can balance the patient’s presentation using both the accepted medical/surgical objective criteria and the less often considered patientcentred criteria. In those situations the decision for amputation gains more credence as evaluation progresses, for those MENACE scale categories in which the highest score (2 points) is not present, appropriate actions and interventions are taken to maximise that score. For example, the patient who lives in an upperfloor apartment with an unreliable lifts should have their residence changed to one with greater accessibility even if this is to occur immediately after the surgery. The planned change allows for the full score for that category to be considered as accomplished despite its implementation postoperatively. The same holds for caregivers needed in the home following surgery. The key to MENACE is to recognise that maximising a successful outcome after the elective performance of a lower extremity amputation must be based on resolving as many patient-centred stumbling blocks as possible. We recognise that the act of doing so may not be appropriate for the surgeon themselves but believe strongly that it can be appropriately achieved by other entities including social workers, local, state and federal entities.

     

    Based on our use of the MENACE scale in our own practices, we believe that a score of less than seven strongly suggests the highest potential for postoperative issues that will have an impact on the patient’s shortand long-term recovery and status. The failure to address identified issues both individually and collectively in the preoperative/perioperative periods may preclude a safe and complication-free recovery. MENACE was created to fill an unmet need. We understand that MENACE will require ‘real-life’ testing and validation. It is our expectation that when used alongside other criteria, it will provide a basis for expansion, revision, confirmation or deletion of the considerations we have proposed when a lower extremity amputation is considered.

     

    Conclusion

    The recommendation for, and performance of, a lower extremity amputation appears to be based primarily on criteria that remain undefined despite advances in all aspects of medicine. Although certain lower extremity presentations preclude safe attempts at limb salvage, there is clearly a trend towards performance based more on subjective criteria of the attending health-care providers than on clear objective patient-based criteria.

     

    Lower extremity amputation does not merely remove all or part of the lower extremity. The interdependence of structure and function, both before and after amputation, and the potentially catastrophic consequences of failing to consider these factors, mandates that there be a specific and definitive categorical assessment of patient-centred factors rather than the current criteria, which are based solely on the skill, education and experience of the medical providers. When these decisions are based solely on their own criteria rather than those of the patient—who represents the primary consideration regarding a successful outcome—then failure to identity and resolve potential patient-centred issues means that the patient is not truly the focus of the intended procedure, although they will suffer any untoward effects. The loss of a lower extremity does not merely mean that a pending problem has been resolved but that the potential loss of the limb now presents its own life-affecting challenges well beyond the time that the surgical incision heals.

     

    References
    1 Quality Improvements Organization. Strategies to Help Reduce
    Diabetes-Related Lower Extremity Amputations Among Minority
    Populations. April 2017, https://tinyurl.com/yd3hcgrn (accessed 7
    September 2017)
    2 Murdoch G, Bennett-Wilson A Jr, Amputation: Surgical Practice and
    Patient Management. Butterworth-Heinemann Medical, 1996.
    3 Tooms RE. Amputations. In: Crenshaw AH (ed). Campbell’s Operative
    Orthopedics (7th edn) Mosby-Year Book,1987: 597–637
    4 Ertl JP. Amputations of the lower extremity. Medscape. 2016. http://bit.
    ly/2uUFuEv (accessed 14 August 2011)
    5 Zeigler-Graham K, Mackenzie EJ, Ephraim PL et al. Estimating the
    prevalence of limb loss in the United States: 2005 to 2050. Arch Phys
    Med Rehabil 2008; 89(3): 422-429. https://doi.org/10.1016/j.
    apmr.2007.11.005
    6 Silbert S., Haimovici H. Criteria for the selection of the level of
    amputation for ischemic gangrene. JAMA 1954; 155(18): 1554–1558.
    https://doi.org/10.1001/jama.1954
    7 Book Notices: Handbook on Amputations JAMA 1942; 120(9):724.
    https://doi.org/10.1001/jama.1942.02830440066028
    8 Netherlands Society of Physical and Rehabilitation Medicine
    (Nederlandse Vereniging van Revalidatieartsen – VRA). Guideline: amputation and prosthetics of the lower extremities. Utrect. 2012. http://bit.ly/2uCbGRM
    9 Reyzelman A, Kim J. A guide to digital amputations in patients with
    diabetes. Podiatry Today. 2011; 24(9). http://bit.ly/2wX6Ew2 (accessed 14
    August 2011)
    10 Kalapataku V. Lower extremity amputations. UpToDate. 2017. http://
    www.uptodate.com/contents/lower-extremity-amputation (accessed 14
    August 2017)
    11 Karadsheh M. Amputations. Orthobullets.com. 2017. http://www.
    orthobullets.com/trauma/1052/amputations (accessed 14 August 2017)
    12 Brigham And Women’s Hospital Department of Rehabilitation
    Services. Physical therapy standard of care: lower extremity amputation.
    2011. http://bit.ly/2vwFFct (accessed 14 August 2011)
    13 Hakami, K. Pre-operative rehabilitation evaluation of the dysvascular
    patient prior to amputation. Phys Med Rehabil Clin N Am. 2009; 20(4):
    677-688. https://doi.org/10.1016/j.pmr.2009.06.015
    14 Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to amputation:
    recognition and treatment. Prim Care Companion J Clin Psychiatry 2007;
    9(4): 303–308
    15 ADA. Information and technical assistance. standards for accessible
    design related to the Americans With Disabilities

    Gel-Based Sensor Continuously Monitors Wounds for Infection

    When bacteria make their way into wounds, they literally threaten life and limb—unless they are detected as quickly as possible. A new sensor can nestle in bandages and alert a nearby smartphone when the bacterial population tips over into dangerous territory.

    Healthy human skin is covered with bacteria such as Staphylococcus aureus and Escherichia coli, which are quick to colonize an open wound. To prevent the bacteria from spreading through the body, which can permanently injure or kill a person, the infected wound may need to be cleaned and treated with antibiotics or—in the most extreme situations—the affected limb may require amputation … read more

    From baker to wound care innovator – my HS story

    Suzanne Moloney, the founder of HidraWear, first experienced the painful symptoms of Hidradenitis suppurativa as a young teen … At the time was a Suzanne a typical teenager who loved sports and running. She kept quiet about what was happening – she was embarrassed, as any 13-year-old would be. By her mid-teens, the lumps were bigger and harder to manage. Suzanne finally mustered up the courage to speak to a GP when they became infected … Suzanne was prescribed antibiotics every time new lumps flared up, which helped but didn’t stop the painful growths coming back. This cycle continued for years as more lumps appeared under her arms and at the tops of her legs … read more

    Is Your Wound Bioburdened? Case 2

    • 50-year-old male with morbid obesity visiting the outpatient wound care center for bilateral lower extremity wounds and lymphedema. Click here for a photo.
    • The wound on his leg was present for several months and previously treated with broad spectrum oral antibiotics for cellulitis. Click here for photo.
    • Pain, odor and erythema detected from wound, prompting the clinician to perform a fluorescence scan. Click here for photo

    read more


    LinkedIn:
    Today’s Wound Clinic

    New Clinical Study Finds MolecuLight i:X® Point-of-Care Imaging Improved Sensitivity

    of Detecting Bacterial Burden in Surgical Site Wounds by 11-Fold

    Authors Suggest that Fluorescence Imaging of Bacterial Burden is Positioned to Change
    Contemporary Paradigms of Post-Surgical Wound Management

    TORONTOJan. 18, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announced the publication of  “Uncovering the high prevalence of bacterial burden in surgical site wounds with point-of-care fluorescence imaging1 in International Wound Journal. The publication reports on the results of an analysis of 58 imaged and biopsied surgical site wounds from the 350-patient multi-centre FLAAG (fluorescence imaging assessment and guidance) clinical trial2.

    Key findings of the study include:

    • 76% of surgical sites that reach the stage of referral to a wound specialist had clinically significant bacterial loads (104 to 109 CFU/g), however only 6.8% exhibited symptoms of infection, resulting in delayed infection management.
    • Point-of-care fluorescence imaging (using the MolecuLight i:X device) for detecting high bacterial loads improved sensitivity by 5.7-fold compared to clinical signs and symptoms alone.
    • Clinician experience with fluorescence imaging and interpretation (>200 imaging sessions) increased sensitivity of fluorescence imaging to 11.3-fold higher than clinical signs and symptoms alone, and accuracy to 2.6-fold higher.

    The incidence of surgical wound complications, including surgical site infections (“SSI”), continue to rise and the development of an SSI is associated with a marked increase in morbidity, a 2-to 11-fold increase in mortality rate, and prolonged hospital stays3. Approximately 2-5% of surgical wounds in the US develop an SSI7-10 at an annual cost of up to $10 billion4-7. This includes extended hospital stays, readmissions, and more resources required to manage complications.

    “While early identification and management of high bacterial burden is critical for the prevention of surgical site infections, this study shows that pathogenic bacterial burden is present in most (>75%) surgical wounds that are referred to a wound specialist, but is largely asymptomatic and therefore goes undetected, delaying bacterial management strategies”, says lead author Associate Professor Sandy-Hodgetts, Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University & Senior Research Fellow, School of Biomedical Sciences, University of Western Australia and the Founder and inaugural President of the International Surgical Wound Complications Advisory Panel (ISWCAP). “Due to its ability to quickly and reliably detect bacterial burden at the point-of-care, fluorescence imaging using the MolecuLight device is positioned to change contemporary paradigms of post-surgical wound management”.

    These findings are part of an important initiative by the International Surgical Wound Complications Advisory Panel (ISWCAP) to study surgical site infections on a global scale and highlight the need for more objective diagnostic techniques to support the early and accurate detection of clinically concerning bacterial burden in surgical wounds. The authors note that this is the first study reporting the use of an advanced diagnostic device for the visualisation and diagnosis of bacterial burden in surgical wounds.

    “MolecuLight fluorescence imaging technology allows clinicians to see into the wound. The point-of-care imaging device enables clinicians to detect and manage elevated levels of bacteria to inform our decision-making,” says Dr. Thomas Serena, the publication’s contributing author, Founder and Medical Director of The SerenaGroup®, and Vice President of ISWCAP.  “Management of bacterial burden should always begin with wound hygiene strategies (e.g., cleansing, debridement), and only escalate to antibiotics when essential.”

    References:

    Sandy Hodgetts, K. et al., Int Wound J. 2021;1–11

    2 L. Le, Advances in Wound Care, 25 Sep 2020

    3Hatch MD et al. J Shoulder Elbow Surg. 2017;26(3):472-477

    4 Badia JM, et al. J Hosp Infect. 2017;96(1):1-15

    5 McLaws ML et al. J Hosp Infect. 2003;53(4):259-267

    6 Sullivan E et al. Surg Infect (Larchmt). 2017;18(4):451-454

    Ban KA et al. J Am Coll Surg. 2017;224(1):59-74

    8 Berrios-Torres SI et al. JAMA Surg. 2017;152(8):784-791

    9 Institute CPS. Canadian Surgical Site Infection Prevention Audit. 2016

    10 Si D et al. BMC Infect Dis. 2014;14:318

     

    About MolecuLight Inc.

    MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant, unmet needs including food safety, consumer cosmetics and other key industrial markets.

    Classifying diabetic foot ulcers

    Dermatologists must be able to distinguish between infected and noninfected diabetic foot ulcers because whether or not a DFU is infected can help determine treatment protocol, says Warrent S. Joseph, D.P.M, FIDSA.
    While dermatologists are unlikely to treat patients with severe foot infections that require hospitalization, they must be able to diagnose and manage mild-to-moderate infections in diabetic foot ulcers (DFUs), and follow current Infectious Diseases Society of America (IDSA) guidelines regarding antibiotic use, according to Warren S. Joseph, D.P.M., FIDSA, who presented at DERMfoot 2018. He is a consultant, lower extremity infectious diseases, Roxborough Memorial Hospital, Philadelphia, and a co-author of the IDSA guidelines, which appeared in Clinical Infectious Diseases in June 2012 … read more

    Using Negative Pressure Wound Therapy With Instillation and Dwell Time to Create a Path …

    to Closure for Older Patients With Chronic Wounds: A Retrospective Case Series
    BACKGROUND: Chronic podiatric wounds are common causes of morbidity and mortality in older patients. Negative pressure wound therapy with instillation and dwell time (NPWTi-d) has been recommended in wounds with high levels of exudate, contaminated wounds, and wounds in which healing progression has stalled. PURPOSE: This retrospective case series describes the use of NPWTi-d to prepare 4 chronic wounds for closure in older patients with multiple comorbidities. METHODS: Patients (N = 4) ranged in age from 65 to 95 years and had wounds present for at least 90 days. Previous treatments included conventional NPWT and debridement. NPWTi-d consisted of instillation of 10 to 20 mL normal saline, dwell time for 1 minute, followed by 3-hour cycles of -125 mm Hg. Antibiotics were administered as needed. Wounds included a 210-day Wagner grade 3 diabetic foot ulcer (3.2 × 1.8 × 0.3 cm3), a 90-day dehisced wound (9.5 × 2.6 × 0.4 cm3), a 300-day neuropathic ulcer … read more

    The Peskin collaborative for advanced wound/surgical healing

    Prof. Brian Scott Peskin, BSc., M.I.T.

    A New Era in Expedited Healing Regardless of Underlying Etiology

     

    Less Scarring
    Fewer Patient Post-Ops
    25%-35% Faster Healing
    with Essential EFAs

    Italian Plastic / Reconstructive Surgery Case Series Study (Italian Translation)

     

    In my practice as a Plastic Surgeon, I have found myself understanding that to
    obtain good postoperative results according to the intensity that varies from minor
    to major operations (the majority are very intense operations) the repair phlogistic
    resolution, edema and the scar tissue are all key factors to success.
    My results have improved according to the use of new surgical techniques as well as
    the use of antibiotics and antiphlogistic drugs.


    However, I must point out a new major factor that
    improved greatly my patients’ surgical results
    after introducing certain “essential fatty acids” 15 days
    prior to 30 days after surgery.


    The level of tissue repair is what I look for especially in my practice and having the
    trial opportunity of five patients using Brian Peskin’s EFA recommendations, I
    found in all five patients an enormously improved result with better recovery by
    just assuming a simple prescribed medical therapy with his EFA-based
    recommendations.

     

    Unlike fish oil, which causes excessive bleeding, Brian Peskin’s Protocol does not
    cause excessive bleeding. In fact, it makes surgery easier and improves patient
    recovery.

     

    This improved recovery included:

    1. Faster healing
    2. Less inflammation
    3. Less scar tissue
    4. Less pain to the patient

    I finally believe and feel it is necessary to continue this very interesting tissue repair
    in the near future.

     

    Dr. ANDREA RONCARATI FERRARA-Via Montebello 1 tel: 0532/200234 Specialista in
    Chirurgia Plastica RAVENNA-Viale Cilla 20 tel: 0544/456511 Ricostruttiva ed Estetica
    info@roncaratiandrea.it

    read more (PDF)

    Peskin Pharmaceuticals© website

    Small molecule control of bacterial biofilms

    Roberta J. Worthington, Justin J. Richards, and Christian Melander

     

    Bacterial biofilms are defined as a surface attached community of bacteria embedded in a matrix of extracellular polymeric substances that they have produced. When in the biofilm state, bacteria are more resistant to antibiotics and the host immune response than are their planktonic counterparts. Biofilms are increasingly recognized as being significant in human disease, accounting for 80% of bacterial infections in the body and diseases associated with bacterial biofilms include: lung infections of cystic fibrosis, colitis, urethritis, conjunctivitis, otitis, endocarditis and periodontitis. Additionally, biofilm infections of indwelling medical devices are of particular concern, as once the device is colonized infection is virtually impossible to eradicate … read more

    Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy

    in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

     

    Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

     

    BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

     

    “We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

     

    Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

     

    Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

     

    In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

     

    DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

     

    References:

    1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
    2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
    3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
    4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
    5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
    6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
    7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
    8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

     

    About Microbion
    Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

     

    About CUBRC
    CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

     

    Safe Harbor Statement
    Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    US Government Funding Disclaimer
    Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

     

    SOURCE Microbion Corporation

    This article was originally published here

    MRSA in Wounds Reduced 99% by E-Bandages

    Electrochemical bandages (e-bandages) that contain hydrogen peroxide could be an effective alternative to antibiotics when managing wound infections, according to a presentation at ASM Microbe 2022, the annual meeting of the American Society for Microbiology held in Washington, DC (abstract 2281) … Researchers from Mayo Clinic and Washington State University conducted experiments in mice. They created wounds on mice and infected them with methicillin-resistant Staphylococcus aureus (MRSA) to establish wound MRSA biofilms … read more

    MXenes-integrated microneedle combined with asiaticoside to penetrate the cuticle for treatment of diabetic foot ulcer

    Pei Wang, Yun Wang, Yang Yi, Yan Gong, Haoran Ji, Yuci Gan, Fei Xie, Jinchen Fan & Xiansong Wang

     

    Without an efficient and transdermal drug delivery system, patients who have skin disorders of various causes tend to experience incomplete or improper wound healing. Diabetic foot ulcer (DFU) resulting from decreased neurovascular response and multi-antibiotic-resistant bacterial infection [4] are an example of chronic wound healing. DFUs are accompanied by high morbidity and mortality and can lead to limb amputations [6] and hospitalization. Unfortunately, most treatments for diabetic skin disorders, including the application of acellular dermal matrix (ADM), electrospun nanofiber, are administered by smearing and are incapable of efficiently delivering drugs through the cuticle. Thus, to promote skin regeneration in patients with diabetes mellitus, it is necessary to develop a better drug delivery system … read more

    FedEx and Direct Relief Deliver 52 Tons of Critical Medical Aid for Ukrainians

    MEMPHIS, Tenn.–(BUSINESS WIRE)–FedEx Corp. (NYSE: FDX) and Direct Relief continue to support those affected by the conflict in Ukraine. On Sunday, June 26, FedEx Express safely delivered 52 tons of critical medical aid to Poland from the United States via a FedEx humanitarian relief flight. This follows FedEx and Direct Relief’s first charter flight of aid for Ukrainian refugees in March and is the latest in a continuous series of shipments from Direct Relief … Aid aboard the FedEx Express Boeing 777 cargo aircraft included substantial quantities of emergency medicines and supplies, including health kits, trauma and wound care items, chronic disease and chemical exposure medications, and antibiotics. All items were provided at the request of, and approved by, Ukraine’s Ministry of Health and local Ukrainian organizations. Direct Relief team members were on site for the offload and the aid will be distributed to health facilities within Ukraine … read more

    Newly Published RCT Shows MolecuLight Fluorescence Point-of-Care Imaging Improved 12-Week Wound Healing by 204% in Diabetic Foot Ulcers

    Study Confirms the Utility of MolecuLight to Inform Clinicians to the Presence and Location of Clinically Significant Bacteria and Improves Treatment Plans & Outcomes over Conventional Diagnostic Methods

     

    LEEDS, UK and TORONTO, July 13, 2022 /PRNewswire/ – MolecuLight Inc., the leader in fluorescence imaging for detection and localization of elevated bacterial load in wounds, announced the publication of an independent, blinded randomized controlled trial in Diabetes Care. The publication on this 56-patient trial, titled “The use of Point-of-Care Bacterial Autofluorescence Imaging in the Management of Diabetic Foot Ulcers: A Pilot Randomized Controlled Trial“1 reported that the use of a MolecuLight i:X® device to visualize the presence of elevated bacterial burden in wounds doubled 12-week wound healing rates (204%) in diabetic foot ulcer patients over standard-of-care alone.

     

    Diabetes is a significant global health ailment: over 416 million people have diabetes worldwide2 and 25% of these patients develop a diabetic foot ulcer (DFU)3, greatly diminishing quality of life and increasing the need for costly and extended treatment. In the UK, the NHS spends £1 billion ($1.25 billion US) annually on DFU care and management24.

     

    “As a clinician in wound care, especially when managing patients with chronic wounds, the holy grail is improvement in wound healing rates”, says David Russell, Associate Professor in Vascular Surgery at University of Leeds and lead author in the study. “In our randomized controlled trial, the results were impressive – the use of a MolecuLight device to inform our wound care decision-making helped us double the number of wounds that were healed at 12 weeks. This has benefits for the patient and our healthcare system.”

     

    Patients were stratified into two groups, one in which the MolecuLight device was not used, and one in which clinicians used the MolecuLight device bi-weekly to assess diabetic foot ulcers for the presence of elevated bacterial burden. For the MolecuLight group, fluorescence imaging was performed after treatment. Fluorescence indicated the presence of elevated bacterial burden in over 80% of the wounds. Additional treatment based on imaging findings was performed as the discretion of the clinician, and most often included further debridement focused on the regions with elevated bacterial loads. Importantly, there was no increase in antibiotic prescribed in the MolecuLight group.

     

    Alongside the impressive 2-fold improvement in healing rates, this study showed an association between baseline fluorescence and wound outcomes. Of the patients with negative fluorescence images at the baseline visit, 53.9% healed at 12-weeks, versus 37.5% with positive baseline fluorescence images. In other words, patients were 36% less likely to heal at 12 weeks if their wound was positive for high bacterial loads at the beginning of their treatment, as depicted by MolecuLight. Wound area reduction was superior in the MolecuLight arm and patient quality of life diverged toward improvement in the MolecuLight arm at 4 weeks and toward deterioration in the control arm at 12 weeks.

     

    “To improve decision-making and care with DFU patients we must be able to measure what we manage. The MolecuLight i:X, as illustrated by the results in this RCT, is a powerful tool for screening DFUs for infection as well as monitoring new or worsening bacterial burden over time”, says David G. Armstrong, Professor of Surgery, Director of the Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine of the University of Southern California as well as the US-appointed delegate to the International Working Group on the Diabetic Foot (IWGDF). “This new study provides further data for the improved healing rates and improved patient care that can be achieved in a clinic with routine use of fluorescence imaging to detect wound bacteria.”

     

    “We congratulate Dr. Russell and the team at Leeds for their excellent study and publication that shows the utility of MolecuLight to detect elevated bacterial burden and to inform clinical decision-making at the point-of-care”, says Anil Amlani, MolecuLight’s CEO. “A doubling of 12-week wound healing is a significant outcome and is consistent with what thousands of wound care clinicians are experiencing worldwide, that MolecuLight enables clinicians to deliver superior, proactive bacterial/infection management that improves wound outcomes”.

     

    The Leeds Diabetes Limb Salvage service is now using the MolecuLight device to image all patients with wounds that are failing to achieve a healing trajectory within 4 weeks. To help manage patient volumes, patients who are negative with MolecuLight are triaged, and are then referred to community care as their wounds are considered manageable and able to achieve a healing trajectory.

     

    This new RCT is part of a broad body of clinical evidence showing the many benefits of the MolecuLight i:X and DX devices across the range of wound care applications to help inform and improve clinical decision-making. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

     

    1. Rahma S et al. Diabetes Care 2022;45(7):1601–1609
    2. Diabetes UK: Diabetes Prevalence, www.diabetes.org.uk/professionals/position-statements-reports/statistics/diabetes-prevalence-2019
    3. Armstrong AG et al. The New England Journal of Medicine, 2017; 376:2367 – 75
    4. Kerr, M, 2017, www.diabetes.org.uk/resources-s3/2017-11/diabetes%20uk%20cost%20of%20diabetes%20report.pdf

     

    About MolecuLight Inc.
    MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

     

    For more information, contact:
    Rob Sandler
    Chief Marketing Officer
    MolecuLight Inc.
    T. +1.647.362.4684
    rsandler@moleculight.com
    www.moleculight.com

    MolecuLight Point-of-Care Wound Imaging Devices Awarded Group Purchasing Agreement with AllSpire Health GPO

    Contract Awarded for Products that Bring Improvement to the Health Care Industry

     

    PITTSBURGH, Sept. 29, 2022 /PRNewswire/ – MolecuLight Corp., the leader in point-of-care fluorescence imaging for the real-time detection of bacteria in wounds, announces it has been awarded a new group purchasing agreement with AllSpire Health GPO, a Mid-Atlantic GPO and a partner of HealthTrust Purchasing Group, engaged with over fifty hospitals in Maryland, New Jersey and Pennsylvania. AllSpire helps health systems optimize their operations by aggregating purchasing volumes, expenses, streamlining supplier negotiations and implementing efficiencies across the supply chain. The MolecuLight i:X® and DX™ wound imaging devices, which will now be available to AllSpire’s members, are helping clinicians to improve the state of wound care and ultimately to improve outcomes.

     

    MolecuLightDX point-of-care imaging system for detection of elevated bacterial loads in wounds and for performing digital wound measurement and tracking (CNW Group/MolecuLight)

    The MolecuLight imaging devices are the only FDA-approved devices that allow clinicians to visualize the presence, location, and load of bacteria (>104 CFU/g) in wounds in real-time. Published results from a recent 350-patient, 14-site clinical trial showed that the clinical standard of care alone detected 15% of wounds with elevated bacterial burden, while the addition of the MolecuLight device led to a 400% improvement in detecting these wounds2. The presence of elevated bacterial loads is known to impede wound healing1 and removal of bioburden is critical to improved wound outcomes1. The i:X and DX provide invaluable bacterial information at the point-of-care to inform clinical decision-making and enable targeted wound therapies. In a 2022 randomized controlled trial (RCT) 3, the highest level of evidence-based research, the improvement in healing rate at 12 weeks doubled in the patients that had care informed by MolecuLight fluorescence imaging compared to those that were not. Improvements in the patients’ quality of life were also reported. Another recent study reporting increased wound healing rates with the incorporation of bacterial information from MolecuLight imaging also found substantially decreased use of antimicrobial dressings and systemic antibiotics4. The MolecuLight devices also perform accurate digital wound measurement, allowing for the consistent monitoring and documentation of wounds.

     

    “We are thrilled to have entered into a supply contract with AllSpire Health GPO,” says Anil Amlani, MolecuLight’s CEO. “Through the i:X and DX, we hope to enable significant cost-savings and improvements in clinical outcomes. AllSpire’s extensive member base can now easily access the MolecuLight wound imaging devices and see the clinical benefits in their wound care practices.”

     

    “We are most impressed with the clinical utility that the MolecuLight i:X and DX devices provide to wound care professionals and are pleased to offer the MolecuLight portfolio via our Group Purchasing Agreement to our member hospitals”, says James Wallick, Senior Director, Strategic Sourcing at AllSpire Health GPO. “AllSpire is dedicated to sourcing the most innovative products that help to improve clinical decision-making and cost-efficiencies. We believe that the MolecuLight devices are highly innovative and will help to provide such clinical and operational benefits”.

     

    In addition to the clinical benefits, MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” procedures and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment.

     

    1. Caldwell et al. Surg Clin North Am, 2020, 100(4)
    2. Le et al. Adv Wound Care, 2021
    3. Rahma S. et.al Diabetes Care 2022;45(7):1601–1609
    4. Price et al. Diagnostics, 2020

     

    About MolecuLight Corp.

    MolecuLight Corp. is the US subsidiary of MolecuLight Inc., a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection of wounds containing elevated bacterial burden (when used with clinical signs and symptoms) and for digital wound measurement. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

     

    About AllSpire Health GPO

     

    Founded in 2016, AllSpire Health GPO, LLC is a collaborative, regional group purchasing organization utilizing innovation analytics, as well as product and purchased service standardization, as a platform to escalate the improvement of clinical outcomes, enable greater access to affordable healthcare, ensure economic sustainability, and enhance patient, physician, and clinician satisfaction among its members. AllSpire Health GPO delivers value via the development and execution of clinical and service line improvement initiatives across the care continuum.

     

    SOURCE MolecuLight

    REGENATIVE LABS AND DR. MICHAEL LAVOR ANNOUNCE CASE STUDY DEMONSTRATING

    NOVEL APPLICATION OF UMBILICAL CORD FLOWABLE TISSUE ALLOGRAFTS IN DECUBITUS ULCERS

    NEWS PROVIDED BY Regenative Labs

     

    PENSACOLA, Fla., Jan. 23, 2023 /PRNewswire/ — A case study analysis of two patients has been presented by Regenative Labs (Regenative), a leading HCT/P manufacturer, in collaboration with Dr. Michael Lavor of Saguaro Surgical. This case study demonstrates the use of Wharton’s Jelly, a connective tissue, allografts in combination with standard of care wound practices to accelerate the healing of refractory, Stage IV sacral wounds in paralyzed patients.

     

    In reference to what he’s seen in the patient population regarding Wharton’s Jelly allografts, Lavor shared, “the patients have begged for more because it is the only thing that has helped them. I believe this is an excellent step prior to surgery, and will save hundreds of thousands of dollars.”

     

    This case study demonstrates an application of Wharton’s Jelly allografts in late-stage sacral decubitus ulcers (SDU), also known as pressure sores, with associated tunneling in combination with standard of care. In the future, research may focus on the frequency and combination of procedural techniques that most efficiently promote granulation tissue formation and volumetric contracture of deep wounds with Wharton’s Jelly allografts.

     

    “This, for wounds, is excellent for closing tunnels,” explained Dr. Lavor.

     

    It was reported that for the first time in ten years, one patient experienced a highly accelerated wound closure rate, and observed volumetric reduction in the wound bed, healthy granulation tissue, and the resolution of deep tunneling. One patient achieved full one closure and epithelization.

     

    Both patients in the presented case study had SDU classified as Stage IV with tissue loss and bone or tendon involvement. One patient had previously experienced a mid-sacral pressure sore with exposed tendon, bone, and tunneling for ten years. The other, had an ischial pressure sore with the same features that persisted for 30 months. After failing multiple conservative treatments such as wound vac placement, antibiotics, wet-to-dry dressings, and silver sulfadiazine dressings, both patients received several applications of Regenative’s Wharton’s Jelly allograft.

     

    In both cases, after eight months of standardized wound care treatment combined with six applications of Regenative’s Wharton’s Jelly allograft, the wounds contracted by over 90% in depth, tunneling, and diameter.

     

    Annually, thousands of individuals are affected by SDU. Treatment for these conditions is costly and far from perfect, with prices as high as an eye-watering 240,000 dollars for skin flap surgery. Inevitably, Stage II pressure ulcers can become serious if not handled swiftly. When deep, tunneling, and with both tendon and bone involvement, such as the two patients in this case study, late-stage pressure sores occur, and pose a great challenge to medical professionals.

     

    Regenative is committed to providing patients with alternative options, and through what may be revealed in these studies, offering proven treatments to better address the root cause of their pain.

     

    Regenative hopes to enlist physicians to take part in studies regarding uncovered uses. Physicians will have their outcomes highlighted, furthering the understanding of regenerative medicine and uncovering new applications for this groundbreaking field of medicine.

     

    “The research at Regenative is very promising, and we’re calling on physicians across the country to engage with us and advance regenerative medicine,” shared Regenative Labs CEO, Tyler Barrett.

     

    Contact Regenative to get your practice involved today.

     

    About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with the daily challenges of innovations in healthcare, the company provides non-addictive, non-invasive options for patients. Regenative Labs’ expert product research and development team comply with FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines. Learn more at Regenative’s website: www.regenativelabs.com

     

    About Dr. Michael Lavor: Dr Michael Lavor has worked for over 28 years bringing the highest quality of medicine to his patients. He is currently based out of Arizona, and is planning to open his own practice within the first 2 quarters of 2023. In addition to his work as Assistant Medical Director at Saguaro Surgical, Dr. Lavor was a member of the Trauma Team at Tucson Medical Center where he also served as Chairman of the Department of General and Vascular Surgery. Dr. Lavor was board certified in General Surgery and was a fellow in the American College of Surgeons, past president of the Rocky Mountain Vascular Surgical Society, a Fellow in the Southwestern Surgical Congress, a member of the Tucson Surgical Society, a member of the International Society of Endovascular Surgery and the Pima County Medical Society. Lavor served in the Navy for ten years as a Navy Corpsman with the Marines; he returned to service in 2009 and served as a Commander / OIC of a wound surgical base in Afghanistan from 2012-2013. He also was a Clinical Associate Professor at the University of Arizona Medical Center Department of Surgery.

    This article was originally published here

    Seasoned Healthcare Executive David Bassin Joins the MolecuLight Board of Directors

    Former Healogics CEO Brings Deep Wound Care Industry Experience to MolecuLight’s
    Rapidly Growing Business

    TORONTOJuly 6, 2023 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging that locates and detects elevated, pathogenic bacterial loads in and around wounds, is pleased to announce the appointment of David Bassin to its Board of Directors as an Independent Board Member.

    David Bassin brings a wealth of expertise and experience in the healthcare industry, particularly in the field of wound care. As the founder of GIO Advisory LLC, he has provided invaluable advisory services to numerous companies and private equity firms based on his extensive background in healthcare, spanning pharmaceutical/device, payer, and provider services. Most recently, Bassin served as the CEO of Healogics, the foremost provider of wound care services in the US, operating over 630 wound care centers and 300 providers. During his tenure, he successfully restructured and refocused the business, resulting in strong earnings growth prior to his transition into advisory services. Prior to his role as CEO, Bassin served as the CFO of Healogics, contributing to the company’s financial growth and success. Bassin’s impressive career also includes significant roles in other healthcare organizations. He served as the CFO of eviCore Healthcare, Inc., where he oversaw multiple dividend recapitalizations and facilitated a merger with the company’s largest competitor, leading to the creation of a company with over 3,000 employees. Additionally, Bassin held the position of CFO at InVentiv Health, Inc., a provider of services to pharmaceutical companies, where he successfully managed a high-growth company and orchestrated a go-private transaction valued at over $1 billion and delivered a significant premium to its shareholders.

    “We are thrilled to welcome David Bassin to the MolecuLight Board of Directors,” said Anil Amlani, CEO of MolecuLight. “His extensive experience in optimizing and scaling organizations across the healthcare industry, particularly in wound care, will be invaluable to MolecuLight as we continue to expand our global presence. Our MolecuLight devices have already become indispensable tools in wound assessment and real-time decision-making for thousands of clinicians worldwide. David’s expertise will greatly support our mission to meet the increasing global demand for our innovative wound care diagnostics and establish them as the gold standard in the field.”

    David Bassin expressed his excitement about joining MolecuLight’s Board of Directors, stating, “There are over 6.5 million patients living with wounds.  As an industry, we need to continue to develop new solutions that improve wound care treatment effectiveness and efficiency.  With a global drive to improve outcomes, reduce costs, and minimize antibiotic usage, MolecuLight’s point-of-care devices have demonstrated their ability to effectively address these critical clinical needs. I am deeply impressed by the organization, the technology’s alignment with market demands, and the significant market traction they have achieved. I am eager to contribute to their growth and help them achieve their ambitious goals.”

    MolecuLight’s groundbreaking i:X® and DX™ imaging devices are the only FDA-cleared and CE and Health Canada approved devices for the real-time detection of elevated bacterial burden in wounds. Supported by over 80 peer-reviewed publications involving 2,600 patients, these devices are widely utilized by leading wound care facilities worldwide.

    About MolecuLight Inc.

    MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s commercial devices, which include the MolecuLight i: and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

    For more information, contact:

    Rob Sandler 
    Chief Marketing Officer
    MolecuLight Inc.
    T. +1.647.362.4684
    rsandler@moleculight.com
    www.moleculight.com

    Image:

    SOURCE MolecuLight

    Innovative Approaches in Diabetic Foot Ulcer Management

    From LEKHA MUTYALA
    Summary:
    Revolutionizing Diabetic Foot Ulcer Care with 3D Technology
    Diabetic foot ulcers (DFUs) affect 1 in 4 individuals with diabetes and contribute significantly to healthcare costs and lower limb amputations worldwide. Traditional treatments—like wound debridement, glycemic control, and surgical interventions—offer limited scalability in the face of rising diabetes prevalence. Fortunately, innovative technologies are reshaping the future of DFU management. 3D-printed antibiotic bandages from Queen’s University promise rapid healing and reduced clinical burden. Meanwhile, Indian researchers have developed custom, pressure-sensitive 3D-printed footwear to enhance balance and recovery. In surgical care, 3D-bioprinted adipose tissue has successfully prevented amputations in high-risk patients. These advancements highlight how personalized, tech-driven solutions can reduce complications, improve outcomes, and lower healthcare costs for diabetic patients. Full article

    ————

    Lekha Mutyala is a podiatry student at Kent State University College of Podiatric Medicine (KSUCPM). In 2024, she won the 38th Annual American Podiatric Medical Writers Association (APMWA) Student Writing Competition for her paper titled “Advancements in Technology and Innovative Approaches in Diabetic Foot Ulcer Management.” This achievement earned her a $1,000 honorarium from an endowment by Dr. and Mrs. Steven Berlin to the APMA Educational Foundation .​

    Additionally, Mutyala was recognized as a 2024–2025 APMA Educational Foundation scholarship recipient, highlighting her academic excellence and commitment to the field of podiatric medicine

    What’s Your Litmus Test ….

    for the Appropriateness of Wound Treatments?

    In this thought-provoking article, the author challenges wound care professionals to critically evaluate the appropriateness of their treatment choices. Despite advances in technology and science, outdated or non-evidence-based approaches remain common in clinical practice. The author introduces three practical “litmus test” questions to guide treatment decisions: 1) What is the rationale for this treatment? 2) What does the science and evidence say? and 3) Could this plan of care be defended in court? Through clear examples—like the misuse of NPWT on necrotic wounds or unnecessary topical antibiotics—the article underscores the importance of logic, clinical evidence, and legal defensibility in creating effective, modern wound care plans … full article


    About the author:

    Bill Richlen - Advanced Wound Debridement

    About the Author: Bill Richlen, PT, WCC, DWC (1970–2024)

    Bill Richlen was a respected physical therapist and wound care educator with over 25 years of clinical and teaching experience. A graduate of the University of Wisconsin–Madison, he specialized in advanced wound care and debridement across long-term care, outpatient, rehab, and home health settings.

    He co-founded Wound Care Gurus, serving as CEO and providing evidence-based education and consulting nationwide. Bill was also a long-time instructor with the Wound Care Education Institute (WCEI), known for his engaging teaching style and commitment to practical, science-driven care. His legacy lives on through the thousands of clinicians he mentored.

    Case series of traumatic injuries to evaluate the efficacy and safety of Aiodine™

    Aiodine™ for Traumatic Wounds: Enhanced Healing and Infection Control

    This case series, published March 26, 2025, in *Wounds International*, reports preliminary findings from four patients treated with **Aiodine™**, a novel topical iodine-based formulation. Conducted at Hainan Medical University’s Wound Department in China, the study highlighted accelerated wound healing and reduced infection in severe traumatic wounds.

    Key Highlights:

    • Broad-Spectrum Antimicrobial Activity: In vitro studies showed Aiodine™ achieves >5 log reduction against both Gram-positive and Gram-negative bacteria in just 30 seconds.
    • Clinical Efficacy: All four patients—who had wounds such as diabetic foot ulcers, pressure injuries, and necrotic lesions—demonstrated significant healing improvements within two weeks, with dramatic reductions in infection rates.
    • Excellent Tolerance: No adverse effects were reported. Patients experienced decreased wound discomfort and improved quality of life during treatment.
    • Next Steps Required: Authors recommend larger randomized, double-blind, placebo-controlled trials to confirm Aiodine™’s safety and effectiveness in broader wound care applications.

    Read the full case series and download the PDF: Wounds International – Aiodine™ Case Series.

    Keywords:
    Aiodine™,
    iodine antimicrobial,
    traumatic wound,
    wound infection,
    wound healing


    🔬 Spotlight: Aiodine™ – A New Era in Topical Antimicrobial Therapy

    Aiodine™ is a next-generation topical antimicrobial solution designed to rapidly eliminate bacteria while supporting wound healing. Unlike traditional iodine formulations, Aiodine™ delivers broad-spectrum bactericidal action with improved tissue compatibility and no reported cytotoxicity in early clinical use.

    What Sets It Apart?

    • Delivers a >5-log bacterial reduction in 30 seconds
    • Effective against antibiotic-resistant strains and biofilm-producing pathogens
    • Non-cytotoxic and well-tolerated, even on fragile wound beds
    • Supports granulation and epithelialization in complex or infected wounds

    Backed by early clinical results in traumatic and chronic wounds, Aiodine™ may offer a valuable alternative in settings where both infection control and tissue preservation are critical.

    Core Services from a Multidisciplinary Diabetic Foot Team

    Core Services from a Multidisciplinary Diabetic Foot Team (ZAP Position Statement)

    A position statement by the Zero All Preventable (ZAP) Amputation group of Foot in Diabetes UK (FDUK), published April 15, 2025 in The Diabetic Foot Journal, outlines the essential services that people with active diabetic foot problems should expect from a multidisciplinary diabetic foot team (MDFT).

    Key Highlights:

    • Team Composition: Core members should include podiatrists, diabetologists, vascular specialists, orthopaedic or podiatric surgeons, plastic surgeons, microbiologists or infectious disease physicians, specialist nurses, psychologists, orthotists, and plaster technicians—all coordinated by a designated MDFT lead.
    • Timely Intervention: Debridement should be performed without delay—typically by a podiatrist—with immediate offloading and pressure redistribution initiated to reduce further tissue damage.
    • Infection and Vascular Management: Patients should have rapid access to antibiotics and surgical debridement for infected wounds, alongside urgent vascular imaging and revascularization when ischemia is suspected.
    • Referral and Prescribing Rights: Podiatrists should hold independent referral rights for imaging (e.g., X-ray, MRI) and, where supported, prescribing authority. Dedicated consultant podiatrists should oversee care coordination across both inpatient and outpatient settings.
    • Mental Health Integration: Recognizing the emotional burden and high mortality rates associated with diabetic foot ulcers, mental health support must be embedded through liaison nurses or access to psychological services.

    This position paper reinforces that fully staffed, responsive, and coordinated multidisciplinary teams—led by experienced podiatric clinicians—are critical in delivering timely care and reducing amputation risk in individuals with diabetes.

    Read the full position statement on the Diabetic Foot Journal website.

    Keywords:
    ZAP Amputation,
    multidisciplinary foot team,
    debridement,
    offloading,
    psychological support

    Suprasorb® Liquacel Pro & Ag: Advanced Gelling Fiber Dressings for Exudate & Bioburden Management

    Suprasorb® Liquacel Pro & Ag: Advanced Gelling Fiber Dressings for Exudate & Bioburden Management

    Wound Care Today highlights two hydroactive gelling fiber dressings—Suprasorb® Liquacel Pro and Suprasorb® Liquacel Ag—engineered for efficient exudate control and infection support in complex wounds.

    Key Highlights:

    • Gel Formation & Vertical Absorbency: Both dressings transform into a conforming gel upon contact with wound exudate, maintaining moisture balance and protecting wound margins from maceration :contentReference[oaicite:1]{index=1}.
    • Robust & Atraumatic: A blend of sodium carboxymethylcellulose (CMC) and strengthening fibers ensures high wet tensile strength—dressing remains intact for smooth removal :contentReference[oaicite:2]{index=2}.
    • Antimicrobial Silver Option: The “Ag” variant incorporates 1.1% silver nanoparticles, offering sustained antimicrobial and anti-biofilm activity, effective against organisms like MRSA :contentReference[oaicite:3]{index=3}.
    • Evidence Supports Use: A 4-week multicenter evaluation (n=19) showed improvements in wound status for 84% of participants, with reduced exudate, infection markers, and antibiotics in the silver group :contentReference[oaicite:4]{index=4}.
    • Clinical Benefits: The dressings help with autolytic debridement, odor control, and biofilm reduction; they’re suitable for shallow, cavity, and exuding wounds under compression :contentReference[oaicite:5]{index=5}.

    These dressings are well-suited for hard-to-heal, moderately to heavily exuding wounds—especially those at risk of biofilm or infection—providing moisture management, exudate lock-in, and atraumatic removal.

    Keywords: gelling fiber, exudate management, silver antimicrobial, autolytic debridement, biofilm control

    Read the full article on Wound Care Today


    🔬 Spotlight: Comparable Gelling Fiber Products

    Explore these clinically validated gelling fiber dressings that perform similarly in exudate management and ease of use:

    Medline Opticell Gelling Fiber: Chitosan-based Cytoform technology forms an absorbent, clear gel—ideal for partial to full-thickness wounds, with up to 7‑day wear time.
    McKesson Gelling Fiber Dressing: Affordable option for managing exudate across various wound types, offering reliable absorbency and wet/tensile strength.
    3M Kerracel Gelling Fiber: Known for strong absorbency, maceration protection, and compatibility with compressive therapy in venous/diabetic ulcers.

    Acid-Fast Bacilli Staining for Nonhealing Ulcers

    Acid-Fast Bacilli Staining Reveals Mycobacterium chelonae in a Nonhealing Ulcer

    Summary: A case report in WOUNDS documents a rare instance of Mycobacterium chelonae infection in a chronic foot ulcer that failed to heal despite appropriate standard care. Acid-fast bacilli (AFB) staining and cultures identified the pathogen in an immunocompetent patient, leading to successful treatment with a four-month course of linezolid and clarithromycin, alongside antimicrobial dressings—resulting in wound closure after 10 weeks.

    Case Highlights:

    • The patient, a 64-year-old woman with type 2 diabetes and managed peripheral arterial disease, had an ulcer unresponsive to multiple antibacterial regimens and debridement.
    • Routine cultures were negative, but a follow-up punch biopsy with AFB staining revealed the presence of M. chelonae.
    • The tailored antibiotic combination, coupled with silver alginate dressings, achieved healing within ten weeks.

    Clinical Implications: While AFB infections are uncommon in chronic ulcers, this case underscores the importance of considering alternative pathogens when wounds are nonhealing. Clinicians should consider biopsy and AFB testing after 4–6 weeks of failed conventional care.

    🔗 Read the full case report on WOUNDS


    Keywords: Stephanie Behme, Shiwei Zhou, Andrew Brown, Gary Rothenberg, Mycobacterium chelonae, acid-fast bacilli, AFB culture, chronic ulcer, linezolid and clarithromycin

    Kirschner Wires Combined With Elastic Tape for Multilayer Tension-Reducing …

    Kirschner Wires + Elastic Tape for Greater Trochanter Stage 4 Pressure Injury

    Summary: This intriguing case report (published in Wounds, August 2025) describes an innovative repair strategy for a large (11 × 7.5 cm), infected stage 4 pressure injury at the greater trochanter in an 89-year-old man. After multiple debridements and negative-pressure wound therapy (NPWT), clinicians employed Kirschner wires and elastic therapeutic tape to create a multilayer, tension-reducing closure.

    Key Highlights:

    • The 89-year-old patient—post–hip fracture fixation and bedridden for 20 days—presented with a necrotic, foul-smelling circular ulcer. MRSA was identified, and he received appropriate antibiotics, serial debridement, and NPWT during the initial hospitalization.
    • On day 31, surgical closure was performed using five 1.5 mm Kirschner wires placed vertically and bent in an inverted “Ω” configuration to align and decompress wound edges across anatomical layers. NPWT continued post-op, followed by elastic tape as the wires were gradually removed.
    • The wound fully healed by day 102. Six-month follow-up confirmed restoration of skin appearance and sensation.
    • Authors propose that this technique effectively reduces surgical tension across skin, subcutaneous tissue, and deep fascia—without undue stress—offering a practical solution for difficult-to-close, deep trochanteric wounds.

    Read the full case report in WOUNDS

    Keywords:
    Kirschner wires,
    elastic tape,
    tension-reducing repair,
    Stage 4 pressure injury,
    greater trochanter,
    negative-pressure wound therapy (NPWT),
    wound debridement

    The impact of diabetes on the outcomes of lower extremity arterial disease in patients ….

    The impact of diabetes on the outcomes of lower extremity arterial disease in patients with vascular surgical interventions in Kosovo

    Summary: This observational study in Kosovo evaluated how type 2 diabetes affects outcomes in patients undergoing vascular surgery for lower extremity arterial disease (LEAD). Among patients treated between November 2023 and April 2024, the study found high amputation risk, significant complication rates, and identified clinical factors associated with poorer outcomes.

    Key Highlights:

    • Patient demographics: Most were between ages 62–71; ~63% male; nearly all (96.3%) were managed with insulin.
    • Adverse events: Toe gangrene requiring amputation occurred in ~25.9% of cases; arterial thrombosis was a common preoperative complication.
    • Hospital stay and treatment: Typical duration was 6–10 days; combined antiplatelet, antidiabetic, and antibiotic therapy used in ~81.5% of patients.
    • Clinical implications: Diabetes markedly worsens surgical outcomes for LEAD, underscoring the need for aggressive risk factor control, tailored perioperative management, and close follow-up.

    Read the full article in the Italian Journal of Medicine

    Keywords:
    Dion Haliti,
    Dea Haliti,
    Laura Leci Tahiri,
    Nora Shabani-Behrami,
    Elena Hajdari,
    Naim Haliti,
    Ragip Shabani,
    Fehim Haliti,
    Qenan Maxhuni,
    Rrahman Ferizi,
    type 2 diabetes mellitus,
    lower extremity arterial disease,
    vascular surgery outcomes

    Mechanisms of microbial infection and wound healing in diabetic foot ulcer

    Mechanisms of microbial infection and wound healing in diabetic foot ulcer: pathogenicity in the inflammatory-proliferative phase, chronicity, and treatment strategies

    Summary: This narrative review examines how microbial infection disrupts the healing phases of diabetic foot ulcers (DFUs), particularly from inflammation to proliferation, and explores treatment strategies. The authors integrate microbial pathogenesis (e.g. virulence, biofilms, polymicrobial synergy) with wound biology to highlight how infection drives chronicity and delay. They also suggest multidimensional therapeutic approaches combining systemic and localized strategies.

    Key Highlights:

    • Pathogenesis of DFU/DFI: Infections impair healing by promoting persistent inflammation, extracellular matrix degradation, impaired angiogenesis, and immune dysregulation.
    • Biofilms & virulence: Biofilm formation and microbial virulence factors shield pathogens, resist antibiotics, and perpetuate inflammatory stimuli.
    • Polymicrobial dynamics: Gram-positive, gram-negative, anaerobes, and fungi interact within wound microbiomes, often synergistically worsening outcomes.
    • Therapeutic strategy framework: The authors advocate a combined approach—glycemic control, antimicrobial therapy tailored to pathogens, debridement, offloading, vascular support, and intelligent dressings.
    • Smart dressing evolution: Future wound dressings should integrate responsive systems (pH, ROS), controlled drug release, and functional enhancements like oxygen delivery or antimicrobial action.

    Read the full article on Frontiers in Endocrinology

    Keywords:
    Qi Wang,
    Chuyu Liu,
    Jing An,
    Jing Liu,
    Yongpeng Wang,
    Yulan Cai,
    diabetic foot ulcer,
    infection mechanisms,
    chronic wounds,
    smart dressings

    Multidisciplinary Management of Early Esophageal Fistulae After Anterior Cervical Surgery

    Multidisciplinary Management of Early Esophageal Fistulae After Anterior Cervical Surgery

    Summary: This case study highlights a coordinated approach to treating esophageal fistulae following anterior cervical spine surgery. By integrating expertise from surgery, otolaryngology, and wound care, clinicians achieved improved outcomes through early diagnosis and collaborative intervention.

    Key Highlights:

    • Early recognition: Prompt imaging and symptom evaluation identified fistula formation.
    • Team strategy: Surgeons, otolaryngologists, and wound specialists worked together for infection control and repair.
    • Treatment methods: Management included surgical diversion, antibiotics, nutritional support, and wound care integration.
    • Patient outcomes: The multidisciplinary method reduced complications and supported tissue recovery.

    Read the full case study on HMP Global Learning Network

    Keywords:
    anterior cervical surgery,
    esophageal fistula management,
    multidisciplinary wound care,
    surgical complications wound care

    Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application

    Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application

    Summary: This empirical study evaluated the use of 2% citric acid ointment for wound-bed preparation in chronic wounds that failed to respond to conventional therapies. The approach aimed to control infection and promote healthy granulation tissue, enabling grafting or secondary healing.

    Key Highlights:

    • Study design: 24 patients with chronic wounds lasting more than 3 weeks and large raw areas unresponsive to standard care.
    • Treatment: Application of 2% citric acid ointment.
    • Microbiology: 32 bacterial strains were isolated—most commonly Staphylococcus aureus (37.5%) and Pseudomonas aeruginosa (25.0%). Many strains were resistant to multiple antibiotics.
    • Outcome: Healthy granulation tissue suitable for split-thickness skin grafting or healing by secondary intention developed in all cases.
    • Effectiveness: Results achieved after 3 to 20 applications of citric acid ointment.

    Read the full article on HMP Global Learning Network

    Keywords:
    citric acid,
    chronic wounds,
    wound bed preparation,
    granulation tissue,
    Staphylococcus aureus,
    Pseudomonas aeruginosa

    Negative Pressure Wound Therapy for Complicated Diabetic Foot Wounds



    Negative Pressure Wound Therapy for Complicated Diabetic Foot Wounds

    Summary: This retrospective case series assesses negative pressure wound therapy (NPWT) in 30 diabetic patients with complicated foot or lower limb infections over 15 years. Following initial debridement and antibiotics, NPWT at -125 mmHg for 7-12 days promoted granulation and healing in 80% of cases, preventing major amputations despite high-risk features like ischemia and polymicrobial infections (e.g., MRSA, E. coli). Five patients (16.6%) required major amputations, and one died. No associations were found with standard classifications (WIFI, IWGDF, TPI). A literature review supports NPWT as an adjunct for faster healing and reduced amputations in selected DFUs, though guidelines caution its use in active infections. The study highlights NPWT’s potential in real-world settings but calls for larger RCTs to confirm benefits.

    Key Highlights:

    • NPWT achieved limb preservation in 80% of high-risk diabetic wounds, with 20% fully healing via grafts or sutures.
    • Common pathogens like MRSA and E. coli were managed effectively post-debridement, reducing infection persistence.
    • Average NPWT duration was 9 days, with hospital stays of 25 days, underscoring its feasibility in clinical practice.
    • Challenges include guideline limitations for infected wounds and need for multidisciplinary approaches to optimize outcomes.
    • Literature shows NPWT halves amputation risks compared to standard care in some trials, supporting its innovative role.

    Read full article

    Keywords:
    diabetic foot ulcers,
    negative pressure wound therapy,
    wound healing innovations,
    diabetic wound infections,
    limb salvage in diabetes

    Clinical Use of DermaBind TL/FM: Advancing Hard-to-Heal Wound Care



    Clinical Use of DermaBind TL/FM: Advancing Hard-to-Heal Wound Care

    Summary: This retrospective case series details real-world clinical experiences with DermaBind TL and FM, dehydrated intact placental membrane allografts from HealthTech Wound Care, applied to hard-to-heal chronic wounds after 30 days of standard therapy failure. Preserving all native layers including the spongy layer with growth factors like hyaluronic acid, TGF-β1, HGF, and IL-1ra, these allografts promote bottom-up healing by enhancing blood flow, facilitating debridement of necrotic tissue, and stimulating granulation and epithelialization. Results indicate faster closure (4-6 weeks vs. national 12-week average), fewer applications needed, and high patient satisfaction, positioning DermaBind as a cost-effective, room-temperature stable option for DFUs, VLUs, and pressure ulcers without antibiotics or freezing.

    Key Highlights:

    • DermaBind’s proprietary preservation retains comprehensive collagen matrix, glycoconjugates, and cytokines for superior regenerative support in stalled wounds.
    • Applied as a protective covering for partial/full-thickness wounds, it outperforms alternatives like Epifix and collagen sponges in healing speed and cost-efficiency.
    • Clinical outcomes show complete epithelization in 4-6 weeks, reducing treatment burden and enhancing functional recovery in chronic cases.
    • Safe for Medicare/Medicaid coverage in VLUs/DFUs; 3-year shelf life at room temperature simplifies logistics for outpatient and long-term care.
    • Emphasizes documented medical necessity and wound measurements for optimal reimbursement and personalized application protocols.

    Read full article

    Keywords:
    DermaBind,
    placental allograft,
    hard-to-heal wounds,
    chronic wound care,
    wound healing innovation

    Biomaterials Revolutionizing Wound Healing and Tissue Regeneration



    Biomaterials: Revolutionizing Wound Healing, Tissue Regeneration, and the Future of Medicine

    Summary: This article by Miss Prachee Bhartiya delves into the transformative role of biomaterials—natural, synthetic, or composite substances engineered for biocompatibility—in modern medicine, particularly in wound healing and tissue regeneration. Highlighting their applications in creating advanced hydrogels for chronic wounds, bioactive dressings for post-surgical sites, and scaffolds for organ repair, it discusses how these materials accelerate recovery, reduce infections, and promote natural tissue growth. The piece also addresses challenges like sustainability and ethics, while envisioning future “smart” biomaterials integrated with AI for personalized, proactive healing in U.S. healthcare.

    Key Highlights:

    • Biomaterials like hydrogels and bioactive dressings provide structural support and release growth factors/antibiotics directly into wounds, speeding healing for burns, chronic ulcers, and surgical incisions.
    • In tissue regeneration, biodegradable polymer scaffolds serve as frameworks for cell growth, dissolving as new tissue forms, with applications in bone repair, nerve regeneration, and cardiovascular grafts.
    • Examples include titanium alloys for orthopedic implants, ceramics for dental bone regeneration, and polymers for controlled drug delivery to optimize wound care outcomes.
    • Future innovations: “Smart” biomaterials that respond to inflammation or infection (e.g., color-changing dressings), 3D bioprinting for custom tissues, and eco-friendly materials from renewable sources like algae.
    • Challenges: Ensuring biocompatibility to avoid rejection, rigorous FDA testing, and sustainable production; ethical focus on transparency and public trust in regenerative advancements.

    Read full article

    Keywords:
    biomaterials,
    wound healing,
    tissue regeneration,
    smart biomaterials,
    regenerative medicine,
    Miss Prachee Bhartiya

    The Charcot Foot: A Missed Diagnosis Can Cost a Limb



    The Charcot Foot: A Missed Diagnosis Can Cost a Limb

    Summary: This article explores Charcot neuroarthropathy, a destructive condition primarily in diabetic patients first described in 1883, which can lead to severe deformities, ulcers, and amputations if misdiagnosed as cellulitis or osteomyelitis. Affecting 0.08-13% of diabetics, acute Charcot presents with painless swelling, erythema, and warmth, progressing to chronic “rocker bottom” deformities increasing plantar pressure and ulceration risk. Diagnosis relies on clinical suspicion, radiographs (often normal early), and MRI for bone marrow edema patterns distinguishing it from infection. Treatment emphasizes immobilization and early referral to prevent limb-threatening complications, underscoring the role of wound care providers in recognizing this mimic to preserve function and reduce amputation rates.

    Key Highlights:

    • Prevalence: 0.08% in general diabetics to 13% in high-risk clinics; often underestimated due to misdiagnosis as infection.
    • Acute symptoms: Edema, erythema, warmth (3+°C higher than contralateral foot), mild pain from neuropathy; chronic: Rocker bottom deformity, hyperkeratotic ulcers from pressure.
    • Diagnosis: MRI most accurate (periarticular edema in Charcot vs. intraosseous in osteomyelitis); three-phase bone scan 93% sensitive; elevation test differentiates from cellulitis (resolves in 10 min).
    • Treatment: Immobilization like fractures; avoid unnecessary I&D or antibiotics; early intervention prevents degeneration and ulceration cycle.
    • Expert quote: “Early diagnosis of Charcot foot and proper treatment are critical to preventing long-term consequences.”

    Read full article

    Keywords: Charcot foot, diabetic neuropathy, wound misdiagnosis, rocker bottom deformity, limb preservation

    Complications of Diabetes Mellitus: Foot Ulcer



    Complications of Diabetes Mellitus: Foot Ulcer

    Summary: This article details a clinical case of a 58-year-old man with type 2 diabetes who developed a right great toe ulcer from ill-fitting shoes, progressing to deep infection, osteomyelitis, and below-knee amputation due to delayed recognition amid neuropathy and vascular issues. It underscores the high prevalence of diabetic foot ulcers (DFUs)—affecting 15% of diabetics lifetime, with 14-24% risking amputation—and the critical need for routine screening, offloading, and aggressive debridement. Expert insights highlight monofilament testing for sensory loss and MRI for bone involvement, advocating multidisciplinary approaches to prevent progression from minor wounds to life-altering complications in wound care.

    Key Highlights:

    • Case details: Ulcer started as a callus from pressure; neuropathy masked pain, allowing infection spread to bone, requiring antibiotics, debridement, and eventual amputation after failed revascularization.
    • Prevalence stats: DFUs occur in 15% of diabetics; 25% of moderate-severe cases lead to amputation; annual U.S. cost exceeds $9 billion.
    • Symptoms and risks: Painless ulcers from sensory loss; vascular insufficiency delays healing; common in males over 40 with >10 years diabetes.
    • Diagnosis: Semmes-Weinstein monofilament for neuropathy; probe-to-bone test (positive in 66% with osteomyelitis); MRI differentiates infection from Charcot.
    • Prevention/treatment: Daily foot checks, proper footwear, glycemic control; offloading casts, hyperbaric oxygen, and vascular surgery for salvage.

    Read full article

    Keywords: diabetic foot ulcer, neuropathy, osteomyelitis, amputation prevention, monofilament testing

    Hydrocolloid Dressing vs Petroleum Ointment for Scar Appearance After Dermatologic Surgery



    Hydrocolloid Dressing vs Petroleum Ointment for Scar Appearance After Dermatologic Surgery

    Summary: This investigator-blinded randomized clinical trial (October 2022–October 2023) at an Indiana university compared a single 1-week hydrocolloid dressing (HCD) application to daily petroleum ointment in 146 adults (mean age 61.9 years) undergoing excisional or Mohs surgery with linear repair. Primary outcome was patient-reported scar appearance via modified Visual Analog Scale (VAS) at 7, 30, and 90 days; secondary included surgeon VAS, complications, and comfort/convenience ratings. HCD yielded similar scar outcomes (e.g., 7-day VAS difference -0.40, 95% CI -0.70 to -0.10) but higher convenience (86.9% vs 46.8%) and comfort (73.8% vs 48.3%), with slightly elevated but non-significant adverse events like bleeding (20.6% vs 8.8%). HCD offers a viable, patient-preferred alternative for those avoiding daily care, balancing efficacy and postoperative risks.

    Key Highlights:

    • Design: 146 patients randomized (72 HCD, 74 petroleum); exclusions included flaps/grafts or adhesive allergies; data analyzed November 2023–March 2025.
    • Scar Appearance: Comparable patient VAS at 7/30/90 days (differences -0.40/-0.08/-0.09); surgeon ratings similar between groups.
    • Complications: Higher in HCD (bleeding 20.6% vs 8.8%, dehiscence 6.2% vs 0%, pain 21.2% vs 12.3%); no antibiotic needs in either.
    • Patient Ratings: HCD more convenient (86.9% vs 46.8%, difference 40.1%) and comfortable (73.8% vs 48.3%, difference 25.4%).
    • Implications: HCD suitable for post-surgical wounds; choose based on cost, preferences, and complication tolerance; further studies on long-term scarring recommended.

    Read full article

    Keywords: hydrocolloid dressing, petroleum ointment, post-surgical scars, VAS scar assessment, dermatologic surgery

    Factors Influencing Major Amputation and Death Following Diabetic Limb Salvage



    Factors Influencing Major Amputation and Death Following Diabetic Limb Salvage

    Summary: This systematic review of 49 studies (2020–2025) and real-world analysis of 72 high-risk diabetic patients via the Mid Essex Diabetes Amputation Reduction Plan (MEDARP) identifies key predictors of major amputation and mortality after limb salvage surgery for diabetic foot ulcers. Risk factors include older age, male sex, renal/cardiovascular disease, ischemia, osteomyelitis, and advanced ulcer classification. MDT models consistently lowered amputation rates (e.g., 35–80% reduction) and improved wound healing/survival, though heterogeneity limited meta-analysis. MEDARP achieved 6.9% major amputation and 12.5% mortality—below published medians—with significant gains in patient-reported outcomes like function and pain. Findings advocate standardized MDT protocols, early revascularization, and glycemic control to enhance limb preservation and chronic wound management.

    Key Highlights:

    • Risk factors: Demographic (age, sex, race), clinical (CKD, PAD, ESRD, high HbA1c, low albumin, elevated CRP), surgical (wound size, infection, revascularization failure) predict 0–67.7% amputation and 9–18% 1-year mortality.
    • MDT benefits: Reduced amputations (e.g., 80% minor, 35% major), faster healing, cost savings; 17 studies showed survival gains, emphasizing coordinated care for DFUs.
    • MEDARP outcomes: 6.9% major amputation, 12.5% mortality in 72 patients; MSK-HQ scores rose from 29.3 to 49.4, MOXFQ pain/social scores improved markedly over 11 months.
    • Interventions: Revascularization, debridement, NPWT, antibiotics, flaps enhance salvage; glycemic optimization (time in range) and local vancomycin lower infection risks.
    • Limitations: Observational data, outcome variability; calls for standardized definitions, prospective trials to refine MDT for chronic diabetic wounds.

    Read full article

    Keywords: diabetic limb salvage, major amputation, multidisciplinary team, diabetic foot ulcers, wound healing MDT, Kit Ferguson, Sifat M Alam, Connor Phillips

    From Webs to Wound Healing: ASU Scientists Harness Silk for Medical Innovation



    From Webs to Wound Healing: ASU Scientists Harness Silk for Medical Innovation

    Summary: Arizona State University researchers, led by Professors Jeff Yarger and Kaushal Rege, are pioneering silk proteins from silkworms and spiders for advanced wound healing, as detailed in ACS Biomaterials Science & Engineering. Their laser-activated sealants (LASEs) embed gold nanorods or indocyanine green in silk fibroin matrices, enabling near-infrared laser-triggered heating to seal wounds in seconds—stronger than sutures while minimizing trauma. Versatile forms (fibers, hydrogels, sponges) loaded with antibiotics like vancomycin promote sustained release, biocompatibility, and biodegradation, targeting chronic wounds such as diabetic foot ulcers and pressure sores by enhancing tissue repair and infection prevention.

    Key Highlights:

    • LASEs close wounds instantly via photothermal activation, outperforming sutures in strength and reducing scarring/infection.
    • Silkworm silk fibroin serves as biocompatible matrix; spider egg-case silk explored for tendon-like scaffolds due to superior toughness.
    • Drug delivery: Sustained vancomycin release combats biofilms in chronic wounds; preclinical models confirm efficacy.
    • Versatility: Processable into 3D scaffolds for tissue engineering, personalized dressings with growth factors.
    • Future: Recombinant spider silk production to scale up; applications in DFUs, burns, and surgical sites for faster, safer healing.

    Read full article

    Keywords: spider silk, silk fibroin, laser-activated sealant, chronic wound healing, biodegradable scaffold

    Application of Deep Breathing Relaxation Techniques to Reduce Pain Intensity ….



    Application of Deep Breathing Relaxation Techniques to Reduce Pain Intensity in Patients with Post-Operative Diabetes Mellitus Ulcers

    Summary:** This study assesses deep breathing relaxation as a non-pharmacological intervention for pain management in post-operative diabetic foot ulcer (DFU) patients, demonstrating its efficacy in lowering pain intensity and enhancing recovery. Involving DFU patients undergoing debridement or amputation, the technique—simple inhalation/exhalation with abdominal focus—reduced VAS pain scores from 6.5 to 3.2 (p<0.05) after 10-minute sessions twice daily. It promotes relaxation, improves oxygenation, and boosts compliance with wound care, offering an accessible tool for diabetic complications in resource-limited settings.

    Key Highlights:

    • DFU Pain: Post-op pain from debridement or surgery exacerbates stress and delays healing in diabetics.
    • Method: Guided deep breathing (4s inhale, 6s exhale) for 10 min BID; simple, no equipment needed.
    • Results: VAS drop 3.3 points; improved sleep and mobility; no side effects.
    • Mechanisms: Lowers cortisol, enhances endorphins, supports glycemic control.
    • Implications: Complements antibiotics/dressings; recommended for nursing protocols in DFU care.

    Read full article

    Keywords: deep breathing, DFU pain, non-pharmacological, post-operative care, relaxation techniques

    Enzyme Involved in Glucose Metabolism Promotes Wound Healing, Study Finds



    Enzyme Involved in Glucose Metabolism Promotes Wound Healing, Study Finds

    Summary:** Georgia State University researchers reveal that pyruvate kinase M2 (PKM2)—an enzyme in glucose metabolism—accelerates wound healing when released by neutrophils. In mouse models, PKM2 enhanced keratinocyte migration and proliferation via metabolic reprogramming, reducing inflammation and improving closure in diabetic ulcers. This suggests PKM2 as a therapeutic target or mimic for stalled chronic wounds, potentially via topical delivery to boost repair without antibiotics.

    Key Highlights:

    • Mechanism: PKM2 shifts glucose to glycolysis for energy in healing cells; neutrophil release directs repair.
    • Models: Diabetic mice showed 40% faster closure with PKM2; reduced TNF-α and boosted VEGF.
    • Implications: Targets chronic wounds with metabolic defects; potential for PKM2 agonists in dressings.
    • Publication: Nature Communications (2025); DOI: 10.1038/s41467-025-51234-6.
    • Expert: Lead author Dr. Ying Li: “PKM2 could transform how we treat non-healing wounds.”

    Read full article

    Keywords: PKM2 enzyme, glucose metabolism, neutrophil release, diabetic ulcers, metabolic reprogramming

    Guideline Adherence, Team Approach to Prevention Impacts Surgical Site Infections



    Guideline Adherence, Team Approach to Prevention Impacts Surgical Site Infections

    Summary:** This review of 20+ studies demonstrates that strict adherence to SSI prevention guidelines—antibiotic timing, normothermia, and hair removal—combined with multidisciplinary teams (surgeons, nurses, IPs) reduces infection rates by 25-40%. Post-discharge wound care education is crucial, as 50% of SSIs occur after hospital stay; tools like apps for monitoring improve compliance and outcomes in high-risk surgeries like orthopedic or vascular procedures.

    Key Highlights:

    • Adherence Impact: 95% compliance lowers SSIs by 30%; gaps in post-op care contribute 60% of cases.
    • Team Benefits: MDT protocols cut re-admissions; nurse-led education boosts patient self-monitoring.
    • Post-Discharge: Digital tools for wound checks; patient guidance on hygiene and signs of infection essential.
    • Evidence: Meta-analysis of 15 RCTs; NNT 8 for guideline bundles.
    • Implications: Standardize education; integrate IPs for waste reduction in wound care.

    Read full article

    Keywords: SSI prevention, guideline adherence, multidisciplinary team, post-discharge care, surgical wounds

    Integrated Chinese-Western Medicine for Refractory DFU



    Integrated Treatment Utilizing Both Chinese and Western Medicine for Refractory Diabetic Foot Ulcers

    Summary: This case report describes a 57-year-old man with a 20-year diabetes history and Wagner grade IV diabetic foot ulcer (DFU) that progressed to near-amputation despite standard Western care. An integrated protocol combining Chinese herbal fumigation (to enhance circulation/debride), acupuncture (for pain/neuropathy), and Western IV antibiotics/sharp debridement led to 90% wound reduction by month 2, granulation by week 8, and complete epithelialization by week 12, with ABI improving from 0.6 to 0.9 and no recurrence at 6 months. The approach highlights TCM’s holistic benefits complementing Western precision for refractory DFUs, suggesting potential for broader use in diabetic wound care.

    Key Highlights:

    • Patient: 57M, BMI 25.4, HbA1c 8.9%; 10×8 cm ulcer with exposed bone, foul odor, severe pain (VAS 8).
    • Treatment: Herbal fumigation (Angelica sinensis, etc.) BID 20 min; acupuncture (ST36/SP6); ceftazidime + debridement daily; glycemic control.
    • Progress: Week 4: 40% reduction, granulation start; Month 3: Full closure; pain to VAS 2; no AEs.
    • Mechanisms: TCM improves microcirculation/immunity; Western targets infection; synergy accelerates repair.
    • Implications: Cost-effective for refractory cases; calls for RCTs to validate in diabetic ulcer management.

    Read full article

    Keywords: integrated medicine, refractory DFU, herbal fumigation, acupuncture, Wagner grade IV

    Histologics LLC Wound Care Launches Soft K-Bride®, a Revolutionary Wound-Bed Prep …



    Histologics LLC Wound Care Launches Soft K-Bride®, a Revolutionary Wound-Bed Prep, Debridement, and Biopsy Device

    Summary: Histologics LLC has launched Soft K-Bride®, a versatile device combining wound-bed preparation, debridement, and biopsy capabilities using proprietary Kylon® technology—a hooked brush array that gently removes necrotic tissue, biofilm, and debris while preserving healthy tissue. Designed for chronic wounds like diabetic ulcers and pressure injuries, it features a measured handle for depth assessment, flat head for excision, and concave face for wiping, enabling precise tangential biopsies for lab analysis. Training emphasizes micro-curette friction to prime beds for grafts, promoting antibiotic stewardship and reducing broad-spectrum use, with no scarring or trauma in use.

    Key Highlights:

    • Kylon® array: Transforms into frictional micro-curettes under pressure for debridement and biopsy without trauma.
    • Design: Incremented handle measures up to 10cm; flat/concave heads for controlled excision and margins.
    • Applications: Diabetic ulcers, pressure injuries, burns, surgical wounds; entraps tissue for culture/molecular testing.
    • Benefits: Training for clinicians; supports graft integration by priming viable surfaces; no scarring reported.
    • Quote: Dr. Neal Lonky: “Surgical excision into viable tissue assures grafts heal effectively; clears biofilm for better outcomes.”

    Read full article

    Keywords: Soft K-Bride, Kylon technology, wound debridement, tangential biopsy, chronic wound prep

    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency ….



    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

    Summary: This narrative review synthesizes DFU’s complex etiology, affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, neuropathy, hyperglycemia-induced immune defects, and biofilms. It covers diagnostic tools (TCOM, ABI, biopsy) and therapies from offloading/compression to advanced options like growth factors, stem cells, and bioengineered skins (50-70% closure rates). Microbial dysbiosis (e.g., Staphylococcus dominance) exacerbates inflammation; the review calls for personalized, multidisciplinary approaches with AI diagnostics and nanotech antimicrobials to reduce global burden and enhance limb salvage.

    Key Highlights:

    • Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection.
    • Immune Dysbiosis: Hyperglycemia shifts macrophages to M1; biofilms (Staph/Pseudomonas) resist antibiotics.
    • Therapies: Offloading (TCCs 80% efficacy); HBOT (50% closure); bioengineered skins (70% in RCTs).
    • Future: AI for risk prediction; nanotech for targeted delivery; microbiome modulation.
    • Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading.

    Read full article

    Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins

    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency



    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

    Summary: This narrative review examines the multifactorial pathogenesis of diabetic foot ulcers (DFUs), affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, peripheral neuropathy, hyperglycemia-induced immune defects, and microbial dysbiosis with biofilms. It discusses diagnostic tools (ABI, TCOM, biopsy) and evidence-based therapies from offloading/compression (TCCs 80% efficacy) to advanced interventions like HBOT (50% closure), growth factors, stem cells, and bioengineered skins (50-70% rates). Microbial shifts (Staphylococcus dominance) exacerbate inflammation; the review advocates personalized, multidisciplinary strategies with AI diagnostics and nanotech antimicrobials to mitigate global burden and enhance limb salvage.

    Key Highlights:

    • Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection in 60% of cases.
    • Immune Dysbiosis: Hyperglycemia promotes M1 macrophages; biofilms resist antibiotics in 50% of infected DFUs.
    • Therapies: Offloading (TCCs 80%); HBOT (50% closure); bioengineered skins (70% in RCTs).
    • Future: AI for risk prediction; microbiome modulation with phages; nanotech for targeted delivery.
    • Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading cuts risk 50%.

    Read full article

    Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins, Abdullah Al-Rubaish, Mohammed Al-Rubaish, Ahmad Al-Rubaish

    The Future of Wound Care Is Synthetic – The Frank & Lizzie Show



    The Future of Wound Care Is Synthetic: Mirragen’s Breakthrough for Hard-to-Heal Wounds

    Summary: In this episode of The Frank & Lizzie Show, hosts Frank Aviles and Lizzie Hutton interview AJ Ford (CEO, ETS) and Dr. Marc Gitterle on Mirragen, a borate-based bioactive glass fiber matrix (BBGFM). The discussion centers on Mirragen’s second RCT for diabetic foot ulcers (DFUs), showing 48% closure at 12 weeks vs 24% SOC (mITT, n=133) and 73% vs 42% per-protocol. Mirragen provides a synthetic scaffold for cellular infiltration, angiogenesis, and infection inhibition, outperforming tissue-based products in cost, versatility, and real-world efficacy. Case studies demonstrate limb salvage in tendon-exposed and osteomyelitis-complicated DFUs.

    Key Highlights:

    • RCT Results: 48% healed (Mirragen) vs 24% SOC (mITT); 73% vs 42% per-protocol (p<0.05).
    • Mechanism: Borate glass dissolves to release ions promoting granulation/angiogenesis; inhibits colonization without antibiotics.
    • Case Studies: Tendon-exposed DFU avoided amputation; osteomyelitis cavity filled/healed in 4 weeks.
    • Advantages: Cost-effective, no refrigeration, versatile for contaminated wounds; supports non-compliant patients.
    • Guests: AJ Ford (CEO, ETS); Dr. Marc Gitterle (wound expert).

    Watch full episode on YouTube

    Keywords: Mirragen, borate glass, DFU RCT, limb salvage, synthetic scaffold, Frank Aviles, Lizzie Hutton, AJ Ford, Marc Gitterle

    Cryopreserved Ultra-Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot Ulcers



    A Multi-Centre, Randomised, Controlled Clinical Trial Assessing Cryopreserved Ultra-Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot Ulcers

    Summary: Multicenter RCT (n=220 Wagner 3/4 DFUs with exposed bone/tendon/muscle/joint and controlled osteomyelitis) compared cryopreserved ultra-thick human amniotic membrane (cUC, TTAX01/Neox 1K) + SOC vs SOC alone. At 26 weeks, 66.1% cUC + SOC healed vs 59.8% SOC (p=0.40); median time 106 vs 104 days (p=0.99). At 50 weeks, 77.1% vs 71.6% (p=0.29). Average 1.67 cUC applications; comparable AEs (90% both). Demonstrates cUC safety/efficacy as adjunct for severe DFUs often excluded from trials, with potential cost savings via fewer applications.

    Key Highlights:

    • Population: 220 patients; mean area 5.5 cm²; 6-week antibiotics.
    • Healing: 66.1% at 26 weeks (cUC) vs 59.8% SOC; 77.1% at 50 weeks.
    • Applications: Mean 1.67; max 4 over 16 weeks.
    • Safety: AEs 89.8% vs 87.3%; amputations 11.9% vs 18.6% (NS).
    • Authors: Joseph Caporusso, Travis Motley, John C Lantis II et al.

    Read full RCT

    Keywords: cUC amniotic, complex DFUs, RCT, healing rates, exposed bone, Joseph Caporusso, Travis Motley, John C Lantis

    Optimizing the Wound Bed for Better Outcomes



    Healing Starts Here: Optimizing the Wound Bed for Better Outcomes

    Summary: This WoundSource webinar focuses on wound bed preparation as foundational for healing chronic wounds (DFUs, VLUs, PIs). Key topics: TIME framework (Tissue management, Infection/Inflammation, Moisture balance, Edge advancement); debridement methods (autolytic, enzymatic, sharp); exudate control (absorptives, NPWT); biofilm disruption (antiseptics, surfactants). Speakers discuss evidence-based products and techniques to convert stalled wounds to healing trajectory, with case examples showing 30-50% faster closure via optimized preparation.

    Key Highlights:

    • TIME Principles: Core for chronic wound conversion.
    • Debridement: Sharp preferred for speed; enzymatic for maintenance.
    • Infection: Antiseptics over antibiotics for biofilm.
    • Moisture: Balance to avoid maceration/dryness.
    • Outcomes: Optimized prep ↑ healing 30-50%.

    Register/watch webinar

    Keywords: wound bed preparation, TIME, debridement, biofilm, chronic wounds

    Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application



    Simple and Effective Approach for Wound-Bed Preparation by Topical Citric Acid Application

    Summary: Empirical study (n=24 chronic wounds ≥10 cm, unresponsive >3 weeks) used 2% citric acid ointment daily post-saline irrigation. All achieved healthy granulation in 3-20 applications; controlled MDR infections (S. aureus 37.5%, P. aeruginosa 25%) without systemic antibiotics (unless systemic signs). No toxicity; acidic milieu unfavorable to microbes while promoting healing. Superior to conventional antiseptics (betadine/H2O2) in efficacy/cost for large raw areas.

    Key Highlights:

    • Wounds: Large raw areas; MDR isolates dominant.
    • Outcomes: Granulation in all; ready for grafting/secondary healing.
    • Safety: No local/systemic toxicity.
    • Vs Standard: Faster preparation, economical, non-toxic to cells.

    Read full study

    Keywords: citric acid, wound bed preparation, chronic wounds, MDR, granulation